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1.1 ATP-Dependent Transporters and Multidrug Resistance
Failure to respond to chemotherapy is a serious impediment in the treatment of cancer. In
this regard, the development of multidrug resistance (MDR) is frequently observed, which
leads to a reduced sensibility of cancer cells toward a broad spectrum of cytostatics. The most
commonly observed mechanism of MDR is associated with the overexpression of transporters
of the ATP binding cassette (ABC) family. These efflux pumps are localized in the cell
membrane and reduce the intracellular concentration of multiple structurally and functionally
unrelated drugs by an active extrusion at the cost of ATP hydrolysis.1–5
Forty eight functional proteins within the human genome belong to the superfamily of
ABC transporters. They can be divided into seven subfamilies (ABCA–ABCG) on the basis
of their gene structure, order of domains, and sequence homology. The proteins are typically
organized as two homologous halves, each containing a highly conserved nucleotide-binding
domain (NBD) at the cytoplasmic face of the membrane and a transmembrane domain
(TMD). The transmembrane sequences consist of α-helices, separated by hydrophilic loops.
In the tertiary structure, the two halves are closely associated to form an internal cavity
through which substrates are transported (Figure 1.1).5–7
The mechanisms of this transport are not fully elucidated; however, they can be described by
widely accepted concepts, e.g., the “hydrophobic vacuum cleaner” and the “flippase” models
by Higgins and Gottesman.8 In the former concept, the transporter pulls the substrate out of
the cell membrane and expels it to the extracellular compartment. The latter model suggests
that the substrate is translocated from the cytoplasmic to the extracellular leaflet of the
membrane bilayer, where it is exposed to the extracellular medium. The catalytic cycle starts
with the binding of ATP at the nucleotide-binding sites and the substrate in distinct regions
of the TMDs. The protein is then assumed to change its conformation in the transmembrane
regions induced by ATP hydrolysis followed by a release of the substrate. The cycle is finished
by a resetting to the basal conformation.5,8–10
Besides their role in drug resistance of cancer cells, ABC transport proteins are expressed
in several non-malignant tissues, among them, important pharmacological barriers of the
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human body. For example, various transporters have been identified in the brush border
membrane of intestinal cells, the canalicular membrane of hepatocytes, and the blood–brain
barrier indicating their pivotal role in detoxification and protection against xenobiotics.1,3,7
Additionally, ABC transporters can significantly affect bioavailability, accumulation, disposi-
tion, and elimination of drugs. Consequently, the evaluation of transport susceptibility of
new drugs as well as drug–drug interactions due to inhibition of efflux pumps have become
important in drug development and safety.1,11,12
While 15 ABC transporters have been observed to export chemotherapeutics in vitro,
only a few have been implicated so far as major contributors to clinical relevant MDR.
These are P-glycoprotein (P-gp/ABCB1), the multidrug resistance-associated proteins 1
and 2 (MRP1/ABCC1 and MRP2/ABCC2), and the breast cancer resistance protein
(BCRP/ABCG2). However, the high degree of sequence homology indicates that further









Figure 1.1: Domain organization of ABC transporters in the cell membrane (top) and models
for the action of multidrug efflux pumps (bottom; modified from ref.5).
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P-glycoprotein was the first discovered and is the most extensively studied ABC transporter.
In 1976, Juliano and Ling found it to be responsible for colchicine resistance in mutated
Chinese hamster ovary cells.13 The ABCB1 gene mapped to chromosome 7q21 encodes for
this 170 kDa protein which possesses the typical architecture of ABC efflux pumps with two
TMDs, each comprised of six α-helices, and two cytoplasmic NBDs (Figure 1.2).3,14
P-gp is present at low levels in many human tissues, but is generally highly expressed
in epithelial cell layers, for example, in the apical cells of the proximal tubules and the
villous membranes of the intestines. In the endothelial cell of the blood–brain barrier it is
exclusively orientated toward the blood. It can therefore be assumed that P-gp is involved in
restricting drug entry, excreting metabolites, or preventing access to sensitive organs such
as the brain.5,15 High expression levels of P-gp are detectable in tumors derived from cells
normally possessing P-gp such as renal and colon carcinomas, however, the protein is also
found in tumors derived from cell types with no intrinsic P-gp expression, e.g., bladder and
ovarian cancer as well as certain sarcomas.3,16
All transporters involved in MDR exhibit unusually broad substrate specificities. P-gp
preferentially transports neutral or positively charged hydrophobic substrates, besides other
pharmaceuticals, anticancer agents such as anthracyclines, taxanes, epipodophyllotoxins, and
Vinca alkaloids.3,5 Radioligand-binding data and functional binding studies indicate that
there are different substrate-binding sites within the transmembrane domains of P-gp. The
molecular basis for a substrate “polyspecificity” was recently revealed by the three-dimensional
structure of mouse P-gp (87% sequence homology to human P-gp). Distinct binding sites
in the internal cavity of two additional X-ray structures with co-crystallized cyclic peptide
inhibitors could be identified.10,14,17
Subsequent to the discovery of P-gp, MRP1 was described in 1992 as the first member of
the ABCC subfamily.18 The 190 kDa membrane-spanning protein is encoded by the ABCC1
gene located on chromosome 16p13.1. MRP1 shares the common structural motif of ABC
proteins. Similar to P-gp, MRP1 is composed of the large core segment containing the
nucleotide binding sites and two TMDs but additionally possesses a third transmembrane
domain with five helices and an extracellular N -terminus (Figure 1.2).7,19,20 Its amino acid
sequence resembles that of P-gp only to a modest extent of ~15%.15
MRP1 is broadly expressed in human tissues, e.g., in endothelial cells of brain capillaries,
epithelial cells of the digestive, urogenital, and respiratory tracts, endocrine glands, and the
hematopoietic system.15,20 Since its discovery in the H69AR cancer cell line, MRP1 has been
found in multidrug-resistant cell lines derived from different tissues and tumor types, for
example, in lung, colon, breast, bladder, and prostate cancer, as well as leukemia.18,21–23 Like
P-gp, it is capable of transporting a wide variety of anticancer agents, e.g., anthracyclines,
Vinca alkaloids, and methotrexate. In contrast to P-gp, MRP1 is facilitating the extrusion
of negatively charged compounds such as numerous glucuronate, sulfate, and glutathione














Figure 1.2: Topological models of the ABC efflux pumps P-gp (top), MRP1 (middle), and
BCRP (bottom; modified from ref.5).
Mayer et al. demonstrated the expression of MRP2 and its selective absence in transport-
deficient mutant hepatocytes in 1995.27 Structurally, MRP2 is similar to MRP1 containing
17 transmembrane segments organized in three TMDs and two NBDs, the corresponding
ABCC2 gene has been localized to chromosome 10q24. In contrast to most ABCC subfamily
members, which are expressed on basolateral membranes, MRP2 is located in the apical
membranes of polarized cells, such as hepatocytes and enterocytes. So, the most important
physiological role of this efflux pump is facilitating the export of organic anions, bile acids,
and xenobiotics into the bile.1,11,15,28 Although MRP2 was detected in renal, lung, colorectal
and hepatocellular carcinomas, further work is required to define its functional significance
in chemotherapeutic drug treatment. The nature of MRP2 substrates is very close to that
handled by MRP1. Interestingly, MRP2 (and MRP1) are able to efflux platinum drugs as
glutathione complexes.11,28,29
The identification of a new member of the ABC transporter family by Doyle et al. in a human
breast cancer subline suggested that this protein was responsible for MDR in tumor cells
without detectable amounts of P-gp and/or MRPs.30 Those resistances were characterized
by decreased accumulation of anticancer drugs such as mitoxantrone and anthracyclines.
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BCRP, the ABCG2 gene product, is a 72 kDa protein with an N -terminal NBD and a C -ter-
minal TMD (Figure 1.2). Presumably, the half-transporter functions as a homodimer.11,31
ABCG2 mRNA expression analyses indicated high levels in the placenta, brain, liver, and
intestines. Given its high expression in the placenta, BCRP might protect the fetus from
toxins. In addition, BCRP contributes to limiting brain permeation of various compounds.31
BCRP is overexpressed in several drug resistant cancer cells, e.g., breast, colon, myeloma
and fibrosarcoma cell lines, however, its contribution to MDR in cancer should be further
evaluated.1,5,31 The substrate specificity of BCRP is widely overlapping with P-gp and MRP1,
although there are some important differences. Like MRP1, BCRP also transports negatively
charged compounds and conjugates. On the other hand, it cannot transport Vinca alkaloids
(substrates of P-gp and MRP1), as well as taxols and verapamil (P-gp subtrates).5,31
1.3 Modulators of P-gp and MRP1
There is a wide variety of published compounds that can reverse MDR mediated by ABC trans-
porters. These inhibitors, modulators, or chemosensitizers interfere with the ability of the
transporter to efflux drugs in vitro and can therefore enhance intracellular accumulation of
cytostatics.5,32 On the molecular level, their mode of action is not well understood. Most
inhibitors are likely to bind to the substrate-binding sites mentioned above. There they can
effectively compete with the substrates for binding. In many cases, the modulators themselves
are transported out by the efflux-pump, followed by a rapid translocation to the inner leaflet
of the membrane, thus resulting in a transport cycle under ATP hydrolysis. On the other
hand, binding of inhibitors was also described at different regions of the nucleotide binding
sites.5,7,32
P-gp directed MDR modulators belong to different chemical and pharmacological classes, e.g.,
representatives of calcium channel blockers, immunosuppressants, calmodulin antagonists,
steroids, flavonoids, and anthranilamides.3,5,33,34 Additionally, they have been categorized
into a first, second, and third generation. The first generation was typically identified from
registered pharmaceuticals, such as verapamil (Figure 1.3), which was found to overcome
P-gp mediated vincristine resistance in leukemia cells (Tsurio et al., 1981).35 Subsequent
studies demonstrated that representatives of other calcium antagonist classes, for instance,
dihydropyridines and benzothiazepines also shared the MDR reversing properties of verapamil.
Until the beginning of the 1990s, examples from other drug categories followed: the anti-
malarial quinine, the macrolide antibiotic erythromycin, the antipsychotic chlorpromazine,
and the immunosuppressant cyclosporin A, which is one of the most effective first generation
MDR modulators. In general, those drugs inhibited ABC transporters at much higher
concentrations than those required for their individual therapeutic activity and thus led
to severe side effects. Consequently, structural analogs of first generation agents were
developed as second generation modulators. For example, the less cardiotoxic dexverapamil
(R-enantiomer of verapamil) was found to be equally effective in modulating P-gp mediated
drug transport. In addition to a reduced toxicity, some compounds such as PSC 833, a
non-immunosuppressive analog of cyclosporin A, demonstrated a 10- to 20-fold better efficacy.
Moreover, VX-710, a simplified analog of tacrolimus, was developed as an inhibitor of P-gp
































Figure 1.3: Representatives of 1st to 3rd generation P-gp modulators.
The last generation of P-gp inhibiting drugs is characterized by a high selectivity for P-gp
and a further increased potency with effective concentrations in the nanomolar range. This
group includes the anthranilamide tariquidar and derivatives like WK-X-34 and XR9577
(Figure 1.3).37–40 Although the lead compound entered two Phase III clinical trials in patients
with non-small cell lung cancer, studies were stopped due to chemotherapy-related toxicity.36
Laniquidar, a 6,11-dihydro-5H -imidazo[2,1-b][3]benzazepine, was developed as an orally active
MDR inhibitor. The 11C labeled derivative [11C]laniquidar was recently evaluated for its
feasibility as a PET tracer for imaging P-gp in rats.41 One of the most potent P-gp inhibitors
described, the dibenzosuberane derivative zosuquidar, is still under clinical development.36
Chemical structures of selected modulators from the recent literature are depicted in Figure 1.4.
Colabufo et al. reported on P-gp modulators with a 2-substituted 3-(methyloxyphenylethyl)-
phenyl scaffold. Introduction of a N -butyltetrahydroisoquinoline side chain (compound I)
resulted in an effective inhibition of the P-gp mediated [3H]vinblastine transport in Caco-2
cells (IC50 = 0.08 µM), whereas transport of [3H]mithoxantrone by BCRP was not affected.42
The same group evaluated a panel of 2-aryloxazoles and 2-arylthiazoles toward P-gp, BCRP,
and MRP1. Although P-gp inhibition dropped in comparison to the reference compounds,
the 2-aryloxazole moiety was found to be a versatile scaffold for new BCRP or MRP1
inhibitors. Furthermore, structural features for the modulation of both ABC transporters
were presented.43 Two series of [1,4]thiazino[3,4-c]oxadiazol-3-ones were derived from the
calcium channel modulator diltiazem.44 For example, compound II reduced the IC50 value
of doxorubicin in A2780/DX3 cell by ~40%. On the basis of the so-called “frozen-analog”
approach, a N,N -bis-arylalkylamine moiety was substituted by a N,N -bis(cyclohexanol)amine
scaffold. The trans/cis isomer III inhibited pirarubucin efflux from doxorubicin-resistant
K562/DIX leukemia cells with an IC50 of 0.01 µM. Moreover, it was able to inhibit basal
ATPase activity and reversed doxorubicin resistance by factor 36.45 Little structural variation
of rhodamine derivatives resulted in an unexpected alteration of ATPase activity.46 Exchange
of a tertiary amide for a thioamide group at the thienyl moiety of compounds like IV caused
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ATPase stimulation for the former and effective inhibition for the latter. In MDCKII-MDR1
cells, the thioamide-derivative IV promoted calcein AM uptake and inhibited vinblastine efflux
with IC50 values around ~2 µM, thus in the range of cyclosporin A. Das et al. reported on a
novel class of cytotoxic agents which reverse MDR.47 The quinoxaline 1,4-dioxides V inhibited
proliferation in a number of human tumor cell lines, especially leukemic and breast cancer
cells. Interaction with P-gp was measured by intracellular accumulation of rhodamine 123
in ABCB1 -transfected L-5178 lymphoma cells. The best compounds increased fluorescent
intensities of rhodamine 123 comparable to the reference verapamil.
Particularly for P-gp, in silico models have been successfully applied to identify new lead
structures33,48,49 and pharmacophore patterns of P-gp ligands addressing different binding








































Figure 1.4: Structures of P-gp modulators from recent literature.
8 1 Introduction
Much effort has been focused on the finding of inhibitors for MRP1, but the number of
published compounds is considerably lower than those available for P-gp.3,53,54 Whereas
most P-gp inhibitors failed to affect MRP1, cyclosporin A and verapamil proved active
against MRP1. Additionally, several specific inhibitors have been described within the last
15 years. The leukotriene D4 receptor antagonist MK 571 inhibited the leukotriene C4
transport by membrane vesicles from MRP1-transfected cells,55,56 and it was frequently used
in recent pharmacological studies (Figure 1.5).57–64 MK 571 exhibited an K i value of 0.6 µM
in MRP1-mediated leukotriene C4 transport,55 IC50 values of 3.3 µM in ATP-dependent
















































Figure 1.5: Structures of known MRP1 inhibitors.
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Among various flavonoids,67 dehydrosilybin was a particularly active inhibitor of leukotriene
C4 transport.68 Recently, Wong et al. demonstrated that (ethylene glycol)-linked flavonoid
homodimers effectively restored doxorubicin and etoposid accumulation in 2008/MRP1 cells.69
The selective estrogen receptor modulator raloxifene was used as a lead structure to conceive
inhibitors of MRP1-mediated MDR. The analogue LY329146 with a bis(methylsulfonyl)amino
group in place of one hydroxyl group in raloxifene showed improved activity.70 The tricyclic
isoxazole LY402913 was identified as a potent and selective modulator by reversing drug
resistance to different MRP1 substrates in HeLa-T5 and A2780 cells. Furthermore, LY402913
delayed tumor progression in a xenograft mouse model.71,72 Another series of selective
and highly efficient MRP1 inhibitors derived from a pyrrolo[3,2-d]pyrimidine template was
reported by Wang et al. Structural modifications led to pyrrolo- and indolopyrimidines,
exhibiting IC50 values of approximately 0.1 µM. Some derivatives such as XR12890 displayed
good pharmacokinetic profiles, e.g., high oral bioavailability and limited interactions with
cytochromes P450.73,74 Recently, we identified the thieno[2,3-d][1,3]thiazin-4-one derivativeVI
as being active at MRP1 and 2.66
1.4 Objectives of the Dissertation
The aim of the presented studies was the synthesis and analytical characterization of potential
bioactive molecules, especially ortho-substituted aromatic (thio)ureas and derived cyclization
products. The main focus was on establishing new synthetic routes to the target compounds
and on making them available for various biological testings.
In a first project, it was intended to transform N -benzoyl-N ′-(o-cyanoaryl)thioureas to an-
nelated 4-aminothieno[2,3-d]pyrimidines and 4-aminoquinazolines with various 2-alkylsulfanyl
substituents (Scheme 1.1). The newly prepared heterocycles as well as substances from the
compound library of our group were to be tested in the group of Prof. Dr. M. Wiese for their
interaction with P-glycoprotein.
An alternative cyclization of the aforementioned N -benzoyl-N ′-(o-cyanoaryl)thioureas to
2-(benzoylimino)-3-(o-cyanoaryl)thiazolidin-4-ones by an adaption of the reaction conditions
was to be investigated (Scheme 1.1). Special attention was to be paid to the influence of
the ring size of the ortho-cyanoaryl substituent on the occurrence of atropisomerism due to
















Scheme 1.1: Transformation of N -benzoyl-N ′-(o-cyanoaryl)thioureas to (hetero)fused


















Scheme 1.2: Aromatic 2-(thio)ureidocarboxylic acids as new modulators of MRP1 (left) and
a potential synthetic entry to 2-sec-amino-4H -3,1-benzothiazin-4-ones (right).
Another major objective of this dissertation was aromatic carboxylic acids bearing either
a substituted urea or thiourea moiety at the neighboring position to the carboxyl group
(Scheme 1.2). This structural feature was identified in a screening for new inhibitors of mul-
tidrug resistance-associated protein 1 in collaboration with the group of Prof. Dr. M. Wiese. To
derive structure–activity relationships for this new class of MRP1 modulators, it was intended
to provide four series of ortho-(thio)ureidocarboxylic acids with a benzene or thiophene ring
as aromatic scaffold. In addition to substances that were taken from the compound library,
further derivatives had to be synthesized, such as a set of 2-[3,3-(dialkyl)thioureido]benzoic
acids and selected 2-[3,3-(dialkyl)thioureido]thiophen-3-carboxylic acids.
Methyl 2-[3,3-(dialkyl)thioureido]benzoates, that served as precursors for the corresponding
benzoic acids mentioned above, were employed to explore synthetic entries to 2-sec-amino-
4H -3,1-benzothiazin-4-ones (Scheme 1.2). An alternative access from 2-(methylthio)-4H -3,1-
benzothiazin-4-one and intermediates of the interconversions were also to be studied. To
assess possible biological activities, a series of benzothiazinones had to be provided for testing
on a panel of eight different proteases and esterases in our group.
The structural characterization of three related salts derived from tetrafluorophthalic acid
and isopropyl amine was the focus of the last project. Among the structures, an anomalous
salt with two dibasic acid molecules per cation was identified (Figure 1.6). In order to
distinguish the anomalous salt from the other structures, crystallographic data and the
results of different spectroscopic methods, such as solution and solid-state NMR, were to be
combined. Furthermore, a possible involvement of fluorine in hydrogen bonding of the crystal














Figure 1.6: Anomalous salt derived from tetrafluorophthalic acid and isopropyl amine.
CHAPTER 2
Fused 4-Aminopyrimidines as Modulators of P-Glycoprotein
Substrate Specificity
2.1 Substrate-Dependent Bidirectional Modulation of P-gp
In contrast to the wide variety of published P-pg inhibitors, a smaller number of substances
showed a reversed effect. They were able to protect cells from distinct cytostatics by stimula-
tion of the efflux pump. Shapiro and Ling75 identified two positively cooperative drug-binding
sites of P-gp. Hoechst 33342 and rhodamine 123 activated the P-gp-mediated transport of
each other. Moreover, different groups of cytostatics stimulated either Hoechst 33342 or
rhodamine 123 transport. A comparable effect has also been discussed for flavonoids.76–78
Recently, erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, was
found to be a substrate-dependent bidirectional modulator of P-gp.79
Kondratov et al.80 investigated a diverse set of p53 inhibitors in a cell-based assay with differ-
ent P-gp substrates, e.g., doxorubicin, daunorubicin, rhodamine 123, vinblastine, and taxol.
The addition of these small molecules improved survival of Con A cells in the presence of
certain cytotoxic substrates, while pump activity was decreased for others, thus changing the
cross-resistance pattern of P-gp. For example, QB102, a tricyclic tetrahydrobenzimidazo[2,1-
b]thiazole, increased resistance to the anthracyclines doxorubicin and daunorubicin, but
showed the opposite effect for taxol and vinblastine. On the basis of daunorubicin ac-
cumulation, other active substances such as the triazacyclopentaindene QB11 and the
thieno[2,3-d]pyrimidine QB13 (Scheme 2.1) were supposed to behave similar to QB102. This
group of compounds was also included in the derivation of a pharmacophore pattern for the
Hoechst 33342 binding site of P-gp.51 In accordance with the biological results, QB11 and
QB13 produced similar overlays as QB102. QB13 complied with the pharmacophore in four
hydrophobic aromatic centers, one hydrogen bond (HB) acceptor point, and one HB donor
point.
It was intended to modify the lead structure QB13 to further characterize the interaction of
the analog substances with P-gp. Therefore, the annelated tetrahydrobenzothieno moiety and
the phenethylsulfanyl residue of QB13 were varied to compose two sets of target compounds
(Scheme 2.1, dashed boxes).
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Scheme 2.1: Structure of the lead compound 29 (QB13) and synthetic route to compounds
17–41.
2.2 Thieno[2,3-d ]pyrimidines and Quinazolines as Analogs of QB13
In the first set (Table 2.1, 18–31), the sulfanyl substituent in position 2 of the heterosystem
was diversified for dimethyl substituted (18–24) and tetrahydrobenzothieno[2,3-d]pyrimidines
(25–31). Besides the phenethyl residue of 29 (QB13), small alkyl (Me, Et), polar aliphatic
((CH2)2OH, CH2CO2Et) and aromatic substituents (CH2COPh, CH(Ph)CO2H) were in-
cluded. Within this set, seven out of 14 compounds were newly prepared, the others were
taken from the substance library (see Table 2.1). The second set (32–41) was intended to
discover possible influences of the ring system fused with the aminopyrimidine. Three tricyclic
thienopyrimidine templates (32–37) as well as two quinazolines (38–41) were combined with
the parent phenethylsulfanyl residue ((CH2)2Ph) or the polar ester function (CH2CO2Et) in
position 2.
The synthesis of the target compounds was accomplished in two or three steps (Scheme 2.1).
2-Aminothiophenes (2–6) were prepared by Gewald synthesis.81 For this purpose, a one-pot
version including the condensation of an appropriate ketone, malononitrile and sulfur in
the presence of diethylamine was applied.82 A direct transformation of acetaldehyde by
this one-pot technique is not possible,83 therefore, 2-aminothiophene-3-carbonitrile (1) was
generated from 1,4-dithiane-2,5-diol.84 Subsequently, 1–6 as well as commercially available
o-aminobenzonitriles 7, 8 were reacted with benzoyl isothiocyanate to afford benzoylthioureas
9–16 (Table 2.1). Thermal ring closure of these intermediates was effected by sodium
hydroxide in an ethanol–water mixture, followed by the addition of alkyl halides.85 The
conditions of the last reaction step were slightly adopted, i.e., prolongation of heating, to
restrain the formation of alternative cyclization products (see Chapter 3).
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Table 2.1: Thieno[2,3-d]pyrimidines 17–37 and quinazolines 38–41 with corresponding yields














Compd R1 R2 R3 Yielda (%) Prepared From EC50 ± SDb (µM)
17 H H CH2CO2Et 58 9 ndc
18* | | Me 1.31 ± 0.49
19 | | Et 51 10 4.59 ± 0.94
20* | | (CH2)2OH ndd
21 Me Me CH2CO2Et 42 10 0.90 ± 0.27
22 | | (CH2)2Ph 32 10 2.25 ± 0.89
23 | | CH2COPh 84 10 1.31 ± 0.63
24* | | CH(Ph)CO2H > 100
25* | Me 2.65 ± 0.80
26* | Et 0.46 ± 0.14
27* | (CH2)2OH 1.92 ± 0.14
28 –(CH2)4– CH2CO2Et 48 12 2.24 ± 0.43
29 | (CH2)2Ph 72 12 1.02 ± 0.48
30 | CH2COPh 77 12 0.64 ± 0.12
31* | CH(Ph)CO2H > 100
32 –(CH2)3– CH2CO2Et 65 11 4.15 ± 1.59
33 –(CH2)3– (CH2)2Ph 61 11 0.97 ± 0.21
34 –CH2−O−(CH2)2– CH2CO2Et 74 13 1.55 ± 0.42
35 –CH2−O−(CH2)2– (CH2)2Ph 47 13 0.56 ± 0.04
36 –CH2−N(Bn)−(CH2)2– CH2CO2Et 49 14 0.64 ± 0.19
37 –CH2−N(Bn)−(CH2)2– (CH2)2Ph 25 14 ndd
38 H H CH2CO2Et 55 15 3.98 ± 1.02
39 H H (CH2)2Ph 69 15 1.10 ± 0.33
40 OMe OMe CH2CO2Et 68 16 1.21 ± 0.60
41 OMe OMe (CH2)2Ph 67 16 1.52 ± 0.35
* Compound was taken from the substance library.
a Yields of products after recrystallization.
b Values are means of at least three experiments.
c Compound was not included in the biological evaluation.
d Compound was not determined due to limited solubility.





























Figure 2.1: Molecular plot of 36 showing the atom-labeling scheme and displacement ellipsoids
at the 30% probability level for the non-H atoms. H atoms are depicted as small
circles of arbitrary radii.86
Structure and purity of the products were confirmed by NMR and elemental analyses.
Two-dimensional NMR experiments (HMQC, HMBC) were carried out for the thieno[2,3-
d]pyrimidine 19 and the quinazoline 38 (see Appendix and Supplementary Information of
ref.87). To the best of our knowledge, 13C assignments of (hetero)-annelated [d]pyrimidines
are only reported for (hetero)aryl substituted 4-aminoquinazolines and 4-aminopyrazolo[3,4-
d]pyrimidines.88,89 Values obtained, e.g., for compound 38 (C-4, 161.3 ppm; C-2, 165.6 ppm)
are in accordance with selected C=N signals given for 4-amino-2-(2-thienyl)quinazoline (160.0
and 164.8 ppm). In the thieno[2,3-d]pyrimidines, the sequence of both signals was reversed
(for example, 21: C-2, 163.0 ppm; C-4, 165.4 ppm). To complete structural elucidation, 36
was subjected to X-ray diffraction analysis (Figure 2.1).86
2.3 Daunorubicin Accumulation and Cell Viability Assays
Biological evaluations were performed by A. de la Haye and K. Sterz from the group of
Prof. Dr. M. Wiese.90 At first, the effects of the substances on daunorubicin accumulation in
the human ovarian cancer cell line A2780 and its P-gp overexpressing counterpart A2780 Adr
were investigated. Cells were pre-incubated with the compounds and daunorubicin was
added as fluorescent substrate of P-gp. The intracellular fluorescence was measured using a
Becton Dickinson FACS-calibur. Details of the assay and the statistical analyses are given
elsewhere.38,87,90
Most compounds showed effects in the daunorubicin accumulation assay. Those reduced
intracellular fluorescence in A2780 Adr cells with EC50 values between 0.5 and 5 µM (Table 2.1,
Figure 2.2), thus behaved similarly as activators of P-gp. This is in accordance with the
effect of QB13 on the accumulation of daunorubicin in Con A cells.80
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Figure 2.2: Concentration–effect curve of 29 (QB13) in the daunorubicin accumulation assay.
The curve represents the average of three independent experiments.
When considering pairs with the same sulfanyl moiety within the first set (18–31), a clear effect
of the dimethyl–tetramethylene exchange (18–24 vs. 25–31) in the thieno[2,3-d]pyrimidines
was not observed. Three out of seven compounds with aliphatic side chains (18, 1.31 µM,
21, 0.90 µM, and 26, 0.46 µM) had activities better or comparable to the lead compound
29 (1.02 µM). The two phenacyl derivatives 23 (1.31 µM) and 30 (0.64 µM) were the most
potent aromatic representatives. Substituted phenylacetic acids (24, 31) showed no effect on
daunorubicin accumulation. This is in agreement with literature data, as P-gp generally does
not transport negatively charged compounds.
In the second set (32–41), most phenethyl derivatives were superior to analogous ethyl
acetates. Only the dimethoxyquinazolines 40, 41 had comparable EC50 values. The pyrano
derivative 35 (0.56 µM) and the N -benzyl-pyrido annelated ester 36 (0.64 µM) were the
most potent substances of this set. A bioisosteric exchange of thiophene for benzene gave
three active quinazolines (39–41) with EC50 values in the range of the lead structure 29.
Taken together, the somewhat higher activities of compounds with aryl substituents in the
sulfanyl side chain might be explained by a further hydrophobic aromatic interaction, as
suggested by the pharmacophore model.51 However, structural modifications of the lead
compound 29 seemed to be well tolerated by P-gp. For example, truncation of the phenethyl
to an ethyl residue led to the most potent compound 26. An additional carbonyl function in
the phenacyl residue of 30 also gained activity. Moreover, the introduction of heteroatoms
(35) and larger substituents (36) within the annelated tetrahydrobenzothieno moiety resulted
in active representatives as well.
To assess transport profiles of different P-gp substrates, cell viability (MTT) assays were per-
formed. Different concentrations (10–100 µM) of a cytostatic drug (daunorubicin, vinblastine
or colchicine) were combined with a fixed nontoxic concentration (31.6 µM) of 21, 22, 28, or
29.91 The four selected compounds showed similar effects in the MTT assay (Figure 2.3 and
Supplementary Information of ref.87). In agreement with the accumulation assay, toxic effects
of daunorubicin were reduced. However, for vinblastine, a potentiation of the cytotoxicity
was observed. The thienopyrimidines showed no effect on colchicine transport. Therefore, we
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could demonstrate a modulation of P-gp substrate specificity for 29 (QB13) and analogous
thieno[2,3-d]pyrimidines. With respect to the transport profile, this family of substances
corresponded to QB102.80 Moreover, the results agree with the overlays of QB11, QB13 and
QB102 in the pharmacophore pattern of the Hoechst 33342 binding site of P-gp.51
Sterz and Möllmann et al. recently reported on a series of imidazo[1,2-a]benzimidazoles
and tetrahydroimidazo[2,1-b]benzothiazoles structurally related to QB11 and QB102, respec-
tively.92 In conformity with the results obtained for the QB13 analogs, derivatives of both
heterocycles stimulated daunorubicin (and rhodamine 123) efflux in A2780 Adr cells. On
the other hand, selected compounds were able to increase toxicity of vinblastine as well as
colchicine in the MTT assay.
In summary, we evaluated a panel of thieno[2,3-d]pyrimidines and quinazolines as activators
of P-gp mediated daunorubicin transport. Structural modifications in different positions
of the scaffolds were well tolerated by the transporter. Moreover, we could demonstrate
a bidirectional modulation of P-gp activity for selected compounds in combination with
different cytostatic drugs.





















































A2780 Adr + compound 21
A2780 + compound 21
A2780
A2780 Adr
Figure 2.3: Concentration–effect curves of daunorubicin (top left), vinblastine (top right),
and colchicine (bottom left) in P-gp-overexpressing cells (A2780 Adr), P-gp-
overexpressing cells + compound 21 (31.6 µM), wild-type cells (A2780), and
wild-type cells + 21 (31.6 µM). Curves show a representative experiment with
three replicates.
CHAPTER 3
Formation of 2-(Benzoylimino)thiazolidin-4-ones by an Alternative
Ring Closure
3.1 Alternative Cyclization of Benzoylthioureas
Several 2-(alkylsulfanyl)-4-aminothieno[2,3-d]pyrimidines (17–37) as well as corresponding
quinazolines (38–41) were accessible by thermal ring closure of benzoylthioureas (9–16)
in aqueous sodium hydroxide solution, followed by the reaction with suitable alkyl halides
(see Chapter 2). However, when this one-pot procedure was applied in the reaction of
benzoylthiourea 10 with ethyl bromoacetate as the alkylating agent, a side product was
formed in addition to the expected thienopyrimidine 21 (Scheme 3.1, Table 3.1). As NMR and
IR spectra of the side product revealed an unaffected nitrile function, the presence of a benzoyl
group and the loss of ethanol, an alternative heterocyclization to a 2-iminothiazolidin-4-one
was assumed. To elucidate which nitrogen of the starting thiourea was incorporated into the
five-membered ring, crystals of the side product were subjected to X-ray diffraction analysis,
and structure 43 was determined (Scheme 3.1).93 The formation of 43 includes alkylation
of the thiourea sulfur prior to acylation of the nitrogen atom bound to the thiophene ring.
In reactions of unsymmetrical thioureas with α-halo esters, regiocontrol in the cyclization
step was influenced by electronic factors and by a possible conjugative stabilization of the
isothiourea imine through a (hetero)aryl substituent and could be promoted by hydrogen
bond interactions.94,95 The finding that the aryl-substituted, and not the electron-poor,
benzoylated nitrogen atom was incorporated into heterocycle 43 is in accordance with
literature reports.96–98
Various biological effects of 2-iminothiazolidin-4-ones have been reported.99–107 FR171113, for
example, a 2-(aroylimino)-3-arylthiazolidin-4-one derivative, is a thrombin receptor antagonist
with potent antiplatelet activity.108
3.2 Preparation and Characterization of Thiazolidin-4-ones
A small library of 2-(benzoylimino)thiazolidin-4-ones (42–49) was generated from benzoyl-
thioureas 9–16 (Table 3.1). Slightly different reaction conditions led to both heterocycles
17
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(Scheme 3.1). The direct addition of ethyl bromoacetate, a lowered temperature, an increased
amount of ethanol, and the reduction of sodium hydroxide suppressed the formation of
thieno[2,3-d]pyrimidines in favor of corresponding thiazolidin-4-ones 42–49. The new 2-(ben-
zoylimino)thiazolidin-4-ones could be purified by a single recrystallization step and were
obtained in mostly good yields. Conversion of 9–16 into 42–49 did not affect the nitrile
function, whereas different behavior was obvious for thiazolidin-4-ones with an unsubstituted
imino function in position 2.109 When such compounds were formed as intermediates, they
underwent a pyrimidine cyclization, and subsequent ethanolysis of the thiazolidin-4-one ring
produced 4-aminopyrimidines. In this way, Gewald et al. have prepared fused pyrimidines
21, 28, and 38 from aromatic o-(chloroacetylamino)nitriles.109
1. 1 M NaOH/  
    EtOH (1 : 2)
    BrCH2CO2Et
    50 °C, 1 h
2. H2O, rt
1. 1 M NaOH/
    EtOH (2.5 : 1)
    reflux, 30 min
2. BrCH2CO2Et


























Scheme 3.1: Formation of alternative cyclization products from benzoylthioureas 9–16;
molecular plots of compounds 17 (left) and 43 (right).93
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Table 3.1: Substitution patterns of thiazolidin-4-ones with corresponding yields.
CN



























a Yields of products after recrystallization.
b Yield after purification by column chromatography.
The structures of compounds 42–49 were confirmed by 1H and 13C NMR spectroscopy.
In contrast to the 1H NMR spectra of thiophene derivatives 42–47, those of benzonitriles
48, 49 showed splitting of the thiazolidin-4-one methylene signal into two doublets with
a coupling constant of 18.6 Hz. This could be attributed to hindered rotation around the
N–Caryl bond, thus leading to atropisomerism.110 The diastereotopic nature of the protons
gave rise to geminal coupling in the spectra. Atropisomerism about N -aryl bonds, e.g., in
thiazolidines or thiazolidin-4-ones, where an ortho substituent of the aryl group accounted
for steric hindrance, was recently reported.111,112 In contrast to these investigations focusing
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on the dimension and electronic properties of that ortho substituent, in our case the size of
the aryl moiety seemed to be crucial for the occurrence of atropisomerism. Increasing the
aryl size from a five-membered thiophene to a six-membered benzene ring led to a reduction
of the gap between the o-nitrile function and the carbonyl and benzoylimino groups of
the adjacent thiazolidin-4-one.113 This is illustrated by comparison of the angles θ in the
crystal structures93 of 42 and 43 (125.9°, 124.2°) with that of 48 (120.1°) as representatives
of the two ring sizes (Figure 3.1). In the three structures, the benzoylimino groups are
almost in plane with the thiazolidin-4-one system. Compounds 42, 43, and 48 display a
Z -configuration about the C=N bonds and an s-cis conformation about the Nimine–Ccarbonyl
bonds (Scheme 3.1). The non-bonded intramolecular distance between the thiazolidin-4-one
sulfur and the benzoyl oxygen atoms of 2.61–2.65 Å indicates a polar interaction between the
O and S atoms.114,115
3.3 Analysis of Rotational Barriers
Theoretical calculations were performed by Dr. P. W. Elsinghorst to affirm the hypothesis
that an internal rotational barrier between the nitrile group and the carbonyl and acylimino
function of the thiazolidin-4-one led to atropisomers in case of the anthranilonitrile derivatives
48 and 49. In this section, a brief summary of the approach and the main findings are
outlined, a detailed description is given in ref.116 and citations therein. On the basis of
their crystal structures, 42, 43 and 48 were subjected to a complete rotation about the
dihedral angle ϕ regarding the C–N bond connecting the cyanoarene and the thiazolidin-
4-one (Figure 3.1). Two rotational barriers were observed, corresponding to the steric
proximity of the cyano and carbonyl group and a clash between the cyano and imine group,
respectively. Compared to 42 and 43, the corresponding energy values of compound 48
increased significantly (64/59 and 66/67 versus 87/95 kJ/mol). This was mainly attributed
to the decreased θ value for 48 (124.2 and 125.9 versus 120.1°; Figure 3.1), thus resulting
in hindered rotation of 48. Calculated rotational barriers of 48 were in accordance with
literature data. For 2-(arylimino)-4-methyl-3-(o-substituted phenyl)thiazolines, theoretical
calculations as well as racemization studies using HPLC on chiral support resulted in energy
values between 85 and 122 kJ/mol.111 Enantiomers of 2-(arylimino)thiazolidin-4-ones with
an o-tolyl, o-methoxyphenyl, o-chlorophenyl, or α-naphthyl substituent at position 3 were









Figure 3.1: (a) Comparison of the angle θ in the crystal structures of 42 (transparent) and
48 (gray).93 (b) Thiazolidin-4-ones 42, 43, and 48 with the rotation angle ϕ.
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The calculations for 42, 43, and 48 were consistent with the spectroscopic data of the
thiazolidin-4-ones. On the one hand, the five-membered cyanothienyl derivatives 42–47
did not form stable atropisomers at room temperature, since the larger angle θ allowed the
substituents to pass each other. On the other hand, the six-membered cyanophenyl derivatives
48, 49 with smaller θ values had sufficient steric repulsion for hindered rotation and were
axially chiral racemates (Figure 3.2). Accordingly, 48, 49 had diastereotopic methylene
protons in their 1H NMR spectra. NMR experiments showed that rotation in 42 could not
be restricted at lower temperatures down to −40 ℃, and that, vice versa, rotation was not
allowed in 48 at higher temperatures up to 70 ℃.
Replacement of one ortho substituent by hydrogen in tri-o-substituted biaryls mostly results
in the loss of axial chirality.110 We prepared the truncated compounds 50 and 51 (Figure 3.2).
As expected, the ethylene protons of 50 showed a simple coupling pattern of two triplets
(3J = 7.7 Hz). Diastereotopic protons in the spectrum of 51 were not observed either, and
the two methylene groups gave rise to two triplets (4J = 1.0 Hz). This can be explained by
long-range coupling through the eclipsing lone pair of the sulfur atom.117–122 The long-range
coupling in the spectrum of 51 is independent of the presence of the cyano group, since it
was also found for compound 53 (4J = 1.0 Hz).
Thiazolidin-4-ones 51 and 53 were obtained by the reaction of anthranilonitrile or aniline with
thioglycolic acid and aqueous formaldehyde according to patent literature.123,124 Compound
50 was prepared from N -benzoyl-N ′-(2-cyanophenyl)thiourea (15) and 1,2-dibromoethane in
DMF in the presence of sodium acetate at room temperature. Thiazolidin-4-one derivative
52 could be synthesized by virtually the same reaction conditions as those used for 42–49.
In both 50 and 52, the aniline nitrogen was incorporated into the five-membered ring.
This could be confirmed by 13C NMR spectroscopy, in particular when the influence of the
































Figure 3.2: The two stereoisomers of 48, not interconvertible at room temperature, and the
truncated structures 50–53.
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An alternative method to prepare 2-iminothiazolidin-4-ones is the treatment of thioureas
with haloacetyl halides.94,100,102 Instead of ethyl bromoacetate, bromoacetyl bromide was
applied for the conversion of 15 into 48. However, the reaction did not proceed uniformly as
reported for other N -aroyl-N ′-arylthioureas.102 The 13C NMR spectrum revealed an additional
signal set obviously caused by the corresponding regioisomer. Klika et al. have proposed
a mechanism for the reaction of N -(anthracen-9-yl)-N ′-ethylthiourea with bromoacetyl
bromide involving S-acylation, acetyl migration, and S-alkylation to produce two isomeric
2-iminothiazolidin-4-ones (Figure 3.3).94
In summary, we have elaborated optimized reaction conditions for the selective preparation
of substituted thiazolidin-4-ones 42–49 from N -benzoyl-N ′-(o-cyanoaryl)thioureas 9–16 and
ethyl bromoacetate. In view of the diverse biological activities of thiazolidin-4-ones, com-
pounds 42–49 can be tested for their potency but might also be a useful scaffold for further
chemical transformations, e.g., modifications of the cyano group or a condensation with
appropriate aromatic aldehydes. Whereas the size of sterically demanding substituents has fre-
quently been reported to influence atropisomerization,110–112 we investigated the less common
influence of ring size by means of NMR measurements and theoretical calculations. In con-
trast to (o-cyanothienyl)-substituted thiazolidin-4-ones 42–47, (o-cyanophenyl)-substituted
derivatives 48, 49 cannot overcome internal rotational barriers at room temperature and










































Figure 3.3: Mechanism for the reaction of N -(anthracen-9-yl)-N ′-ethylthiourea with bromo-
acetyl bromide (modified from ref.94).
CHAPTER 4
Aromatic Carboxylic Acids as Multidrug Resistance-Associated
Protein 1 Modulators
4.1 Chemistry of Aromatic 2-(Thio)ureidocarboxylic Acids
The starting point for this study was the evaluation of low molecular weight compounds
from the substance library of our group for modulating effects on MRP1 in a fluorometric
calcein AM assay.66,125 Initially, the selection was focused on carboxylic acids with respect to
the anionic nature of the MRP1 substrates. More than 75 structurally diverse carboxylic
acids were inspected (see Supplementary Information of ref.66). Among them, some aromatic
2-(thio)ureidocarboxylic acids showed modulating activity on MRP1. On the basis of these
initial results, it was intended to provide four series of aromatic carboxylic acids (Figure 4.1).
All compounds bear either a substituted urea or thiourea moiety at the neighboring position

































2-ureidobenzoic acids 2-thioureidobenzoic acids
2-ureidothiophene-3-carboxylic acids 2-thioureidothiophene-3-carboxylic acids
Figure 4.1: Different series of aromatic carboxylic acids.
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Most compounds from the 2-ureidobenzoic acid series (54–69, Table 4.1) were taken from the
substance library. They were accessible either from the reaction of isatoic anhydrides A with
benzylamine or appropriate secondary amines,126 or by reacting N -(mesyloxy)phthalimides C
with secondary amines (Scheme 4.1).127 Moreover, a new synthetic route was introduced:
To prepare 2-(3,3-diethylureido)benzoic acid (55), anthranilic acid (B, R3 = R4 = H) was
pretreated with N,N ′-carbonyldiimidazole followed by the addition of diethylamine. Similarly,
the naphthalene derivative 69 was obtained from 3-amino-2-naphthalenecarboxylic acid (B,
R3R4 = –CH=CH–CH=CH–).
The two-step synthetic route to the new 2-thioureidobenzoic acids 78–85 (Table 4.2) is
depicted in Scheme 4.2. The methyl benzoate precursors 70–77 were prepared from sec-
ondary amines and methyl 2-isothiocyanatobenzoate128 in dichloromethane and subsequently
saponified with aqueous ethanolic sodium hydroxide. Representatives of both groups were also
applied for the preparation of 2-sec-amino-4H -3,1-benzothiazin-4-ones. A detailed description
of the synthesis and interconversion of these heterocycles is given in Chapter 5.
2-Ureidothiophene-3-carboxylic acids 86–89 (Table 4.3) were synthesized by two alternative
methods (Scheme 4.3). Thieno[2,3-d][1,3]oxazine-4-ones D underwent ring-opening upon
treatment with sodium hydroxide. Because a disubstituted amino group prevented Dimroth
rearrangement to pyrimidinediones,129,130 the desired non-cyclized ureas 86, 88, and 89
were obtained. According to this literature method, 88 was prepared in 72% yield, whereas
the other compounds of this series were taken from the substance library. Trifluoroacetic
acid promoted the cleavage of the tert-butyl ester group in E to give the corresponding
isopropylurea 87. Both routes started with the Gewald thiophene synthesis81,82 to alkyl
2-aminothiophene-3-carboxylates. In contrast to the preparation of 2-aminothiophene-3-
carbonitriles, which were employed as starting materials for thienopyrimidines (Chapter 2)
and thiazolidin-4-ones (Chapter 3), cyanoacetic esters are used instead of malononitrile to
obtain the corresponding 2-aminothiophene-3-carboxylates. Those were converted either
with isopropyl isocyanate to E or in five reaction steps to the heterocycles D.131 In analogy
to 2-ureidobenzoic acids, o-ureidothiophenecarboxylic acids are accessible from thiaisatoic
anhydrides, the thiophene analogs of isatoic anhydride.132,133 The latter entry was not applied
in the course of this work.
Synthetic pathways to thiophene-3-carboxylic acids with a thiourea moiety at position 2
(102–122, Table 4.4) are shown in Scheme 4.4. Fourteen out of 21 compounds were taken
from the substance library. Those were obtained by sodium hydroxide-promoted cleavage of
the thiazinone ring of compounds H.131 Similar to the preparation of 2-thioureidobenzoic
acids 78–85, a direct saponification of the ethyl esters G was applied for compounds 103,
105–107, and 120–122. With respect to R3 and R4, either non-, mono-, and disubstituted
thiophenes (102–111) or fused compounds (112–122) were included. All substances were
accessible by an initial Gewald reaction. To obtain the aromatic fused isothiocyanate 94, three
additional steps were necessary (Scheme 4.5).131,134 The final compound 101 (Scheme 4.4)
was achieved following the first mentioned route, i.e., conversion of methyl 3-aminothiophene-
2-carboxylate to the isothiocyanate and the diethylthioureido derivative, which was cyclized
with concentrated sulfuric acid to the corresponding 4H -thieno[3,2-d][1,3]thiazin-4-one and
reopened to 101.131
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1. CDI, 2. HNR1R2
CH2Cl2 or THF, rt
1. HNR1R2, acetone, reflux































HNR1R2, H2O, rt, or 
HNR1R2, EtOH, H2O, reflux






















Scheme 4.2: Preparation of 2-thioureidobenzoic acids 78–85.
1. 1.5 M NaOH/acetone (2 : 1) 
    reflux, 2. 3 M HCl































Scheme 4.3: Synthetic routes to 2-ureidothiophene-3-carboxylic acids 86–89.
















































1. concd H2SO4 
rt, 2. H2O, or
1. PPA, 170 °C 
2. ice, EtOH
1. NaOH, dioxane































Scheme 4.5: Preparation of ethyl 2-isothiocyanatobenzo[b]thiophene-3-carboxylate (94).
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Compd NR1R2 R3 R4 Yield (%) Prepared from IC50 ± SD (µM)
54* NHBn H H A nid
55 N(Et)2 H H 54 B 26.4 ± 10.1
56* N(Me)CH2CO2Me H H C ni
57*,a,b,c N(Me)cyclohexyl H H A 12.3 ± 2.8
58* N(Me)Ph H H A ni
59* N(Me)Bn H H A 42.6 ± 1.6
60* N(Me)CH2CH2Ph H H A ni
61* 1-pyrrolidinyl H H C 43.1 ± 11.1
62* 4-morpholinyl H H C ni
63* N(Me)cyclohexyl H Me A 22.8 ± 6.2
64* N(Me)Ph H Me A ni
65* N(Me)Bn H Me A ni
66* N(Me)CH2CH2Ph H Me A ni
67* 4-morpholinyl H Me A ni
68* 4-morpholinyl Me Me C 43.4 ± 13.3
69a,b,c N(Et)2 –CH=CH–CH=CH– 68 B 5.38 ± 0.68
* Compound was taken from the substance library.
a Compound showing no effect in the P-gp assay.
b Compound (at 31.6 µM) inhibited BCRP between 25 and 65% relative to the inhibitory effect of
XR9577 (at 10 µM).
c No cytotoxicity (IC50 > 100 µM).
d ni, no inhibition of the MRP1-mediated transport.
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Compd NR1R2 Yield (%) Prepared from IC50 ± SD (µM)
78 N(Et)2 78 70 21.6 ± 5.3
79a,b,c N(Me)cyclohexyl 90 71 16.2 ± 4.2
80 N(Me)Ph 66 72 198 ± 29
81 N(Me)Bn 61 73 29.1 ± 9.1
82 N(Me)CH2CH2Ph 81 74 24.0 ± 6.9
83 1-pyrrolidinyl 85 75 18.3 ± 4.6
84 1-piperidinyl 84 76 20.7 ± 2.5
85 4-morpholinyl 75 77 nid
a Compounds showing no effect in the P-gp assay.
b Compound (at 31.6 µM) inhibited BCRP less than 20% relative to the inhibitory
effect of XR9577 (at 10 µM).
c No cytotoxicity (IC50 > 100 µM).
d ni, no inhibition of the MRP1-mediated transport.










Compd NR1R2 R3 R4 Yield (%) Prepared from IC50 ± SD (µM)
86*,a,b,c N(Et)2 –(CH2)3– D 11.6 ± 3.1
87* NHCH(Me)2 –(CH2)4– E nid
88a,b,c N(Et)2 –(CH2)4– 72 D 8.29 ± 4.22
89* 4-morpholinyl –(CH2)4– D ni
* Compound was taken from the substance library.
a Compounds showing no effect in the P-gp assay.
b Compounds (at 31.6 µM) inhibited BCRP between 25 and 65% relative to the inhibitory
effect of XR9577 (at 10 µM).
c No cytotoxicity (IC50 > 100 µM).
d ni, no inhibition of the MRP1-mediated transport.
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Table 4.4: 3-(Diethylthioureido)thiophene-2-carboxylic acid 101 and 2-(thioureido)-thiophene-


















Compd NR1R2 R3 R4 Yield (%) Prepared from IC50 ± SD (µM)
101*,a,b,c 4.18 ± 0.70
102*,a,b,c N(Et)2 H H H 4.46 ± 0.58
103a,c,d N(Me)cyclohexyl H H 78 G (95) 4.51 ± 0.49
104* N(Et)2 H CH(Me)2 H 14.5 ± 5.5
105 4-morpholinyl H Ph 84 G nih
106c,e N(Et)2 Ph H 90 G (96) 14.3 ± 4.7
107 4-morpholinyl Ph H 73 G (97) 27.5 ± 3.3
108* N(Et)2 Me Me H 20.4 ± 2.1
109*,a,b,c N(Me)cyclohexyl Me Me H 4.19 ± 1.51
110* 4-morpholinyl Me Me H 18.3 ± 4.5
111* N(Et)2 CONH2 Me H > 100
112*,a,b,c N(Et)2 –(CH2)3– H 2.56 ± 1.11
113* N(Me)2 –(CH2)4– H ni
114*,a,b,c N(Et)2 –(CH2)4– H 2.71 ± 0.35
115* N(Me)cyclohexyl –(CH2)4– H ndi
116* 4-morpholinyl –(CH2)4– H ni
117* 4-methyl-1-piperazinyl –(CH2)4– H ni
118*,a,c,f N(Et)2 –(CH2)3CH(CH3)– H 4.06 ± 1.05
119*,a,b,c N(Et)2 –(CH2)5– H 5.97 ± 3.83
120a,c,g N(Et)2 –CH=CH–CH=CH– 41 G (98) 0.932 ± 0.041
121a,b,c N(Me)cyclohexyl –CH=CH–CH=CH– 81 G (99) 1.23 ± 0.29
122 4-morpholinyl –CH=CH–CH=CH– 65 G (100) ni
* Compound was taken from the substance library.
a Compound showing no effect in the P-gp assay.
b Compound (31.6 µM) inhibited BCRP between 25 and 65% relative to the inhibition of XR9577 (10 µM).
c No cytotoxicity (IC50 > 100 µM).
d Partial inhibition of BCRP with IC50app = 10.2 ±3.6 µM.
e 20% inhibition at 31.6 µM, 40% inhibition at 100 µM in the P-gp assay.
f Partial inhibition of BCRP with IC50app = 9.10 ±1.71 µM.
g Partial inhibition of BCRP with IC50app = 6.16 ±1.36 µM.
h ni, no inhibition of the MRP1-mediated transport.
i nd, not detectable, concentration-dependent decrease of fluorescence in 2008 WT and 2008 MRP1 cells.
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4.2 Results from Calcein AM, Hoechst, and Cell Viability Assays
Biological evaluations were carried out by Dr. S. Leyers, J. Wiendlocha, and D. Baumert
from the group of Prof. Dr. M. Wiese. This section outlines the general approach as well as
the main findings from the biological assays, for a detailed description see refs.135–137
An accumulation assay using the MRP1 substrate calcein AM was performed to determine
the influence of the test compounds on the transporter protein MRP1.54,66,125 Calcein AM
is a lipophilic, non-fluorescent acetoxymethyl ester of calcein that easily penetrates cellular
membranes. Intracellular calcein AM can either be transported out of the cell by MRP1
or cleaved by unspecific cytosolic esterases to produce the fluorescent calcein. The human
ovarian cancer cell line 2008 stably expressing MRP1 was used. In 2008 MRP1 cells, the efflux
of calcein AM leads to a decreased intracellular fluorescence, compared to the corresponding
wild-type cell line, 2008 WT. An MRP1 inhibitor blocks calcein AM efflux, leading to an
enhancement of calcein concentration and intracellular fluorescence (Figure 4.2). In contrast,
as the wild type does not exhibit MRP1, addition of an inhibitor to 2008 WT cells has no
effect on fluorescence (Figure 4.3). When performing the assay, XR9577 (Figure 1.3),138 a
selective blocker of P-gp and BCRP, having no effect on MRP1,39 was added to inhibit P-gp,
which is present to a minor degree in both MRP1-expressing and wild-type cells. The assay
medium contained cobalt ions to quench extracellular calcein fluorescence so that only the
fluorescence of intracellular calcein is measured.
A subset of active compounds was defined and tested for the ability to affect P-gp in a similar
calcein AM assay using P-gp overexpressing A2780/ADR cells. Furthermore, these compounds
were investigated for modulation of BCRP in MCF-7 MX cells in an accumulation assay with
the fluorescent substrate Hoechst 33342.139 Cytotoxicity of the subset of compounds was
determined in 2008 WT cells by measuring viability via MTT assay.91 The MTT assay was
also used to assess potentiating effects of two exemplary 2-ureidothiophene-3-carboxylic acids
(103, 120) in combination with the cytotoxic drugs vinblastine and daunorubicin.


























Figure 4.2: Fluorescence–time curves for different concentrations of 120 determined with the
calcein AM assay in 2008 MRP1 cells. Data are averages from a typical experiment
with two replicates belonging to a series of three independent experiments.
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Figure 4.3: Concentration–effect curve of compound 120 in MRP1-transfected cells (open
circles) in comparison to the wild-type cells (closed circles). Curves represent the
average of at least five independent experiments. For normalization of data, slopes
from fluorescence–time curves were transformed to relative units by subtracting
the lowest determined single value from all other data and thus setting it to 0%.
The highest measured single value was defined as 100%.
In search of MRP1 inhibitors, we identified active representatives of 2-ureidobenzoic acids.
All 2-ureidobenzoic acids (54–69) investigated are outlined in Table 4.1. The presence of a
diethylureido and a cyclohexylmethylureido moiety provided active compounds (55, 57, 63,
69). A replacement of the cyclohexyl residue by a phenyl, benzyl, or phenethyl group mostly
led to a loss of potency (57 versus 58, 60; 63 versus 64–66). While the introduction of a
5-methyl substituent (R4 = Me) did not improve biological activity, an additional fused ben-
zene ring was advantageous (55 versus 69). The naphthalene derivative 69 (IC50 = 5.38 µM)
was the only potent substance among the 2-ureidobenzoic acids. Compound 69 did not
inhibit P-gp, showed a weak inhibition of BCRP and was not cytotoxic. Whereas seven of
the 16 2-ureidobenzoic acids inhibited MRP1, no active compound was identified from a
series of 13 related anthranilic acid derivatives (see Supplementary Information of ref.137),
i.e., benzoic acids with a 2-alkylamino, 2-arylamino, 2-acylamino, 2-alkoxycarbonylamino, or
2-(3-aroylureido) substituent.
Compounds 78–85 are benzoic acids with a thiourea moiety at position 2 (Table 4.2). As
in the ureidobenzoic acid series, a cyclohexylmethylureido moiety in 79 (IC50 = 16.2 µM)
accounted for activity. This substance did not inhibit P-gp but showed also a weak inhibition
of BCRP. No cytotoxicity was observed for 79. Toward MRP1, all compounds, except of 80
and 85, had IC50 values below 30 µM. When comparing analogous ureas with thioureas, a clear
effect of the oxygen–sulfur exchange could not be observed (55, 57–62 versus 78–83, 85).
Five benzoic acids with a 2-(3-aroylthioureido) residue and optional aromatic substituents
have also been investigated and proved to be inactive. The replacement of the carboxyl group
in 78 by a cyano function abolished activity, indicating the importance of this moiety (see
Supplementary Information of ref.137).
IC50 values of 2-ureidothiophene-3-carboxylic acids 86–89 are in given in Table 4.3. A
2-(3-isopropylureido) or 2-[(4-morpholinylcarbonyl)amino] residue gave inactive compounds.
The activities of the two diethylurea derivatives 86 and 88 (IC50 = 11.6 and 8.29 µM) were
between those of the two benzoic acid-derived diethylureas 55 and 69. Both compounds,
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86 and 88, did not affect P-gp-mediated transport but were also weak inhibitors of BCRP.
They did not exhibit cytotoxicity. Four thiophene-3-carboxylic acids with 2-acylamino or
2-alkoxycarbonylamino groups in place of the 2-ureido function were also evaluated but had
no effect on MRP1-mediated transport (see Supplementary Information of ref.137).
Thiophenecarboxylic acids 101–122 with an o-thioureido substituent are outlined in Table 4.4.
Again, the carboxyl group was required for activity as the corresponding methyl ester of
101 and the corresponding carbonitrile of 114 did not affect MRP1 (see Supplementary
Information of ref.137). Within the thioureido residue, a diethylamino or cyclohexylmethyl-
amino substitution pattern was advantageous over a more polar one, i.e., morpholino or
methylpiperazino. The two isomeric thiophenes 101 and 102 were equipotent.
Starting from 2-(3-diethylthioureido)thiophene-3-carboxylic acid (102), the influence of
substituents in positions 4 and 5 was examined. The potency was somewhat diminished
by introducing two methyl groups (102 versus 108), or an isopropyl group (104), but was
lost by replacing the 5-methyl by a polar carboxamide moiety (111). A fused cycloaliphatic
ring was tolerated in most cases and provided slightly improved inhibitors, i.e., the tri- and
tetramethylene compounds (102 versus 112 and 114). Introduction of a methyl group into
the tetramethylene chain of 114 resulted in a slight decrease of activity (118). As in the
2-ureidobenzoic acid series (compound 69) a bicyclic aromatic system was advantageous.
An additional fused benzene ring in the benzothiophene 120 accounted for the most potent
MRP1 inhibitor of our study with an IC50 value of 0.932 µM. Increased potency of 120
compared to the analogous cycloaliphatic derivative 114 could be due to planarity of the
fused aromatic system. Removing the steric fixation of the annelated benzene ring in favor of
a substituted benzene ring considerably dropped activity (120 versus 106).
Although it was demonstrated by means of X-ray crystallography that the biaryl structure
in 106 is nearly in plane (ϕ = 16°, Figure 4.4), the extended aromatic system might lead
to steric repulsion. An exchange of the diethylamino group in 120 for a cyclohexylmethyl-
amino substituent in the thioureido residue led to the other potent benzothiophene 121
(IC50 = 1.23 µM). Again, the exchange of the dialkyl moiety for a polar morpholino substituent
in 122 resulted in a loss of activity. When comparing the MRP1-inhibiting properties of
analogously substituted thiophenes (86, 88 versus 112, 114), thioureas were superior to
ureas. The bioisosteric benzene–thiophene exchange improved the activity as can be seen
from the comparison of the parent diethylthioureidocarboxylic acids (78 versus 101 and
102).
Selected MRP1 inhibitors of this series (Table 4.4) were evaluated as modulators of P-gp, but
only 106 showed a weak inhibitory activity. However, inhibition of BCRP was observed in
all these cases. Compounds 103, 118, and 120 behaved as partial inhibitors of BCRP with
a maximum inhibitory effect of 60% relative to XR9577 and apparent IC50 values between 6
and 10 µM. The selected MRP1 inhibitors of this series were not cytotoxic. In the modified
MTT assay, MRP1-expressing cells were treated with 103 or 120 (in a fixed concentration of
31.6 µM) and vinblastine or daunorubicin (in different concentrations). These combinations
did not result in an increased cytotoxicity of vinblastine and daunorubicin, respectively (see
Supplementary Information of ref.137).











Figure 4.4: Torsion angle ϕ between phenyl (dark gray) and thiophene (light gray) planes
in the crystal structure of 106. Heteroatoms are designated according to the
atom-labeling scheme.140
4.3 Structural Features for Bioactivity
On the basis of the structure–activity relationships detailed above, we combined the advanta-
geous structural features as can be deduced from the biological activities of the four series of
aromatic carboxylic acids (Figure 4.5). The best MRP1 inhibitors of the present series are
more potent than verapamil, indomethacin, MK 571, and cyclosporin A for which IC50 values
between 5 and 12 µM had been determined in the calcein AM assay (Table 4.5).66 They have
the same order of activity as dehydrosilybin (IC50 = 1.1 µM),53 LY329146 (IC50 = 0.8 µM),53
LY402913 (IC50 = 1.8 µM),141 and compound VI (IC50 = 1.2 µM)66 but are less potent
than the recently reported pyrrolo- and indolopyrimidines such as XR1289073,74 (Figure 1.5).
The structural features derived for the aromatic carboxylic acids of this study (Figure 4.5)
reflects their differences to other classes of MRP1 inhibitors. The essential components are a
carboxyl group at a (hetero)aromatic scaffold with a (thio)urea function in ortho-position.
The terminal nitrogen of the (thio)urea should be disubstituted, preferentially with two alkyl
groups (e.g., diethyl or cyclohexylmethyl). The (hetero)aromatic ring (A) consists of benzene
or thiophene, while the orientation of the sulfur seems to have minor influence on activity.






Figure 4.5: Structural features for bioactive aromatic 2-(thio)ureidocarboxylic acids.
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Table 4.5: Standard inhibitors with corresponding IC50 values at MRP1, P-gp, and BCRP




Verapamil 9.66 ± 2.79 5.42 ± 1.33 525 ± 73c
Indomethacin 12.0 ± 3.5 nib ndd
MK571 7.57 ± 1.10 ni nd
Cyclosporin A 4.78 ± 0.61 4.92 ± 0.20 63.1 ± 14.7c
a Values are means ±SD of at least three independent exper-
iments carried out on different occasions.
b ni, no inhibition.
c taken from ref.139
d nd, not detected.
In addition to the calcein AM accumulation assays in 2008 MRP1 cells, toxicity for 16
selected compounds was evaluated in corresponding wild-type cells (Table 4.1–Table 4.4)
and no cytotoxic properties were observed. However, compounds 103 and 120 failed to
reverse multidrug resistance of MRP1-expressing cells against vinblastine and daunorubicin,
respectively. Although different transport mechanisms of substrates are well characterized
for MRP1, the mechanism of inhibition is poorly understood.2,5,53,54,142 Perrotton et al.
investigated modulating effects of (R)- and (S)-verapamil on MRP1.143 Both enatiomers
induced an increase in calcein AM accumulation in MRP1-overexpressing cells, thus implying
effective inhibition of the efflux pump. In potentiation assays, only (R)-verapamil reverted
resistance of MRP1-BHK-21 cells to vincristine. As 103 and 120 in our case, (S)-verapamil
did not show a cytotoxicity-potentiating effect. The different modulation of MRP1 by both
enatiomers was discussed as explanation of controversial results of verapamil in reversion of
chemoresistance.61,143–145
The most potent representatives of the four series were evaluated for modulating effects on
BCRP- and P-gp mediated transport. All selected substances showed a weak inhibition of
Hoechst 33342 efflux mediated by BCRP. Overlapping inhibitors of different ABC transporter
are discussed in the literature.3,7,12,31,43 Our finding that carboxylic acids are capable of an
interaction with BCRP is in agreement with a recently published report revealing MK 571
to be a BCRP inhibitor.12 On the other hand, all MRP1 inhibitors with IC50 values less
than 10 µM did not affect P-gp. As P-gp generally does not transport negatively charged
compounds, it might be concluded that the presence of a carboxylic acid moiety accounts for
this selectivity.
Structural modifications of the title compounds might be useful for further studies, e.g., an
exchange of rings A and/or B for other heteroaromatics, additional substituents at N-3 of the
(thio)urea (cyclohexylethyl or di(iso)propyl), and a bioisosteric replacement of the carboxyl
group against a tetrazole moiety.146
CHAPTER 5
Synthesis and Interconversion of 2-Substituted
4H-3,1-Benzothiazin-4-ones
5.1 Biological Activities of Fused 3,1-Benzothiazin-4-ones
It was the aim of this study to search for synthetic entries to 4H -3,1-benzothiazin-4-ones with
amino or alkylthio substituents at position 2. Representatives of this heterocyclic class are
assumed to possess biological activities since they might provide four heteroatoms as potential
hydrogen bond acceptors and the fused phenyl ring for possible pi–pi interactions. Analogous
4H -3,1-benzoxazin-4-ones have attracted considerable attention as serine hydrolase inhibitors.
Their interaction with serine hydrolases involves the acylation of the active-site serine due to
enzymatic ring cleavage, followed by slow deacylation of the acyl-enzyme intermediate.147
2-Amino and 2-alkylthio substituted 4H -3,1-benzoxazin-4-ones have been characterized as
potent inhibitors of human leukocyte elastase (HLE),148–151 cathepsin G,152,153 chymase,154
C1r serine protease of the complement system,155,156 thrombin,157 and human cytomegalovirus
protease.158 6-Methyl-2-p-tolylamino-4H -3,1-benzoxazin-4-one (URB754) was identified as
a potent inhibitor of the endocannabinoid-deactivating enzyme monoacylglycerol lipase.159
2-Aryl substituted 4H -3,1-benzoxazin-4-ones have been evaluated as specific inhibitors of the
tissue factor/factor VIIa-induced pathway of coagulation.160
Biological activities of 4H -3,1-benzothiazin-4-ones and hetero-fused analogues have been in-
vestigated less extensively.161 Examples include 6-thiaoxanosine, an imidazo[1,5-a][1,3]thiazin-
7(3H )-one riboside with strong antiviral and anticancer properties162 and the antiproliferative
compound 2-(2,4-dihydroxyphenyl)-4H -3,1-benzothiazin-4-one.163 2-Arylamino substituted
thieno[1,3]thiazin-4-ones and analogous [1,3]thiazino[5,4-b]indole-4-ones have been reported
as inhibitors of HLE.164,165
5.2 Chemistry of 2-sec-Amino-4H-3,1-benzothiazin-4-ones
Our initial approach to produce 2-sec-amino-4H -3,1-benzothiazin-4-ones was the treatment
of methyl 2-thioureidobenzoates 70–77 (see Chapter 4) with concentrated sulfuric acid. This
35
36 5 Synthesis and Interconversion of 2-Substituted 4H-3,1-Benzothiazin-4-ones
procedure was introduced to prepare 2-aminothieno[2,3-d][1,3]thiazin-4-ones,166 for example,
the p-aminobenzoic acid derivative VI (Figure 1.5),66 and successfully applied to other
heterocyclic systems.164,165,167–169 Accordingly, Tarzia et al. have prepared the benzothiazine
analogue of URB754 that way.170 Ring closure to 4H -3,1-benzothiazin-4-ones was also achieved
by treatment of 2-benzoylaminothiobenzamide with concentrated sulfuric acid.171
The reaction of compounds 70, 71, and 75–77 with concentrated sulfuric acid at room
temperature conveniently afforded the desired benzothiazinones 123, 124, and 128–130
(Scheme 5.1). The benzyl(methyl)thiourea derivative 73 was not converted to 126 due to
N -debenzylation under the strong acidic conditions used. The methyl(phenyl)thiourea 72
gave the corresponding benzothiazinone 125 in only 20% yield, and the methyl-(2-phenyl-
ethyl)thiourea 74 could not be transformed to 127. Therefore, an alternative synthetic route
was chosen. Benzoic acid derivatives 80–82, which were hydrolyzed from the corresponding
methyl benzoates 72–74 (see Chapter 4), were cyclized with acetic anhydride172,173 to yield
125–127, thus allowing the facile introduction of aromatic structures within the 2-substituent
of 123–130.
A synthetic access to 2-(methylthio)-4H -3,1-benzothiazin-4-one (132) was envisaged via the
dithiocarbamate 131, which was prepared from anthranilic acid, carbon disulfide and methyl
iodide. This intermediate underwent an easy cyclocondensation upon treatment with acetic
anhydride. Only one representative of this heterocyclic class, i.e., 6,7-difluoro-2-(methylthio)-
4H -3,1-benzothiazin-4-one, has already been described by Mazuoka et al.174 The preparation
of further 2-alkylthio-4H -3,1-benzothiazinones as well as their biological investigation are
outlined in refs.175,176
To explore an alternative entry to 2-sec-amino-4H -3,1-benzothiazin-4-ones, the S -methyl
derivative 132 was reacted with secondary amines. However, the corresponding 2-amino-
benzothiazinones were not formed and instead, we obtained 2-thioureidobenzamides 133–135.
The attack of an amine on 132 might either occur at the C-2 or C-4 carbons. An attack
at C-2 followed by C-2–S-3 bond breakage would not lead to 133–135. The nucleophilic
substitution of the methanethiol group would generate 2-aminobenzothiazinones 123–130.
Such intermediates could subsequently undergo ring cleavage due to the attack of the amine
at C-4 to produce 133–135. When treating the 2-morpholinobenzothiazinone 130 with
morpholine under the conditions used for the conversion of 132 to 133–135, compound 135
was indeed obtained. However, a different mechanism was proposed based on the isolation
of the intermediate 136 in the reaction of 132 with morpholine (Scheme 5.2). Hence, the
secondary amine attacks the 2-(methylthio)benzothiazinone 132 at C-4, followed by ring
opening and subsequent transformation of the dithiocarbamate substituent into a thiourea.
Leistner and Wagner reported on a similar formation of 2-thioureidothiobenzamides when
reacting 2-(methylthio)-4H -3,1-benzothiazin-4-thione with secondary amines.177
With the novel 2-thioureidobenzamides 133–135 in hand, we also investigated their utility
as precursors to 123–130. Indeed, the corresponding 2-aminobenzothiazinones 123, 128
and 130 were obtained in quantitative yield and high purity by reacting the benzamide
derivatives 133–135 with concentrated sulfuric acid (Scheme 5.1).




















74,82,127         R1 = Me, R2 = (CH2)2Ph 
75,83,128,134  NR1R2 = 1-pyrrolidinyl
76,84,129         NR1R2 = 1-piperidinyl
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70,78,123,133  R1 = R2 = Et
71,79,124         R1 = Me, R2 = c-Hex
72,80,125         R1 = Me, R2 = Ph
73,81,126         R1 = Me, R2 = Bn
concd H2SO4, rt, or HCl 
MeOH, reflux, 2 min (135)
HNR1R2, acetone
rt, then reflux (130)




















Scheme 5.2: Reaction pathway from 132 to 135.
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Table 5.1: Cyclization reactions of benzoic acid derivatives 78, 82, and 131 with acetic









127  X = S
138  X = O
132  X = S






123  X = S
137  X = O
Educt Reagent Thiazinone (X = S) Yielda (%) Oxazinone (X = O) Yielda (%)
78 TFAA 123 26 137 65
82 Ac2O 127 65b —
82 TFAA 127 28 138 68
131 Ac2O 132 93b —
131 TFAA 132 91 139 2
a Yields of products after purification by column chromatography.
b Yield after recrystallization.
Heating the 2-thioureidobenzamides 133–135 in methanolic hydrochloric acid yielded methyl
thioureidobenzoates 70, 75, and 77 (Scheme 5.1). This transformation is formally an acid-
catalyzed amide alcoholysis under conditions where a simple benzamide such as 4-benzoyl-
morpholine did not react.127 A ring closure–reopening mechanism operative in the conversion
of 133–135 to the corresponding methyl 2-thioureidobenzoates is initiated by the rapid cyclo-
condensation to intermediate 2-aminobenzothiazinones 123–127. This could be concluded as
the product 130 was identified after short-time treatment of 135 with methanolic hydrochloric
acid. Prolonged heating of 130 then led to formation of the methyl thioureidobenzoate 77.
In the course of this study, acetic anhydride was successfully used in cyclocondensations to
convert the benzoic acid derivatives 80–82 and 131 to benzothiazinones 125–127 and 132,
respectively. Unexpectedly, the replacement of acetic anhydride by trifluoroacetic anhydride
(TFAA) produced different results (Table 5.1). The treatment of 2-thioureidobenzoic acids
(78/82) with this reagent gave mixtures of the corresponding benzothiazinones (123/127)
and benzoxazinones (137/138) with the latter compounds being the dominant products.
On the other hand, the benzothiazinone 132 was the main product of the reaction of the
dithiocarbamate 131 with TFAA while the corresponding benzoxazinone 139 was only formed
in traces. The formation of 137 and 138 is envisaged to occur by a nucleophilic attack of
the carboxyl oxygen at the activated thiocarbonyl carbon.129,178–182 Further investigations
are needed to clarify the mechanism of this desulfurisation–cyclization.
In the 13C NMR spectra of the benzothiazinone representatives 123 and 132 the char-
acteristic signals for C-2/C-4 appeared at 155/185 ppm (123) and 164/182 ppm (132).
The other benzothiazinones had similar NMR data. The corresponding chemical shifts of
the benzoxazinones were observed at 153/160 ppm (137) and 164/159 ppm (139), respectively.





















Figure 5.1: Molecular plot of 126 showing the atom-labeling scheme and displacement ellip-
soids at the 30% probability level for the non-H atoms. H atoms are depicted as
small circles of arbitrary radii.183
These values were in accordance with literature data for 4H -3,1-benzoxazin-4-ones.160,179,184–186
A similar influence of the sulfur–oxygen exchange on the chemical shift of the C-4 carbon
was observed for pairs of 2-thien-2-yl and 2-cyano substituted 4H -3,1-benzothiazin(oxazin)-
4-ones.179,187 The structure of the title compounds was furthermore confirmed by X-ray
crystal structure analysis of 126 (Figure 5.1).183 The thiazinone rings adopt an almost planar
conformation with the largest deviation from the least square planes defined by the six atoms
of the heterocyclic ring being 0.022 Å.
5.3 Enzyme Inhibition Studies
2-Aminobenzothiazinones 123–130 and the 2-methylthio derivative 132 were evaluated as
potential inhibitors of HLE188 (Table 5.2). Other representative members of serine pro-
teases (human cathepsin G, bovine chymotrypsin and bovine trypsin) were also investigated.
The compounds were furthermore assessed toward the cysteine protease human cathep-
sin L and the metalloprotease angiotensin converting enzyme (ACE). Two serine esterases,
acetylcholinesterase (AChE) and cholesterol esterase (CEase), which share the acyl transfer
mechanism with serine proteases were also included in the inhibition studies. Biological
investigations were carried out by J. Zhou and S. Hautmann. Detailed descriptions of the
assays as well as the calculations of IC50 values are given in ref.176 and citations therein.
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Table 5.2: Enzyme inhibitory activities of 2-substituted 4H -3,1-benzothiazin-4-ones.
IC50 values (µM)
Compd HLE Cathepsin G Chymotrypsin Trypsin Cathepsin L ACE AChE CEase
123 > 100a >100 > 25 > 100 > 50 > 100 >25 > 25
124 > 100 > 50 > 100 > 100 8.93 ± 1.58e > 100 > 50 > 50
125 > 25 > 100 10.4 ± 0.5c > 100 > 50 > 100 > 100 > 50
126 > 25 > 100 22d > 100 22f > 100 > 50 25g
127 > 25 > 100 > 50 > 100 > 50 > 100 > 100 > 50
128 > 100 > 100 > 100 > 100 > 100 > 100 > 50 > 100
129 > 100 > 100 > 25 > 100 > 50 > 100 > 25 > 50
130 > 100 > 100 > 50 > 100 > 25 > 100 > 25 > 25
132 3.31 ± 0.24b > 100 > 100 > 100 > 100 > 100 > 50 > 25
a Limits were calculated from duplicate measurements at one or two inhibitor concentrations.
b Duplicate measurement at five different inhibitor concentrations.
c Duplicate measurement at five different inhibitor concentrations, see Supplementary Information of ref.176
d Duplicate measurement at one inhibitor concentration (10 µM).
e Triplicate measurement at five different inhibitor concentrations, see Supplementary Information of ref.176
f Duplicate measurement at two inhibitor concentrations (10 and 20 µM).
g Quadruplicate measurement at one inhibitor concentration (5 µM).
None of the investigated 2-aminobenzothiazinones inhibited HLE. As 2-amino-substituted
4H -3,1-benzoxazin-4-ones are potent inhibitors of HLE, a replacement of the ring oxygen by
sulfur resulted in a loss of activity, which can be attributed to the increased intrinsic stability
of the benzothiazinones. The second order rate constant for the alkaline hydrolysis of 130
(1.7 M−1s−1) was significantly lower than that of the analogous 2-(morpholin-4-yl)-4H -3,1-
benzoxazin-4-one (28 M−1s−1).189 2-(N -Cyclohexyl-N -methylamino)-4H -3,1-benzothiazin-4-
one (124) exhibited a remarkable inhibitory capacity against human cathepsin L.190 This
compound was selective for cathepsin L with respect to the other enzymes investigated in this
study. It might therefore serve as a lead structure for cysteine protease inhibitors. Further
investigations are needed to inspect selectivity among cysteine proteases.
2-(Methylthio)-4H -3,1-benzothiazin-4-one (132) was identified as HLE inhibitor with an
IC50 value in the low micromolar range. This compound carries a 2-substituent with the least
steric demand among all the benzothiazinones tested. HLE has a primary substrate specificity
for small aliphatic amino acid residues at P1 position. It can therefore be assumed, that the
methylthio moiety is accommodated by the S1 subsite of HLE. The concentration-dependent
inhibition by 132 is presented in Figure 5.2. The progress curves of the HLE-catalyzed
substrate consumption were linear over the 10-min time course. Thus, the time-independent
inhibition indicated a non-covalent interaction of 132 with HLE. Provided that 132 behaved
kinetically as a competitive inhibitor, a K i value of 1.2 µM corresponds to the IC50 value
of 3.3 µM.191 Noteworthy, the 2-methylthiobenzothiazinone 132 did not inhibit any of the
other enzymes studied here.
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Figure 5.2: Plot of the steady-state rates versus inhibitor concentration for the inhibition of
HLE by compound 132.
In summary, different routes to 2-sec-amino-4H -3,1-benzothiazin-4-ones 123–130 have been
explored. A particularly versatile method involved the acetic anhydride-promoted cycloconden-
sation of 2-thioureidobenzoic acids 80–82, which were readily accessible by saponification of
the corresponding methyl 2-thioureidobenzoates (72–74). The preparation of 2-(methylthio)-
4H -3,1-benzothiazin-4-one (132) from anthranilic acid was demonstrated using a two-step
procedure. We could also show that 132 was ring-opened to 2-thioureidobenzamides 133–135,
which on their own proved to be further precursors to 2-sec-amino-4H -3,1-benzothiazin-4-ones
123–130. Unexpectedly, one 2-aminobenzothiazinone, 124, inhibited human cathepsin L, a
cysteine protease of therapeutic importance. In the course of this study, biological activities of
2-alkylthio-4H -3,1-benzothiazin-4-ones have been evaluated for the first time, and compound
132 was identified as an inhibitor of human leukocyte elastase.

CHAPTER 6
Structural Characterization of Salts From Tetrafluorophthalic Acid
and Isopropylamine
6.1 Carbon-Bound Fluorine in Medicinal Chemistry
The ability of covalently bound fluorine to accept hydrogen bonds has been the subject
of a scientific debate.192–194 This issue has attracted much interest in analyses of crystal
structures of fluorine-containing molecules,195–198 particularly in cases of aromatic carbon-
bound fluorine-mediated hydrogen bonds.199 The introduction of fluorine is a commonly used
strategy in medicinal chemistry to improve properties of bioactive compounds.200,201 Although
a hydrogen–fluorine exchange results in only minor steric changes, the high electronegativity
of fluorine and the resulting polarization of the C–F bond remarkably alter the physico-
chemical properties of molecules.193,199 Therefore, the introduction of fluorine can lead
to enhanced binding interactions, increased metabolic stability or selective reactivity.202
Favorable (fluorophilic) and unfavorable (fluorophobic) environments within target proteins
have been determined. Such approaches have been exploited to develop inhibitors of serine and
cysteine proteases192–194,203–206 or to design potent inhibitors of angiogenesis by fluorination
of phthalic acid derivatives.207–210 In the course of studies on salts of tetrafluorophthalic acid,
one has to face limitations by the absence of aromatic protons in 1H NMR, and fluorine–
carbon couplings in 13C NMR spectroscopy. The structural characterization is additionally
complicated as a dibasic acid (H2Y) is able to form salts with a monoacid base (R) in
different stoichiometric ratios. Besides a neutral (R2Y) and a normal acid salt (RHY), various
anomalous salts (e.g., RH3Y2, R2H4Y3) can be formed.211–213
6.2 Preparation of Isopropylammonium Tetrafluorophthalates
The reaction of tetrafluorophthalic acid with two equivalents of isopropylamine in boiling
toluene gave the expected neutral salt bis(isopropylammonium) tetrafluorophthalate (140) in
quantitative yield (Scheme 6.1). Equimolar amounts of isopropylamine and tetrafluorophthalic
acid led to the normal acid salt 141. When 140 was kept at room temperature in aqueous
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i-Pr-NH2 (1 equiv) 
H2O, rt H2O / H+, rt
Scheme 6.1: Preparation of tetrafluorophthalates 140–142.
acidic solution, crystals of a different compound were obtained. This material was not the
expected tetrafluorophthalic acid, but an anomalous acid salt with two dibasic acid molecules
per cation,211,212,214 compound 142. The exact assignment of the stoichiometry of the three
salts was not possible by 13C NMR measurements in solution. However, the structures
were assumed from elemental analysis and confirmed by X-ray crystallography as well as
solid-state NMR experiments.
6.3 Crystal Structures and Hydrogen Bonding Patterns
There are only few literature reports on X-ray crystal structures of tetrafluorophthalic acid
and its salts. Examples are the structures of tetrafluorophthalic acid,215 l-histidinium
tetrafluorohydrogenphthalate216 and dipotassium tetrafluorophthalate.217,218 For compounds
140–142, selected bond lengths and angles from the crystal data are listed in Table 6.1,
hydrogen bonding parameters are presented in Table 6.2.219
The three structures crystallized in the monoclinic system with space group C2/c (140) and
P21/n (141, 142), respectively. As has been shown for dipotassium tetrafluorophthalate,218
molecules of compound 140 (Figure 6.1) have a crystallographic C2-symmetry with the
twofold rotation axis through the center of the C1–C1# as well as the C3–C3# bonds.
The dihedral angle between the planes of both carboxylate fragments (O1/C7/O2 and
O1#/C7#/O2#) is 58.8° and 59.3° between a carboxylate group and the tetrafluorobenzene
ring. This differs from the conformation in dipotassium tetrafluorophthalate, in which a
carboxylate group is nearly perpendicular (89.1°) to the other and inclined at an angle of
82.0° to the benzene ring.218 In the crystal structure of 141 (Figure 6.2), the dihedral angle
between the planes of the carboxylate fragment (O1/C7/O2) and the protonated carboxyl
group (O3/C8/O4) is 56.4°. The angles of both groups relative to the tetrafluorobenzene
ring are 50.8° (O1/C7/O2) and 58.6° (O3/C8/O4), respectively.
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C7–O1 1.212(4) C7′–O1′ 1.210(4)
C7–O2 1.310(5) C7′–O2′ 1.316(4)
C8–O3 1.233(4) C8′–O3′ 1.212(4)
C8–O4 1.264(4) C8′–O4′ 1.311(4)
O1–C7–O2 125.4(3) O1′–C7′–O2′ 125.2(3)
O3–C8–O4 126.1(3) O3′–C8′–O4′ 124.8(3)
C6–C1–C7–O1 71.3(5) C6′–C1′–C7′–O1′ 99.5(4)
C6–C1–C7–O2 −103.6(4) C6′–C1′–C7′–O2′ −74.2(4)
C3–C2–C8–O3 −149.4(3) C3′–C2′–C8′–O3′ 166.7(3)
C3–C2–C8–O4 29.8(5) C3′–C2′–C8′–O4′ −13.0(5)
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Table 6.2: Hydrogen bonding parameters for 140–142.
D–H· · ·A D–H (Å) H· · ·A (Å) D· · ·A (Å) D–H· · ·A (°)
140
N1–HN1A· · ·O1a 0.95(2) 1.83(2) 2.775(2) 173(1)
N1–HN1B· · ·O2 0.96(2) 2.08(2) 2.826(1) 134(1)
N1–HN1B· · ·O2b 0.96(2) 2.23(2) 2.886(2) 125(1)
N1–HN1C· · ·O1c 0.92(2) 1.90(2) 2.807(1) 171(1)
141
O3–HO3· · ·O1d 0.99(2) 1.62(2) 2.551(1) 155(2)
N1–HN1A· · ·O1e 0.91(2) 2.02(2) 2.929(1) 178(1)
N1–HN1B· · ·O2f 0.91(2) 1.87(2) 2.771(2) 170(2)
N1–HN1C· · ·O4g 0.93(2) 2.02(2) 2.859(2) 148(2)
N1–HN1C· · ·F3h 0.93(2) 2.42(2) 3.029(1) 123(1)
C11–H11B· · ·O3e 0.98(2) 2.50(2) 3.388(2) 150(1)
142
N1–H1A· · ·O1 0.91(1) 1.95(2) 2.840(4) 168(4)
N1–H1B· · ·O1′ 0.91(1) 2.02(2) 2.851(4) 152(4)
N1–H1B· · ·O3′ 0.91(1) 2.62(3) 3.237(4) 126(3)
N1–H1C· · ·O2′i 0.91(1) 2.41(2) 3.248(4) 154(4)
O2–H2· · ·O3j 0.84(1) 1.79(2) 2.588(4) 157(4)
O2′–H2′· · ·O4j 0.84(1) 1.77(1) 2.612(3) 174(5)
O4′–H4′· · ·O4k 0.84(1) 1.77(1) 2.603(4) 175(5)
C9–H9· · ·O2j 1.00 2.54 3.424(5) 148
C11–H11a· · ·O3 0.98 2.50 3.313(5) 140
Symmetry transformations used to generate equivalent atoms:
a x, −y + 1, z + 1/2
b −x, y, −z + 1/2
c x, y, z + 1
d x+ 1/2, −y + 5/2, z + 1/2
e −x+ 1/2, y − 1/2, −z + 3/2
f −x, −y + 2, −z + 2
g −x+ 1/2, y − 1/2, −z + 5/2
h x+ 1/2, −y + 3/2, z + 1/2
i −x+ 1, −y + 2, −z + 1
j −x+ 1, −y + 1, −z + 1
k x, y + 1, z
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Molecules of 142 contain a tetrafluorophthalic acid component (Figure 6.3, left) and a
tetrafluorohydrogenphthalate unit (Figure 6.3, right). The two protonated carboxyl groups of
the tetrafluorophthalic acid component are twisted to each other by 74.6° and have dihedral
angles relative to the tetrafluorobenzene ring of 75.3° (O1′/C7′/O2′) and 12.0° (O3′/C8′/O4′).
A resembling conformation was observed for the crystals from the sole tetrafluorophthalic
acid with corresponding dihedral angles between the carboxyl groups and the aromatic ring of
81.0° and 13.4°, respectively.215 In the tetrafluorohydrogenphthalate unit of 142, the planes of
the deprotonated and protonated carboxyl groups have a dihedral angle of 66.3°, and each of
them is inclined to the tetrafluorobenzene ring by 30.4° (O3/C8/O4) and 75.6° (O1/C7/O2).
The latter two values show the same tendency compared to those observed in 141, but differ
from typical orientations in hydrogenphthalates with angles between carboxylate fragments
and phenyl planes in the range of 65–85° and smaller angles (5–40°) between carboxyl groups
and benzene rings.220
Only N–H· · ·O hydrogen bonds have been observed in the crystal structure of compound
140 (Figure 6.1). All the three hydrogen atoms of the isopropylammonium group are part of
hydrogen bonds including two between the nitrogen and two O1 atoms of different molecules
as well as one bifurcated interaction to connect the nitrogen with two O2 atoms of different
molecules (Table 6.2). The hydrogen-acceptor distances of the two-center hydrogen bonds
(1.83, 1.90 Å) were in accordance with literature data (mean value 1.84 Å, between mono-
substituted ammonium groups and carboxylate oxygens).221 The distances of the three-center
(bifurcated) hydrogen bond are longer, and their angles have typical values (134, 125°) for
intermolecular three-center hydrogen bonds.222 As expected,222,223 the major component of






























Figure 6.1: Molecular plot of 140 showing the atom-labeling scheme and displacement ellip-
soids at the 30% probability level for the non-H atoms. H atoms are depicted as
small circles of arbitrary radii and dashed lines represent hydrogen bonds.219
































Figure 6.2: Molecular plot of 141 showing the atom-labeling scheme and displacement ellip-
soids at the 30% probability level for the non-H atoms. H atoms are depicted as





































Figure 6.3: Molecular plot of 142 showing the atom-labeling scheme and displacement ellip-
soids at the 30% probability level for the non-H atoms. H atoms are depicted as
small circles of arbitrary radii and dashed lines represent hydrogen bonds.219
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Different types of hydrogen bonds were found in compound 141. Besides N–H· · ·O, O–H· · ·O,
and C–H· · ·O bonds, one fluorine of the aromatic ring was incorporated into a hydrogen bond
of type N–H· · ·F. All three ammonium hydrogen atoms are part of hydrogen bonds with
four different tetrafluorohydrogenphthalate molecules. The hydrogen bond network is shown
in Figure 6.2. As in structure 140 two hydrogens are incorporated in two-center N–H· · ·O
hydrogen bonds. In the presented structure 141, both contacts are formed with oxygens of
carboxylate fragments. The HN1B· · ·O2 distance (1.87 Å) is in accordance with literature
value mentioned above,221 but the HN1A· · ·O1 bond is somewhat longer (2.02 Å).
In contrast to 140 and 142, a fluorine atom, i.e., F3 in para-position to the protonated
carboxyl group, is involved in the hydrogen bonding network of structure 141. The hydrogen
atom HN1C is forming a three-center (bifurcated) hydrogen bond to acceptors fluorine F3 and
oxygen O4 from two different tetrafluorohydrogenphthalate molecules. The major component
of this unsymmetrical bifurcated hydrogen bond is directed to the oxygen, as it is more
linear (148° versus 123°) and has a shorter hydrogen-acceptor distance in comparison to the
minor one directed to the fluorine (2.02 Å versus 2.43 Å). There are structures reported
with bifurcated hydrogen bonds to fluorine and oxygen, but the donors/acceptors do not
belong to three different molecules in such cases.196,224 The protonated oxygen O3 of the
carboxyl group is part of an intermolecular O–H· · ·O bond to oxygen O1 of the carboxylate
fragment. Such strong contacts (O· · ·O distance 2.55 Å) were also observed in crystals of
other hydrogenphthalates.220,225–227 Moreover, the carboxyl oxygen O3 accepts a C–H· · ·O
hydrogen bond from a methyl group of the isopropyl ammonium molecule.
In the structure of 142, N–H· · ·O, O–H· · ·O, and C–H· · ·O hydrogen bonds were observed,
all of them being intermolecular (Figure 6.3). As in structures 140 and 142, two two-center
and one three-center N–H· · ·O hydrogen bonds were formed (Table 6.2). The hydrogen-
acceptor distance (1.95 Å) of the two-center hydrogen bond to the carbonyl oxygen of a
protonated carboxyl group (N1–H1A· · ·O1) agreed with published data (mean value 1.94 Å,
between mono-substituted ammonium groups and carboxyl oxygens).221 Again, the bifurcated
hydrogen bond has a major and a minor component. Their H· · ·O distances are longer (2.02,
2.62 Å) and their angles are smaller (152, 126°) compared to the above-mentioned two-center
bond. Further hydrogen bonds were formed with protonated carboxyl groups as donors,
which again can be classified as strong contacts.228 Only the oxygens of the carboxylate
group (O3, O4) are multiple acceptors229 for two hydrogen bonds each, with O and C as
hydrogen donating atoms. Benedict et al. reported on the structure of potassium hydrogen
diphthalatedihydrate where a hydrogen phthalate dimer is bridge by two symmetry-related
H atoms, each with half-site occupancies.230 As discussed above, also 142 can be regarded as
an anomalous acid salt with two dibasic acid molecules per cation. Such anomalous acid salts
have been the objective of studies regarding their solid structure and the nature of hydrogen
bonds.211,212,214
In total four N–H· · ·O hydrogen bonds are directed toward the carboxylate oxygens of 140,
the carboxylate fragment of 142 accepts four hydrogen bonds from N–H or C–H donors,
whereas three hydrogen bonds from O–H or N–H are directed toward the carboxylate oxygens
of 141. Taken together, the three crystal structures of 140, 142 and 141 show different
binding geometries and hydrogen bonding arrangements. Only in the structure of 141, a
fluorine atom acts as a hydrogen bond acceptor.
50 6 Structural Characterization of Salts From Tetrafluorophthalic Acid and Isopropylamine
6.4 Spectroscopic Characteristics
1H and 13C NMR spectra of compounds 140–142 were recorded in DMSO-d6. The 1H NMR
spectra of the three salts are similar, showing the expected signals for the aliphatic protons.
The shifts for the aromatic carbons were assigned on the basis of 13C–19F coupling constants
and substituent increments.231 2JC–F coupling constants for carbons 1 and 2 were 14 and
16 Hz, respectively, and 1JC–F coupling constants for carbons 3–6 were in the range of
236–253 Hz. In all cases, only four different signals for the carbons of the tetrafluorophthalic
acid components appeared in the spectra. Noteworthy, different positions relative to the
protonated or deprotonated carboxyl moieties in 141 and 142 were not reflected, additionally,
the two tetrafluorophthalic acid units of 142 were not distinguishable. This can be attributed
to a rapid proton migration in solution. Similar observations have been made for related
proton transfers in 1,3-dicarbonyl compounds232 and dicarboxylic acids.233
When comparing the salts 140–142, we noticed substantially different 13C chemical shifts
for the CO carbons and for those bearing the COO(H) groups (ipso-C). The values correlate
with the ratio of carboxylate fragments to carboxyl groups. The neutral salt 140 with
exclusively carboxylate fragments provides shifts of 164.5 ppm (CO) and 125.9 ppm (ipso-C),
respectively. The values of the normal acid salt 141 with COO− and COOH in equal amounts
are 163.1 ppm (CO) and 122.2 ppm (ipso-C). A COO−/COOH ratio of 1:3 in the anomalous
salt 142 yields 162.9 ppm (CO) and 120.3 ppm (ipso-C).
The signals of compound 142 are close to the values of tetrafluorophthalic acid. We have
recorded the 13C NMR spectrum of tetrafluorophthalic acid under the same conditions to
obtain chemical shifts in agreement with reported values234 and coupling constants as follows:
118.27 (d, 2JC–F = 15 Hz, C-1/2), 141.33 (dtd, 1JC–F = 254 Hz, 2JC–F = 15 Hz, 3JC–F = 5 Hz,
C-4/5), 144.47 (dd, 1JC–F = 252 Hz, 2JC–F = 10 Hz), 162.8 (CO). Thus, the ipso-carbon
signal in tetrafluorophthalic acid is further upfield shifted by 2.07 ppm, compared to the one
of compound 142. In particular, the value for the ipso-position (substituent increment231 for
COONa: 8.4, for COOH: 2.1) indicates the stoichiometric ratio, whereas the shifts of the
other benzene carbons are inappropriate because of carbon–fluorine couplings.
In accordance with the stoichiometric ratio, the peak intensity of the carbonyl singlet relative
to the aliphatic signals is larger in 141 than in 140. However, similar ratios were observed
for the normal acid (141) and the anomalous salt (142).
Further NMR experiments were performed to characterize the structure of the anomalous acid
salt 142. In solution, only one set of 13C NMR signals was observed and thus, all carboxyl
groups appear to be equivalent. This might be attributed to fast proton transfer processes
which are facilitated by intermolecular N–H· · ·O and O–H· · ·O hydrogen bonds. Due to the
rapid proton migration,232,233 even at lower temperature the corresponding carbons of 142
could not be differentiated by NMR measurements in solution. Spectra of 142 recorded in
MeOD in the range of 293–213 K are given in Figure 6.4. A temperature-dependent shift of
the signals231 occurred, but a splitting of the carbon signals was not observed. Explicitly,
a single resonance for the carboxylate and protonated carboxyl groups, as well as a single
signal for the ipso-carbons remained.
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Anomalous acid salts and proton transfers have been investigated using 13C solid-state NMR
techniques.212,214,232 In the course of our study, solid-state NMR experiments were carried
out by Dr. W. Hoffbauer from the Institute of Inorganic Chemistry, University of Bonn. In
the spectra of 140, 141, and 142 (Figure 6.5), chemical shifts of fluorine-substituted carbons
appear together as broad signals (136–149, 135–149, and 138–151 ppm, respectively). As
expected, the spectrum of bis(isopropylammonium) tetrafluorophthalate (140) did not show
a splitting in the carbon signals, since the corresponding carbons are equivalent.
The anomalous acid salt 142, however, provided a solid-state 13C NMR spectrum significantly
different from that recorded in solution. A splitting into three resonances arising from the
ipso-carbons was observed. Thus, the ipso-carbons (C1, C2) of the tetrafluorohydrogen-
phthalate unit (114.2, 120.3 ppm) became distinguishable from the ipso-carbons (C1′, C2′)
of the tetrafluorophthalic acid component. The signal for the latter two equivalent carbons
(122.3 ppm) could be assigned on the basis of its integration (twofold higher AUC). The
asymmetry of the normal acid salt 141, induced by the different protonation, is also reflected
by two signals for the ipso-carbons. Integration of the corresponding peak areas gave similar
values (3.1 versus 3.6).
Vila et al. studied 1,3-diphenyl-propane-1,3-dione and noticed splitting of the ipso-carbon
and carbonyl carbon signals.232 In contrast, the solid-state 13C NMR spectra of 141 and
142 do not reveal a dissimilarity of the CO carbons, since their signals are not separated.
The occurrence of one common signal for COO− and COOH carbons is in agreement with
the relatively low sensitivity of the 13C isotropic chemical shift to protonation, as can be
explained by relations between main components δ22 and δ11 of the 13C chemical shift
tensor.235 However, as a matter of principle, such a differentiation is possible. Ilczyszyn
et al. have determined the structure of a sarcosine–maleic acid (1:1) complex by X-ray
diffraction and distinguished the charged and uncharged carboxyl(ate) groups by means
of solid-state 13C NMR spectroscopy.236 Barry et al. characterized normal and anomalous
tetramethylammonium salts of dicarboxylic acids and observed different 13C NMR shifts for
nonequivalent carboxyl(ate) carbons in solid state.214 In the cases of 141 and 142, crystal
and bonding forces which influence bond angles and distances and thus the resulting 13C
chemical shift212 might be responsible for a coalescence of the CO signals.
In summary, we have characterized three salts derived from tetrafluorophthalic acid and
isopropylamine. Crystallographic data revealed that a fluorine atom is involved in the
hydrogen bonding network of structure 141. Molecules of the anomalous salt 142 contain a
tetrafluorophthalic acid component and a tetrafluorohydrogenphthalate unit. The compounds
were also characterized by means of solution and solid-state NMR. The ipso-carbons of 141
and 142, whose signals are equivalent in solution, could be distinguished in the solid state,
thus reflecting the asymmetric nature of 141 and the anomalous salt structure of 142.















































































































In this work, different series of ortho-substituted aromatic (thio)ureas and derived heterocycles
were synthesized for various biological testings. The studies included the establishment of
new synthetic routes and the analytical characterization of the target compounds.
A panel of 2-alkylsulfanyl-substituted 4-aminothieno[2,3-d]pyrimidines and 4-aminoquinazo-
lines was devised on the basis of a lead structure that was described as a modulator of
the ABC transporter P-glycoprotein. As depicted in Scheme 7.1, the synthesis of new
representatives included the preparation of various N -benzoyl-N ′-(o-cyanoaryl)thioureas from
aromatic o-aminonitriles and their subsequent transformation with different alkyl halides.
In addition to the confirmation of structure and purity, 13C signals of the heterocycles were
assigned on the basis of two-dimensional NMR experiments. The substances were evaluated for
their ability to affect P-glycoprotein in the group of Prof. Dr. M. Wiese. At first, daunorubicin
accumulation was measured in human ovarian cancer cells that overexpressed the drug-efflux
transporter. In accordance with the lead compound, most (hetero)fused 4-aminopyrimidines
activated daunorubicin efflux from the cells. Additionally, a bidirectional modulation of
P-glycoprotein activity could be demonstrated by the combination of different cytostatics and
selected compounds in cell viability measurements. The cells showed an increased resistance
to daunorubicin, while, in contrast, a potentiation of vinblastine cytotoxicity was observed.
In a second project, the cyclization of N -benzoyl-N ′-(o-cyanoaryl)thioureas with ethyl
bromoacetate under alkaline conditions was examined in detail. Optimized reaction con-
ditions were elaborated for the selective preparation of either fused 4-aminopyrimidines
or 2-(benzoylimino)thiazolidin-4-ones (Scheme 7.1). Again, a small library of the latter
heterocycles was generated from the aforementioned intermediates. Atropisomerism in the
thiazolidin-4-ones was found to be influenced by the size of the o-cyanoaryl ring. This
phenomenon was investigated by means of NMR measurements and X-ray crystallography
and further supported by theoretical calculations. In contrast to (o-cyanothienyl)-substituted
thiazolidin-4-ones, (o-cyanophenyl)-substituted derivatives cannot overcome internal rota-
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Scheme 7.1: Preparation of (hetero)fused 2-alkylsulfanyl-4-aminopyrimidines 17–41 and
2-(benzoylimino)-3-(o-cyanoaryl)thiazolidin-4-ones 42–49.
The development of new inhibitors of multidrug resistance-associated protein 1 in collabora-
tion with the group of Prof. Dr. M. Wiese was another main objective of the dissertation.
On the basis of an initial screening, four series of aromatic benzoic and thiophenecarboxylic
acids with a substituted urea or thiourea moiety at the neighboring position to the car-
boxyl group were provided. In addition to compounds from the substance library of our
group, new (hetero)aromatic carboxylic acids were synthesized. This included the appli-
cation of novel synthetic routes, such as the N,N ′-carbonyldiimidazole-based conversion of
anthranilic acids to 2-(3,3-dialkyl)ureidobenzoic acids or the direct saponification of methyl
2-thioureidobenzoates and ethyl 2-thioureidothiophene-3-carboxylates to the corresponding
carboxylic acids (Scheme 7.2 and Scheme 7.3).
In the group of Prof. Dr. M. Wiese, the four different compound series were evaluated as
inhibitors of multidrug resistance-associated protein 1 and selected substances were examined
toward P-glycoprotein and breast cancer resistance protein to assess selectivity. Two 2-thio-
ureidobenzo[b]thiophene-3-carboxylic acids were identified as particularly potent inhibitors of
the former efflux transporter with IC50 values of around 1 µM. Additionally, structure–activity
relationships were derived from the biological data. The essential components of this new
family of nontoxic multidrug resistance-associated protein 1 inhibitors are a carboxyl group
at a (hetero)aromatic scaffold with a (thio)urea function in ortho-position (Scheme 7.2). The
terminal nitrogen of the (thio)urea should be disubstituted, preferentially with two alkyl
groups. The (hetero)aromatic ring consists of benzene or thiophene, while an additional fused










































Scheme 7.2: Novel synthetic pathways to aromatic o-(thio)ureidocarboxylic acids (left) and
structural features for the inhibition of multidrug resistance-associated protein 1
(right).
Different routes that were explored to produce 2-sec-amino-4H -3,1-benzothiazin-4-ones are
shown in Scheme 7.3. Those compounds were accessible from the aforementioned methyl
2-thioureidobenzoates as well as the corresponding carboxylic acids. The preparation of
2-(methylthio)-4H -3,1-benzothiazin-4-one from anthranilic acid was accomplished by a two-
step procedure. Its direct conversion to 2-sec-amino-4H -3,1-benzothiazin-4-ones failed,
however, a ring-opening reaction to novel 2-thioureidobenzamides was found, which on their
own proved to be further precursors to the target compounds. In addition, interconversion
pathways were elucidated, for example, by isolation and characterization of intermediates. In
the course of this study, biological activities of 4H -3,1-benzothiazin-4-ones were evaluated on
a panel of eight proteases and esterases in our group. 2-(N -Cyclohexyl-N -methylamino)- and
2-(methylthio)-4H -3,1-benzothiazin-4-one were identified as selective inhibitors of cathepsin L
and human leukocyte elastase, respectively.
Another project focused on the structural characterization of three related salts derived
from tetrafluorophthalic acid and isopropylamine. Among them, an anomalous salt with two
dibasic acid molecules per cation was identified (Figure 7.1). Data from X-ray crystallography
were employed to describe geometrical arrangements as well as hydrogen-bonding networks
of the salts. In the crystal structure of isopropylammonium tetrafluorohydrogenphthalate,
an aromatic carbon-bound fluorine was incorporated into a N–H· · ·F hydrogen bond. The
compounds were furthermore characterized by means of solution and solid-state NMR spec-
troscopy. In the solid-state spectra of two salts, a signal splitting of the ipso-carbons bearing
the carboxyl/carboxylate groups occurred. This observation was in agreement with the anoma-
lous salt structure of isopropylammonium tetrafluorohydrogenphthalate × tetrafluorophthalic
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Figure 7.1: Different salts derived from tetrafluorophthalic acid and isopropylamine.
59
Major parts of the results presented herein were published in the following articles:
Pietsch, M.; Häcker, H.-G.; Schnakenburg, G.; Hoffbauer, W.; Nieger, M.; Gütschow, M. Struc-
tural characterization of two salts derived from tetrafluorophthalic acid and isopropylamine.
J. Mol. Struct. 2008, 878, 131–138.
Leyers, S.; Häcker, H.-G.; Wiendlocha, J.; Gütschow, M.; Wiese, M. A 4-aminobenzoic acid
derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins.
Bioorg. Med. Chem. Lett. 2008, 18, 4761–4763.
Häcker, H.-G.; Grundmann, F.; Lohr, F.; Ottersbach, P. A.; Zhou, J.; Schnakenburg, G.;
Gütschow, M. 2-Amino- and 2-alkylthio-4H -3,1-benzothiazin-4-ones: synthesis, interconver-
sion and enzyme inhibitory activities. Molecules 2009, 14, 378–402.
Häcker, H.-G.; Elsinghorst, P. W.; Michels, S.; Daniels, J.; Schnakenburg, G.; Gütschow, M.
2-(Benzoylimino)thiazolidin-4-ones: formation by an alternative ring closure and analysis of
rotational barriers. Synthesis 2009, 1195–1203.
Häcker, H.-G.; Leyers, S.; Wiendlocha, J.; Gütschow, M.; Wiese, M. Aromatic 2-(thio)ureido-
carboxylic acids as a new family of modulators of multidrug resistance-associated protein 1:
synthesis, biological evaluation, and structure–activity relationships. J. Med. Chem. 2009,
52, 4586–4595.
Häcker, H.-G.; Schnakenburg, G.; Hoffbauer, W.; Daniels, J.; Pietsch, M.; Gütschow, M. Iso-
propylammonium tetrafluorohydrogenphthalate: structural characterization and comparison
to two related salts with different stoichiometric ratios. J. Mol. Struct. 2009, 934, 23–27.
Häcker, H.-G.; de la Haye, A.; Sterz, K.; Schnakenburg, G.; Wiese, M.; Gütschow, M. Analogs
of a 4-aminothieno[2,3-d]pyrimidine lead (QB13) as modulators of P-glycoprotein substrate




8.1 General Methods and Materials
Thin-layer chromatography was carried out on Merck aluminum sheets, silica gel 60 F254.
Preparative column chromatography was performed on Merck silica gel 60 (70–230 mesh).
Melting points were determined on a Boëtius hot stage microscope apparatus (PHMK,
VEB Wägetechnik Rapido, Radebeul, Germany). IR spectra were obtained on a Bruker
Tensor 27 FT-IR spectrometer.
1H NMR (500 MHz) and 13C NMR spectra (125 MHz) were recorded on a Bruker Avance
DRX 500 in CDCl3 at 298 K, in DMSO-d6 at 303 K, or in MeOD at different temperatures.
Chemical shifts δ are given in ppm referring to the signal center using the solvent peaks
for reference: CDCl3 7.26/77.0 ppm, DMSO-d6 2.49/39.7 ppm, MeOD 3.35/49.3 ppm. To
characterize spin multiplicities, the following abbreviation were used within the compounds
descriptions: s, singlet; d, doublet; t, triplet; q, quartet; quint, quintet; sept, septet. Broadened
signals are designated as br.
Solid-state, magic-angle spinning (MAS) NMR experiments were carried out by Dr. W. Hoff-
bauer (Institute of Inorganic Chemistry, University of Bonn) on a Varian Infinity+ spec-
trometer equipped with a commercial 4 mm MAS-NMR double-resonance probe. The
magnetic field strength was 9.4 T corresponding to a 13C and 1H resonance frequency of
100.98 and 401.52 MHz, respectively. The 13C MAS-NMR spectra were acquired with a
ramped 13C{1H} cross-polarization experiment. The spectra shown were obtained in 1 h
with a repetition delay of 5 s at rt. At 12 kHz spinning frequency the 13C pulse lengths was
2.5 µs, 100 kHz spectral width and 800 transients. A line broadening of 50 Hz was used in
data processing. The 13C chemical shifts refer to tetramethylsilane. Values for the spectral
parameters (integral, full width half maximum) were achieved from the least square fitting of
the experimental spectrum by the spectrometer software.




Crystal structure data were collected on a Nonius KappaCCD diffractometer equipped with a
low-temperature device (Cryostream, Oxford Cryosystems) at the Institute of Inorganic Chem-
istry, University of Bonn. The structures were solved by Dr. J. Daniels (17, 42, 48, 106, 141),
Dr. M. Nieger (142), and Dr. G. Schnakenburg (36, 43, 126, 140). For all compounds, a sum-
mary of data collection, structure refinement, and the corresponding CCDC-number is given in
the Appendix. The supplementary crystallographic data can be obtained free of charge from
the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
Solvents and reagents were obtained from Acros (Geel, Belgium), Alfa Aesar (Karlsruhe,
Germany), Fluka (Taufkirchen, Germany), Merck Schuchardt (Hohenbrunn, Germany), or
Sigma-Aldrich (Steinheim, Germany).
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M = 124.16 g/mol
Compound 1 was prepared by a method according to Hallas and Towns.84 Diethylamine (3.18 g,
4.48 mL, 44.0 mmol) was slowly added to a stirred, ice-cooled suspension of 1,4-dithiane-
2,5-diol (3.00 g, 19.0 mmol) and malononitrile (2.61 g, 39.0 mmol) in MeOH (50 mL). The
mixture was stirred at 0 ℃ for further 15 min. After evaporation of the solvent, the crude
material was recrystallized from PhMe to give 1 as orange prisms; yield: 2.60 g (54%), mp
102–104 ℃ (PhMe; lit.84 103.5–104 ℃).
1H NMR (500 MHz, DMSO-d6) δ 6.37 (d, J = 5.8 Hz, 1H, 4/5-H), 6.70 (d, J = 5.7 Hz, 1H,
4/5-H), 7.05 (br s, 2H; NH2).
13C NMR (125 MHz, DMSO-d6) δ 83.40 (C-3), 108.76 (C-4/5), 116.56 (CN), 125.63 (C-4/5),
165.23 (C-2).
Anal. Calcd for C5H4N2S: C, 48.37; H, 3.25; N, 22.56. Found: C, 48.54; H, 3.21; N, 22.63.
2-Aminothiophene-3-carbonitriles 2–6; General Procedure
Compounds 2–6 were prepared by a procedure described by Gewald et al.81 Diethylamine
(7.10 g, 10.0 mL, 97.1 mmol) was added within 10 min to a stirred mixture of the appropriate
ketone (100 mmol), malononitrile (6.61 g, 100 mmol) and sulfur (3.21 g, 100 mmol) in EtOH
(50 mL). If temperature raised above 50 ℃ the mixture was cooled with an ice bath. After
3 h the reaction mixture was poured into water (150 mL) and cooled to 5 ℃. The precipitate






M = 152.22 g/mol
Conversion of butan-2-one according to the aforementioned procedure gave 2 as orange
needles; yield: 3.54 g (24%), mp 138–140 ℃ (EtOH; lit.81 141–142 ℃).
1H NMR (500 MHz, DMSO-d6) δ 1.93 (s, 3H, CH3), 2.06 (s, 3H, CH3), 6.82 (br s, 2H,
NH2).
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13C NMR (125 MHz, DMSO-d6) δ 12.17 (CH3), 12.59 (CH3), 85.61 (C-3), 113.80 (C-4/5),
116.72 (CN), 128.54 (C-4/5), 162.03 (C-2).





M = 164.23 g/mol
Conversion of cyclopentanone gave 3 as pale yellow needles; yield: 6.90 g (42%), mp 150–151℃
(EtOH; lit.237 154 ℃).
1H NMR (500 MHz, DMSO-d6) δ 2.25 (quint, J = 7.3 Hz, 2H, 5-H), 2.55 (tt, J = 7.3, 1.9 Hz,
2H, 4/6-H), 2.64 (tt, J = 7.3, 1.9 Hz, 2H, 4/6-H), 6.98 (br s, 2H, NH2).
13C NMR (125 MHz, DMSO-d6) δ 26.88 (C-4–6), 28.14 (C-4–6), 29.03 (C-4–6), 79.00 (C-3),
116.55 (CN), 121.51 (C-6a), 141.14 (C-3a), 168.74 (C-2).





M = 178.25 g/mol
Conversion of cyclohexanone gave 4 as white needles; yield: 14.1 g (79%), mp 144–145 ℃
(EtOH; lit.81 147–148 ℃).
1H NMR (500 MHz, DMSO-d6) δ 1.64–1.73 (m, 4H, 5/6-H), 2.30–2.34 (m, 2H, 4/7-H),
2.37–2.41 (m, 2H, 4/7-H), 6.89 (br s, 2H, NH2).
13C NMR (125 MHz, DMSO-d6) δ 21.95 (C-4–7), 23.11 (C-4–7), 23.63 (C-4–7), 24.16 (C-4–7),
83.44 (C-3), 116.28 (C-7a/CN), 117.00 (C-7a/CN), 131.25 (C-3a), 162.86 (C-2).
Anal. Calcd for C9H10N2S: C, 60.64; H, 5.65; N, 15.72. Found: C, 60.04; H, 5.63; N, 15.45.





O M = 180.23 g/mol
Conversion of tetrahydro-4H -pyran-4-one gave 5 as pale yellow prisms; yield: 15.3 g (85%),
mp 238–240 ℃ (decomposition).
1H NMR (500 MHz, DMSO-d6) δ 2.42 (tt, J = 5.7, 1.9 Hz, 2H, 4-H), 3.81 (t, J = 5.7 Hz,
2H, 5-H), 4.41 (t, J = 1.9 Hz, 2H, 7-H), 7.07 (br s, 2H, NH2).
13C NMR (125 MHz, DMSO-d6) δ 24.70 (C-4), 63.82 (C-5/7), 63.92 (C-5/7), 83.03 (C-3),
114.62 (C-7a/CN), 115.87 (C-7a/CN), 129.31 (C-3a), 163.70 (C-2).








M = 269.36 g/mol
Conversion of N -benzyl-4-piperidone gave 6 as yellow prisms; yield: 20.1 g (75%), mp
155–156 ℃ (EtOH; lit.238 147–150 ℃).
1H NMR (500 MHz, DMSO-d6) δ 2.41 (t, J = 5.7 Hz, 2H, 4-H), 2.68 (t, J = 6.0 Hz, 2H,
5-H), 3.28 (t, J = 1.9 Hz, 2H, 7-H), 3.62 (s, 2H, CH2Ph), 6.99 (br s, 2H, NH2), 7.21–7.28 (m,
1H, 4′-H), 7.30–7.34 (m, 4H, 2′/3′/5′/6′-H).
13C NMR (125 MHz, DMSO-d6) δ 24.33 (C-4), 49.13 (C-5/7), 50.43 (C-5/7), 61.84 (CH2Ph),
82.92 (C-3), 114.68 (C-7a), 116.08 (CN), 127.16 (C-4′), 128.37 (C-2′/3′/5′/6′), 128.87 (C-
2′/3′/5′/6′), 130.01 (C-3a′), 138.44 (C-1′), 163.43 (C-2).




M = 118.14 g/mol






M = 178.19 g/mol
This compound was obtained from Fluka (Taufkirchen, Germany).
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8.3 N-Benzoyl-N ’-(o-cyanoaryl)thioureas
N-Benzoyl-N ′-(o-cyanoaryl)thioureas 9–16; General Procedure
Benzoyl chloride (8.43 g, 6.96 mL, 60.0 mmol) was added dropwise to a stirred solution
of NH4SCN (5.18 g, 68.0 mmol) in anhydrous acetone (20 mL) at 0 ℃. The mixture was
refluxed for 5 min and then cooled to rt, and the precipitated NH4Cl was removed by suction
filtration. Subsequently, the resulting BzNCS solution was cooled (ice) and a solution of
the appropriate (o-aminoaryl)carbonitrile (1–8, 50.0 mmol) in acetone was added dropwise.
Upon complete addition, the reaction mixture was allowed to warm to rt and stirred for
3 h. The precipitated product was collected by filtration and washed with acetone (−20 ℃,
30 mL). Additional substance was obtained by cooling the remaining solution overnight (8 ℃).









2′ M = 278.36 g/mol
Pale yellow solid; yield: 11.9 g (83%); mp 199–202 ℃; RF = 0.56 (petroleum ether–EtOAc,
2:1). IR (KBr): 3231, 3114, 2217, 1673 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 7.28 (d, J = 5.7 Hz, 1H, 4′/5′-H), 7.33 (d, J = 5.7 Hz, 1H,
4′/5′-H), 7.53–7.57 (m, 2H, 3/5-H), 7.66–7.69 (m, 1H, 4-H), 8.00–8.02 (m, 2H, 2/6-H), 12.26
(br s, 1H, NH), 14.50 (br s, 1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 97.10 (C-3′), 114.20 (CN), 120.04 (C-4′/5′), 124.64 (C-
4′/5′), 128.60 (C-2/3/5/6), 129.06 (C-2/3/5/6), 131.65 (C-1), 133.64 (C-4), 150.07 (C-2′),
169.51 (CO), 176.09 (CS).











M = 315.41 g/mol
Off-white solid; yield: 12.9 g (82%); mp 208–210 ℃ (lit.85 208–210 ℃); RF = 0.59 (toluene–
EtOAc, 4:1). IR (KBr): 3274, 2917, 2217, 1672 cm−1.
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1H NMR (500 MHz, DMSO-d6) δ 2.16 (s, 3H, CH3), 2.28 (s, 3H, CH3), 7.53–7.58 (m, 2H,
3/5-H), 7.65–7.71 (m, 1H, 4-H), 7.97–8.03 (m, 2H, 2/6-H), 12.19 (br s, 1H, NH), 14.40 (br s,
1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 12.18 (CH3), 12.26 (CH3), 99.13 (C-3′), 114.14 (CN),
126.17 (C-4′/5′), 128.60 (C-2/3/5/6), 128.98 (C-4′/5′), 129.06 (C-2/3/5/6), 131.68 (C-1),
133.63 (C-4), 145.96 (C-2′), 169.57 (CO), 175.43 (CS).










2′ M = 327.42 g/mol
Pale yellow solid; yield: 15.3 g (93%); mp 213–214 ℃; RF = 0.71 (toluene–EtOAc, 4:1).
IR (KBr): 2859, 2216, 1670 cm−1.
1H NMR (500 MHz, CDCl3) δ 2.49 (quint, J = 7.3 Hz, 2H, 5′-H), 2.90 (tt, J = 7.3, 1.6 Hz,
2H, 4′-H), 2.95 (tt, J = 7.3, 1.6 Hz, 2H, 6′-H), 7.56–7.60 (m, 2H, 3/5-H), 7.68–7.72 (m, 1H,
4-H), 7.95–7.80 (m, 2H, 2/6-H), 9.14 (br s, 1H, NH), 14.20 (br s, 1H, NH).
13C NMR (125 MHz, CDCl3) δ 28.08 (C-4′/5′), 28.11 (C-4′/5′), 29.55 (C-6′), 94.42 (C-3′),
113.97 (CN), 127.72 (C-2/3/5/6), 129.30 (C-2/3/5/6), 130.88 (C-1), 134.14 (C-4), 136.32
(C-6a′), 141.69 (C-3a′), 151.58 (C-2′), 167.08 (CO), 173.90 (CS).










2′ M = 341.45 g/mol
Yellow solid; yield: 15.9 g (93%); mp 219–220 ℃ (lit.85 214–216 ℃); RF = 0.89 (toluene–
EtOAc, 4:1). IR (KBr): 3289, 2921, 2212, 1670 cm−1.
1H NMR (500 MHz, CDCl3) δ 1.79–1.86 (m, 4H, 5′/6′-H), 2.62–2.68 (m, 4H, 4′/7′-H), 7.51–
7.55 (m, 2H, 3/5-H), 7.63–7.66 (m, 1H, 4-H), 7.90–7.93 (m, 2H, 2/6-H), 9.12 (br s, 1H, NH),
14.16 (br s, 1H, NH).
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13C NMR (125 MHz, CDCl3) δ 22.01 (C-4′–7′), 22.99 (C-4′–7′), 23.86 (C-4′–7′), 24.07 (C-4′–7′),
98.61 (C-3′), 113.71 (CN), 127.68 (C-2/3/5/6), 129.23 (C-2/3/5/6), 129.75 (C-7a′), 130.79
(C-1/3a′), 131.80 (C-1/3a′), 134.07 (C-4), 146.83 (C-2′), 167.04 (CO), 174.02 (CS).












M = 343.42 g/mol
Pale yellow solid; yield: 16.7 g (97%); mp 218–220 ℃; RF = 0.66 (toluene–EtOAc, 4:1).
IR (KBr): 3312, 2841, 2217, 1672 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 2.67 (tt, J = 5.7, 1.6 Hz, 2H, 4′-H), 3.89 (t, J = 5.7 Hz,
2H, 5′-H), 4.66 (t, J = 1.6 Hz, 2H, 7′-H), 7.53–7.57 (m, 2H, 3/5-H), 7.66–7.70 (m, 1H, 4-H),
7.99–8.02 (m, 2H, 2/6-H), 12.25 (br s, 1H, NH), 14.48 (br s, 1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 23.90 (C-4′), 63.86 (C-5′/7′), 63.91 (C-5′/7′), 96.85 (C-3′),
113.36 (CN), 126.66 (C-7a′), 128.60 (C-2/3/5/6), 129.06 (C-3a′), 129.08 (C-2/3/5/6), 131.64
(C-1), 133.66 (C-4), 148.08 (C-2′), 169.60 (CO), 175.64 (CS).













M = 432.56 g/mol
Off-white solid; yield: 19.3 g (89%); mp 138–140 ℃; RF = 0.56 (petroleum ether–EtOAc,
2:1). IR (KBr): 3287, 2830, 2219, 1668 cm−1.
1H NMR (500 MHz, CDCl3) δ 2.76 (t, J = 5.4 Hz, 2H, 4′-H), 2.84 (t, J = 5.6 Hz, 2H, 5′-H),
3.55 (t, J = 1.6 Hz, 2H, 7′-H), 3.71 (s, 2H, CH2Ph), 7.25–7.28 (m, 1H, 4′′-H), 7.31–7.35 (m,
4H, 2′′/3′′/5′′/6′′-H), 7.51–7.55 (m, 2H, 3/5-H), 7.63–7.66 (m, 1H, 4-H), 7.90–7.93 (m, 2H,
2/6-H), 9.16 (br s, 1H, NH), 14.23 (br s, 1H, NH).
13C NMR (125 MHz, CDCl3) δ 24.07 (C-4′), 49.39 (C-5′/7′), 50.72 (C-5′/7′), 61.69 (CH2Ph),
98.01 (C-3′), 113.48 (CN), 127.21 (C-7a′/4′′), 127.41 (C-7a′/4′′), 127.72 (C-2/3/5/6), 128.44
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(C-2′′/3′′/5′′/6′′), 129.03 (C-2′′/3′′/5′′/6′′), 129.26 (C-2/3/5/6), 130.36 (C-3a′), 130.74 (C-1),
134.15 (C-4), 137.69 (C-1′′), 147.64 (C-2′), 167.16 (CO), 174.07 (CS).











M = 281.33 g/mol
White solid; yield: 11.1 g (79%); mp 169–172 ℃ (lit.239 172–173 ℃); RF = 0.64 (toluene–
EtOAc, 4:1). IR (KBr): 3120, 2229, 1675 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 7.48–7.52 (m, 1H, 4′/5′/6′-H), 7.53–7.57 (m, 2H, 3/5-H),
7.65–7.69 (m, 1H, 4-H), 7.74–7.80 (m, 2H, 4′/5′/6′-H), 7.89–7.91 (m, 1H, 3′-H), 7.99–8.03 (m,
2H, 2/6-H), 11.85 (br s, 1H, NH), 12.56 (br s, 1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 110.64 (C-2′), 116.56 (CN), 127.90 (C-3′–6′), 128.64
(C-2/3/5/6), 128.93 (C-2/3/5/6), 132.03 (C-1), 133.24 (C-3′–6′), 133.45 (C-3′–6′), 133.85
(C-4), 141.32 (C-1′), 168.37 (CO), 181.54 (CS).












M = 341.38 g/mol
Yellow solid; yield: 16.4 g (96%); mp 201–204 ℃; RF = 0.55 (toluene–EtOAc, 4:1). IR (KBr):
3073, 2229, 1761, 1676 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 3.83 (s, 3H, CH3), 3.83 (s, 3H, CH3), 7.40 (s, 1H, 3′/5′-H),
7.42 (s, 1H, 3′/5′-H), 7.53–7.57 (m, 2H, 3/5-H), 7.65–7.69 (m, 1H, 4-H), 7.98–8.01 (m, 2H,
2/6-H), 11.83 (br s, 1H, NH), 12.47 (br s, 1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 56.28 (CH3), 56.31 (CH3), 101.58 (C-2′), 111.83 (C-
3′/6′/CN), 114.38 (C-3′/6′/CN), 116.86 (C-3′/6′/CN), 128.64 (C-2/3/5/6), 128.89 (C-2/3/5/6),
132.06 (C-1), 133.43 (C-4), 135.90 (C-1′), 147.77 (C-4′/5′), 152.66 (C-4′/5′), 168.50 (CO),
181.57 (CS).
Anal. Calcd for C17H15N3O3S: C, 59.81; H, 4.43; N, 12.31. Found: C, 59.79; H, 4.64; N,
12.18.
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8.4 4-Aminothieno[2,3-d ]pyrimidines and 4-Aminoquinazolines
Thieno[2,3-d ]pyrimidines 17–37, and Quinazolines 38–41; General Procedure
The appropriate N -benzoyl-N ′-(o-cyanoaryl)thiourea (9–16, 3.00 mmol) was heated under
reflux for 30 min in a mixture of EtOH (3.0 mL) and NaOH (1 M, 7.5 mL). The solution was
cooled to rt and the appropriate alkyl halide (3.60 mmol, 1.2 equiv) was slowly added. After
1 h, the solid was removed by suction filtration, washed with H2O (100 mL) and dried under
reduced pressure. Pure material was obtained by recrystallization from EtOH, if not stated
otherwise.







M = 269.34 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-2-thienyl)thiourea (9) and ethyl bromoacetate gave 17
as colorless plates; yield: 468 mg (58%); mp 116–117 ℃ (EtOH); RF = 0.45 (petroleum
ether–EtOAc, 2:1). IR (KBr): 3388, 3162, 2903, 1735, 1647 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 1.19 (t, J = 7.1 Hz, 3H, CH2CH3), 3.95 (s, 2H, SCH2),
4.11 (q, J = 7.1 Hz, 2H, CH2CH3), 7.37 (d, J = 6.0 Hz, 1H, 5′/6′-H), 7.47 (d, J = 6.0 Hz,
1H, 5′/6′-H), 7.57 (br s, 2H, NH2).
13C NMR (125 MHz, DMSO-d6) δ 14.23 (CH2CH3), 32.82 (SCH2), 60.88 (CH2CH3), 113.23
(C-4a′), 119.69 (C-5′/6′), 120.69(C-5′/6′) , 158.06 (C-7a′), 164.46 (C-2′), 166.89 (C-4′), 169.36
(CO).








M = 225.33 g/mol








M = 239.36 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-4,5-dimethyl-2-thienyl)thiourea (10) and ethyl bromide
gave 19 as colorless plates; yield: 366 mg (51%); mp 216–218 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 1.28 (t, J = 7.4 Hz, 3H, CH2CH3), 2.32 (s, 3H, CH3), 3.35
(s, 3H, CH3), 3.04 (q, J = 7.3 Hz, 2H, CH2CH3), 6.88 (br s, 2H, NH2).
13C NMR (125 MHz, DMSO-d6) δ 12.95 (CH3), 13.91 (CH3), 14.96 (CH2CH3), 24.21
(CH2CH3), 113.33 (C-4a), 124.79 (C-5/6), 125.82 (C-5/6), 157.90 (C-7a), 164.26 (C-2),
165.68 (C-4).







M = 255.36 g/mol
Compound was taken from the substance library.








M = 297.40 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-4,5-dimethyl-2-thienyl)thiourea (10) and ethyl bromoac-
etate gave 21 as colorless plates; yield: 375 mg (42%); mp 149–151 ℃ (EtOH; lit.109
148–151 ℃); RF = 0.17 (toluene–EtOAc, 4:1). IR (KBr): 3506, 3298, 3140, 2978, 1733,
1644 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 1.18 (t, J = 7.1 Hz, 3H, CH2CH3), 2.33 (s, 3H, CH3), 2.35
(s, 3H, CH3), 3.93 (s, 2H, SCH2), 4.10 (q, J = 7.1 Hz, 2H, CH2CH3), 6.98 (br s, 2H, NH2).
8.4 4-Aminothieno[2,3-d ]pyrimidines and 4-Aminoquinazolines 73
13C NMR (125 MHz, DMSO-d6) δ 12.95 (CH3), 13.89 (CH3), 14.25 (CH2CH3), 32.75 (SCH2),
60.88 (CH2CH3), 113.49 (C-4a′), 124.82 (C-5′/6′), 126.23 (C-5′/6′), 157.91 (C-7a′), 162.97
(C-2′), 165.40 (C-4′), 169.38 (CO).








M = 315.46 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-4,5-dimethyl-2-thienyl)thiourea (10) and phenethyl bro-
mide gave 22 as colorless needles; yield: 300 mg (32%); mp 166–167 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 2.33 (s, 3H, CH3), 2.36 (s, 3H, CH3), 2.93 (t, J = 7.7 Hz,
2H, CH2), 3.29 (t, J = 7.7 Hz, 2H, CH2), 6.91 (br s, 2H, NH2), 7.18–7.22 (m, 1H, 4′-H),
7.26–7.32 (m, 4H, 2′/3′/5′/6′-H).
13C NMR (125 MHz, DMSO-d6) δ 12.96 (CH3), 13.93 (CH3), 31.44 (CH2), 35.44 (CH2),
113.39 (C-4a), 124.82 (C-5/6), 125.90 (C-5/6), 126.31 (C-4′), 128.44 (C-2′/3′/5′/6′), 128.73
(C-2′/3′/5′/6′), 140.67 (C-1′), 157.93 (C-7a), 164.07 (C-2), 165.69 (C-4).









M = 329.44 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-4,5-dimethyl-2-thienyl)thiourea (10) and phenacyl bro-
mide gave 23 as colorless needles; yield: 830 mg (84%); mp 154–156 ℃ (EtOH; lit.85
152–153 ℃).
1H NMR (500 MHz, DMSO-d6) δ 2.30 (s, 3H, CH3), 3.34 (s, 3H, CH3), 4.70 (s, 2H, SCH2),
6.92 (br s, 2H, NH2), 7.52–7.57 (m, 2H, 3′′/5′′-H), 7.63–7.68 (m, 1H, 4′′-H), 8.02–8.05 (m,
2H, 2′′/6′′-H).
74 8 Experimental
13C NMR (125 MHz, DMSO-d6) δ 12.93 (CH3), 13.87 (CH3), 37.69 (SCH2), 113.46 (C-4a′),
124.78 (C-5′/6′), 126.16 (C-5′/6′), 128.42 (C-2′′/3′′/5′′/6′′), 128.83 (C-2′′/3′′/5′′/6′′), 133.42
(C-4′′), 136.43 (C-1′′), 157.87 (C-7a′), 163.08 (C-2′), 165.36 (C-4′), 194.89 (CO).
Anal. Calcd for C16H15N3OS2: C, 58.33; H, 4.59; N, 12.76. Found: C, 58.34; H, 4.47; N,
12.62.









M = 345.44 g/mol
Compound was taken from the substance library.
1H NMR (500 MHz, DMSO-d6) δ 2.32 (s, 3H, CH3), 3.34 (s, 3H, CH3), 5.52 (s, 1H, CH),
6.95 (br s, 2H, NH2), 7.24–7.28 (m, 1H, 4′′-H), 7.29–7.34 (m, 2H, 3′′/5′′-H), 7.48–7.52 (m,
2H, 2′′/6′′-H).
13C NMR (125 MHz, DMSO-d6) δ 12.97 (CH3), 13.89 (CH3), 52.69 (CH), 113.51 (C-
4a′), 124.81 (C-5′/6′), 126.17 (C-5′/6′), 127.75 (C-4′′), 128.54 (C-2′′/3′′/5′′/6′′), 128.57 (C-






M = 251.37 g/mol






M = 265.40 g/mol
Compound was taken from the substance library.






M = 281.40 g/mol
Compound was taken from the substance library.







M = 323.43 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)thiourea (12) and
ethyl bromoacetate gave 28 as white needles; yield: 468 mg (48%); mp 139–140 ℃ (EtOH;
lit.109 138–141 ℃); RF = 0.22 (toluene–EtOAc, 4:1). IR (KBr): 3511, 3296, 3130, 2930, 1740,
1632 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 1.18 (t, J = 7.1 Hz, 3H, CH2CH3), 1.75–1.79 (m, 4H,
6′/7′-H), 2.69–2.70 (m, 2H, 5′/8′-H), 2.83–2.84 (m, 2H, 5′/8′-H), 3.93 (s, 2H, CH2), 4.10 (q,
J = 7.1 Hz, 2H, CH2CH3), 6.86 (br s, 2H, NH2).
13C NMR (125 MHz, DMSO-d6) δ 14.26 (CH2CH3), 22.06 (C-6′/7′), 22.37 (C-6′/7′), 24.83
(C-5′/8′), 25.43 (C-5′/8′), 32.76 (SCH2), 60.88 (CH2CH3), 112.45 (C-4a′), 126.96 (C-4b′/8a′),
129.48 (C-4b′/8a′), 157.76 (C-9a′), 163.09 (C-2′), 166.09 (C-4′), 169.37 (CO).







M = 341.49 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)thiourea (12) and
phenethyl bromide gave 29 as white needles; yield: 740 mg (72%); mp 159–162 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 1.77–1.80 (m, 4H, 6/7-H), 2.68–2.72 (m, 2H, 5/8-H),
2.83–2.87 (m, 2H, 5/8-H), 2.93 (t, J = 7.7 Hz, 2H, CH2), 3.29 (t, J = 7.7 Hz, 2H, CH2), 6.91
(br s, 2H, NH2), 7.18–7.22 (m, 1H, 4′-H), 7.27–7.32 (m, 4H, 2′/3′/5′/6′-H).
76 8 Experimental
13C NMR (125 MHz, DMSO-d6) δ 22.09 (C-6/7), 22.40 (C-6/7), 24.85 (C-5/8), 25.47 (C-
5/8), 31.46 (CH2), 35.42 (CH2), 112.32 (C-4a), 126.31 (C-4′), 126.96 (C-4b/8a), 128.44
(C-2′/3′/5′/6′), 128.73 (C-2′/3′/5′/6′), 129.16 (C-4b/8a), 140.66 (C-1′), 157.79 (C-9a), 164.18
(C-2), 166.38 (C-4).









M = 355.48 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)thiourea (12) and
phenacyl bromide gave 30 as white needles; yield: 820 mg (77%); mp 176–179 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 1.75–1.78 (m, 4H, 6′/7′-H), 2.65–2.68 (m, 2H, 5′/8′-H),
2.81–2.85 (m, 2H, 5′/8′-H), 4.70 (s, 2H, SCH2), 6.85 (br s, 2H, NH2), 7.51–7.56 (m, 2H,
3′′/5′′-H), 7.63–7.67 (m, 1H, 4′′-H), 8.02–8.05 (m, 2H, 2′′/6′′-H).
13C NMR (125 MHz, DMSO-d6) δ 22.05 (C-6′/7′), 22.36 (C-6′/7′), 24.81 (C-5′/8′), 25.41
(C-5′/8′), 37.70 (SCH2), 112.40 (C-4a′), 126.91 (C-4b′/8a′), 128.42 (C-2′′/3′′/5′′/6′′), 128.83
(C-2′′/3′′/5′′/6′′), 129.40 (C-4b′/8a′), 133.42 (C-4′′), 136.42 (C-1′′), 157.72 (C-9a′), 163.19
(C-2′), 166.05 (C-4′), 194.89 (CO).











M = 371.48 g/mol
Compound was taken from the substance library.
1H NMR (500 MHz, DMSO-d6) δ 1.75–1.80 (m, 4H, 6′/7′-H), 2.68–2.72 (m, 2H, 5′/8′-H),
2.82–2.86 (m, 2H, 5′/8′-H), 5.55 (s, 1H, CH), 6.91 (br s, 2H, NH2), 7.26–7.32 (m, 1H, 4′-H),
7.33–7.37 (m, 2H, 3′′/5′′-H), 7.47–7.51 (m, 2H, 2′′/6′′-H).
8.4 4-Aminothieno[2,3-d ]pyrimidines and 4-Aminoquinazolines 77
13C NMR (125 MHz, DMSO-d6) δ 22.06 (C-6′/7′), 22.37 (C-6′/7′), 24.85 (C-5′/8′), 25.42 (C-
5′/8′), 52.01 (CH), 112.55 (C-4a′), 126.98 (C-4b′/8a′), 128.09 (C-4′′), 128.55 (C-2′′/3′′/5′′/6′′),
128.76 (C-2′′/3′′/5′′/6′′), 129.57 (C-4b′/8a′), 136.57 (C-1′′), 157.73 (C-9a′), 163.04 (C-2′),









M = 309.41 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-5,6-dihydro-4H -cyclopenta[b]thien-2-yl)thiourea (11) and
ethyl bromoacetate gave 32 as colorless plates; yield: 599 mg (65%); mp 180–182 ℃ (EtOH);
RF = 0.19 (toluene–EtOAc, 4:1). IR (KBr): 3490, 3290, 3119, 2906, 1734, 1641 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 1.18 (t, J = 7.1 Hz, 3H, CH2CH3), 2.34–2.39 (m, 2H,
6′-H), 2.85–2.89 (m, 2H, 5′/7′-H), 2.96–2.99 (m, 2H, 5′/7′-H), 3.94 (s, 2H, SCH2), 4.10 (q,
J = 7.1 Hz, 2H, CH2CH3), 6.96 (br s, 2H, NH2).
13C NMR (125 MHz, DMSO-d6) δ 14.25 (CH2CH3), 27.34 (C-6), 28.81 (C-5/7), 29.11 (C-5/7),
32.81 (SCH2), 60.90 (CH2CH3), 109.55 (C-4a), 134.63 (C-4b/7a), 136.02 (C-4b/7a), 157.39
(C-8a), 163.09 (C-2), 169.38 (CO), 171.42 (C-4).







M = 327.47 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-5,6-dihydro-4H -cyclopenta[b]thien-2-yl)thiourea (11) and
phenethyl bromide gave 33 as white needles; yield: 599 mg (61%); mp 176-177 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 2.35–2.41 (m, 2H, 6-H), 2.85–2.90 (m, 2H, 5/7-H), 2.94 (t,
J = 7.7 Hz, 2H, CH2), 2.96–3.01 (m, 2H, 5/7-H), 3.30 (t, J = 7.7 Hz, 2H, CH2), 6.92 (br s,
2H, NH2), 7.18–7.22 (m, 1H, 4′-H), 7.27–7.31 (m, 4H, 2′/3′/5′/6′-H).
13C NMR (125 MHz, DMSO-d6) δ 27.33 (C-6), 28.83 (C-5/7), 29.12 (C-5/7), 31.48 (CH2),
35.38 (CH2), 109.41 (C-4a), 126.32 (C-4′), 128.44 (C-2′/3′/5′/6′), 128.73 (C-2′/3′/5′/6′),
78 8 Experimental
134.26 (C-4b/7a), 136.03 (C-4b/7a), 140.66 (C-1′), 157.40 (C-8a), 164.20 (C-2), 171.76
(C-4).











M = 325.41 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-4,7-dihydro-5H -thieno[2,3-c]pyran-2-yl)thiourea (13) and
ethyl bromoacetate gave 34 as colorless blocks; yield: 726 mg (74%); mp 192–193 ℃ (EtOH);
RF = 0.40 (toluene–EtOAc, 4:1). IR (KBr): 3489, 3294, 3161, 2968, 1727, 1631 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 1.18 (t, J = 7.1 Hz, 3H, CH2CH3), 2.95 (tt, J = 5.5,
1.9 Hz, 2H, 5′-H), 3.91 (t, J = 5.5 Hz, 2H, 6′-H), 3.95 (s, 2H, SCH2), 4.10 (q, J = 7.1 Hz,
2H, CH2CH3), 4.71 (t, J = 1.9 Hz, 2H, 8′-H), 6.97 (br s, 2H, NH2).
13C NMR (125 MHz, DMSO-d6) δ 14.25 (CH2CH3), 26.02 (C-5), 32.80 (SCH2), 60.90
(CH2CH3), 63.94 (C-6/8), 64.58 (C-6/8), 111.89 (C-4a), 124.86 (C-4b/8a), 127.23 (C-4b/8a),
157.81 (C-9a), 163.60 (C-2), 166.60 (C-4), 169.32 (CO).










M = 343.47 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-4,7-dihydro-5H -thieno[2,3-c]pyran-2-yl)- thiourea (13)
and phenethyl bromide gave 35 as white needles; yield: 488 mg (47%); mp 179–181 ℃
(EtOH).
1H NMR (500 MHz, DMSO-d6) δ 2.92–2.98 (m, 4H, 5-H/CH2), 3.29–3.32 (m, 2H, CH2), 3.92
(t, J = 5.5 Hz, 2H, 6-H), 4.72 (t, J = 1.9 Hz, 2H, 8-H), 6.93 (br s, 2H, NH2), 7.18–7.22 (m,
1H, 4′-H), 7.26–7.32 (m, 4H, 2′/3′/5′/6′-H).
8.4 4-Aminothieno[2,3-d ]pyrimidines and 4-Aminoquinazolines 79
13C NMR (125 MHz, DMSO-d6) δ 26.07 (C-5), 31.48 (CH2), 35.39 (CH2), 63.97 (C-6/8),
64.61 (C-6/8), 111.76 (C-4a), 124.86 (C-4b/8a), 126.33 (C-4′), 126.91 (C-4b/8a), 128.44
(C-2′/3′/5′/6′), 128.73 (C-2′/3′/5′/6′), 140.63 (C-1′), 157.84 (C-9a), 164.69 (C-2), 166.89
(C-4).













M = 414.54 g/mol
Reaction of N -benzoyl-N ′-(6-benzyl-3-cyano-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)thio-
urea (14) and ethyl bromoacetate gave 36 as yellow needles; yield: 611 mg (49%); mp
143–144 ℃ (EtOH); RF = 0.24 (toluene–EtOAc, 4:1). IR (KBr): 3501, 3283, 3107, 2911,
1741, 1634 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 1.19 (t, J = 7.1 Hz, 3H, CH2CH3), 2.77 (t, J = 5.7 Hz,
2H, 5′/6′-H), 2.94 (t, J = 5.7 Hz, 2H, 5′/6′-H), 3.60 (s, 2H, 8′-H), 3.70 (s, 2H, CH2C6H5),
3.96 (s, 2H, SCH2), 4.11 (q, J = 7.1 Hz, 2H, CH2CH3), 6.94 (br s, 2H, NH2), 7.26–7.30 (m,
1H, 4′′-H), 7.33–7.38 (m, 4H, 2′′/3′′/5′′/6′′-H).
13C NMR (125 MHz, DMSO-d6) δ 14.25 (CH2CH3), 25.65 (C-5′), 32.78 (SCH2), 48.97
(C-6′/8′), 51.39 (C-6′/8′), 60.75 (CH2C6H5), 60.89 (CH2CH3), 111.95 (C-4a′), 125.61 (C-
4b′/8a′/4′′), 127.11 (C-4b′/8a′/4′′), 127.23 (C-4b′/8a′/4′′), 128.40 (C-2′′/3′′/5′′/6′′), 128.94
(C-2′′/3′′/5′′/6′′), 138.29 (C-1′′), 157.80 (C-9a′), 163.44 (C-2′), 166.43 (C-4′), 169.33 (CO).











M = 432.60 g/mol
Reaction of N -benzoyl-N ′-(6-benzyl-3-cyano-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)thio-
urea (14) and phenethyl bromide gave 37 as an off-white solid; yield: 323 mg (25%); mp
172–173 ℃ (acetone).
80 8 Experimental
1H NMR (500 MHz, DMSO-d6) δ 2.76 (t, J = 5.7 Hz, 2H, 5/6-H), 2.91–2.96 (m, 4H, 5/6-
H/CH2), 3.30 (t, J = 7.7 Hz, 2H, CH2), 3.59 (s, 2H, 8-H), 3.69 (s, 2H, CH2C6H5), 3.96 (s, 2H,
CH2), 6.88 (br s, 2H, NH2), 7.18–7.22 (m, 1H, 4′-H), 7.26–7.37 (m, 9H, 2′/3′/5′/6′/2′′–6′′-H).
13C NMR (125 MHz, DMSO-d6) δ 25.69 (C-5), 31.47 (CH2), 35.39 (CH2), 49.01 (C-6/8), 51.42
(C-6/8), 60.77 (CH2C6H5), 111.82 (C-4a), 125.62 (C-4b/8a), 126.32 (C-4′), 126.79 (C-4b/8a),
127.23 (C-4′′), 128.41 (C-2′′/3′′/5′′/6′′), 128.44 (C-2′/3′/5′/6′), 128.73 (C-2′/3′/5′/6′), 128.94
(C-2′′/3′′/5′′/6′′), 138.31 (C-1′′), 140.64 (C-1′), 157.82 (C-9a), 164.54 (C-2), 166.72 (C-4).









M = 263.32 g/mol
Reaction of N -benzoyl-N ′-(2-cyanophenyl)thiourea (15) and ethyl bromoacetate gave 38 as
white needles; yield: 438 mg (55%); mp 153–154 ℃ (EtOH; lit.109 151–152 ℃); RF = 0.88
(EtOAc). IR (KBr): 3406, 3173, 2973, 1735, 1646 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 1.19 (t, J = 7.0 Hz, 3H, CH2CH3), 3.98 (s, 2H, SCH2), 4.11
(q, J = 7.0 Hz, 2H, CH2CH3), 7.36 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H, 6′-H), 7.45 (dd, J = 8.2,
1.3 Hz, 1H, 8′-H), 7.69 (ddd, J = 7.9, 7.1, 1.6 Hz, 1H, 7′-H), 7.85 (br s, 2H, NH2), 8.13 (dd,
J = 8.2, 1.6 Hz, 1H, 5′-H).
13C NMR (125 MHz, DMSO-d6) δ 14.26 (CH2CH3), 32.79 (SCH2), 60.86 (CH2CH3), 112.70
(C-4a′), 123.92 (C-5′), 124.55 (C-6′), 126.09 (C-8′), 133.41 (C-7′), 150.04 (C-8a′), 161.34
(C-4′), 165.58 (C-2′), 169.54 (CO).







M = 281.38 g/mol
Reaction of N -benzoyl-N ′-(2-cyanophenyl)thiourea (15) and phenethyl bromide gave 39 as
colorless rhombes; yield: 582 mg (69%); mp 143–146 ℃ (EtOH).
8.4 4-Aminothieno[2,3-d ]pyrimidines and 4-Aminoquinazolines 81
1H NMR (500 MHz, DMSO-d6) δ 2.98 (t, J = 7.7 Hz, 2H, CH2), 3.33 (t, J = 7.8 Hz, 2H,
CH2), 7.19–7.23 (m, 1H, 4′-H), 7.29–7.33 (m, 4H, 2′/3′/5′/6′-H), 7.36 (ddd, J = 8.2, 6.9,
1.3 Hz, 1H, 6-H), 7.54 (dd, J = 8.2, 1.3 Hz, 1H, 8-H), 7.70 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H,
7-H), 7.80 (br s, 2H, NH2), 8.13 (dd, J = 8.2, 1.3 Hz, 1H, 5-H).
13C NMR (125 MHz, DMSO-d6) δ 31.44 (CH2), 35.65 (CH2), 112.72 (C-4a), 123.90 (C-5),
124.30 (C-6), 126.20 (C-8), 126.29 (C-4′), 128.47 (C-2′/3′/5′/6′), 128.74 (C-2′/3′/5′/6′), 133.29
(C-7), 140.88 (C-1′), 150.33 (C-8a), 161.26 (C-4), 166.67 (C-2).









M = 323.37 g/mol
Reaction of N -benzoyl-N ′-(2-cyano-4,5-dimethoxyphenyl)thiourea (16) and ethyl bromoac-
etate gave 40 as white needles; yield: 659 mg (68%); mp 178–181 ℃ (EtOH); RF = 0.27
(toluene–EtOAc, 4:1). IR (KBr): 3108, 2888, 1725, 1661 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 1.20 (t, J = 7.0 Hz, 3H, CH2CH3), 3.01 (s, 3H, OCH3),
3.86 (s, 3H, OCH3), 3.97 (s, 2H, SCH2), 4.12 (q, J = 7.0 Hz, 2H, CH2CH3), 6.87 (s, 1H,
5′/8′-H), 7.51 (br s, 2H, NH2), 7.52 (s, 1H, 5′/8′-H).
13C NMR (125 MHz, DMSO-d6) δ 14.25 (CH2CH3), 32.65 (SCH2), 55.76 (OCH3), 56.09
(OCH3), 60.81 (CH2CH3), 103.34 (C-5′/8′), 105.87 (C-4a′), 106.01 (C-5′/8′), 147.13 (C-6′/7′),
147.56 (C-6′/7′), 154.49 (C-8a′), 160.32 (C-4′), 163.25 (C-2′), 169.66 (CO).









M = 341.43 g/mol
Reaction of N -benzoyl-N ′-(2-cyano-4,5-dimethoxyphenyl)thiourea (16) and phenethyl bro-
mide, followed by recrystallization from MeOH gave 41 as orange needles; yield: 682 mg
(67%); mp 165–167 ℃ (MeOH).
82 8 Experimental
1H NMR (500 MHz, DMSO-d6) δ 2.97 (t, J = 7.7 Hz, 2H, CH2), 3.32 (t, J = 7.7 Hz, 2H,
CH2), 3.83 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 6.95 (s, 1H, 5/8-H), 7.18–7.23 (m, 1H, 4′-H),
7.28–7.33 (m, 4H, 2′/3′/5′/6′-H), 7.46 (br s, 2H, NH2), 7.52 (s, 1H, 5/8-H).
13C NMR (125 MHz, DMSO-d6) δ 31.34 (CH2), 35.57 (CH2), 55.81 (OCH3), 56.08 (OCH3),
103.34 (C-5/8), 105.87 (C-4a), 106.13 (C-5/8), 126.27 (C-4′), 128.45 (C-2′/3′/5′/6′), 128.76
(C-2′/3′/5′/6′), 140.92 (C-1′), 147.43 (C-6/7), 154.46 (C-8a), 160.26 (C-4), 164.46 (C-2).




N-[3-(o-Cyanoaryl)-4-oxo-1,3-thiazolidin-2-ylidene]benzamides 42–49; General Procedure
The appropriate N -benzoyl-N ′-(o-cyanoaryl)thiourea (9–16, 1.00 mmol) was dissolved in a
mixture of EtOH (3.0 mL) and NaOH (1 M, 1.5 mL). The solution was heated to 50 ℃ and
ethyl bromoacetate (200 mg, 133 µL, 1.20 mmol) was added within 1 min. If turbidity was
observed, a few drops of 1 M NaOH were added to prevent precipitation. After heating at
50 ℃ for 1 h, the mixture was cooled to rt and H2O (5 mL) was added. The precipitate was
removed by suction filtration, washed with H2O (50 mL), and dried in vacuo. Pure material












M = 327.38 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-2-thienyl)thiourea (9) and ethyl bromoacetate gave 42
as white needles; yield: 245 mg (71%); mp 191–192 ℃ (EtOH); RF = 0.40 (petroleum
ether–EtOAc, 2:1). IR (KBr): 3111, 2970, 2234, 1755, 1648 cm−1. Material for X-ray
crystallography was recrystallized from EtOAc.
1H NMR (500 MHz, DMSO-d6) δ 4.29 (s, 2H, 5′-H), 7.46–7.51 (m, 2H, 3/5-H), 7.59–7.63 (m,
2H, 4/4′′/5′′-H), 7.93–7.96 (m, 2H, 2/6-H), 7.99 (d, J = 5.7 Hz, 1H, 4′′/5′′-H).
13C NMR (125 MHz, DMSO-d6) δ 33.58 (C-5′), 109.71 (C-3′′), 113.25 (CN), 127.15 (C-4′′/5′′),
128.86 (C-2/3/5/6), 129.52 (C-2/3/5/6), 129.77 (C-4′′/5′′), 133.71 (C-4), 134.61 (C-1), 143.04
(C-2′′), 171.48 (C-2′/CO), 172.66 (C-2′/CO), 176.12 (CO).















M = 355.43 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-4,5-dimethyl-2-thienyl)thiourea (10) and ethyl bromoac-
etate gave 43 as pale yellow plates; yield: 223 mg (63%); mp 218–221 ℃ (EtOH); RF = 0.62
(toluene–EtOAc, 4:1). IR (KBr): 2230, 1751, 1649 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 2.26 (s, 3H, CH3), 2.45 (s, 3H, CH3), 4.27 (s, 2H, 5′-H),
7.48–7.52 (m, 2H, 3/5-H), 7.60–7.62 (m, 1H, 4-H), 7.96–7.98 (m, 2H, 2/6-H).
13C NMR (125 MHz, DMSO-d6) δ 12.56 (CH3), 13.24 (CH3), 33.44 (C-5′), 111.67 (C-3′′),
113.24 (CN), 128.89 (C-2/3/5/6), 129.57 (C-2/3/5/6), 132.05 (C-4′′/5′′), 133.68 (C-4), 134.60
(C-1), 136.16 (C-4′′/5′′), 138.21 (C-2′′), 171.49 (C-2′/CO), 172.41 (C-2′/CO), 176.25 (CO).














M = 367.44 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-5,6-dihydro-4H -cyclopenta[b]thien-2-yl)thiourea (11) and
ethyl bromoacetate gave 44 as colorless needles; yield: 243 mg (66%); mp 175–176 ℃ (EtOH);
RF = 0.49 (petroleum ether–EtOAc, 2:1). IR (KBr): 2934, 2224, 1746, 1654 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 2.40–2.47 (m, 2H, 5′′-H), 2.87–2.92 (m, 2H, 4′′/6′′-H),
3.01–3.06 (m, 2H, 4′′/6′′-H), 4.27 (s, 2H, 5′-H), 7.48–7.51 (m, 2H, 3/5-H), 7.60–7.62 (m, 1H,
4-H), 7.96–7.99 (m, 2H, 2/6-H).
13C NMR (125 MHz, DMSO-d6) δ 27.37 (C-4′′/5′′), 27.82 (C-4′′/5′′), 30.04 (C-6′′), 33.43
(C-5′), 105.62 (C-3′′), 113.08 (CN), 128.87 (C-2/3/5/6), 129.58 (C-2/3/5/6), 133.68 (C-4),
134.57 (C-1), 143.32 (C-2′′/3a′′/6a′′), 143.39 (C-2′′/3a′′/6a′′), 144.16 (C-2′′/3a′′/6a′′), 171.56
(C-2′/CO), 172.43 (C-2′/CO), 176.28 (CO).
8.5 2-(Benzoylimino)thiazolidin-4-ones 85














M = 381.47 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)thiourea (12) and
ethyl bromoacetate gave 45 as colorless plates; yield: 223 mg (58%); mp 194–197 ℃ (EtOH);
RF = 0.76 (toluene–EtOAc, 4:1). IR (KBr): 2934, 2227, 1754, 1642 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 1.82–1.86 (m, 4H, 5′′/6′′-H), 2.65–2.69 (m, 2H, 4′′/7′′-H),
2.80–2.84 (m, 2H, 4′′/7′′-H), 4.27 (s, 2H, 5′-H), 7.48–7.52 (m, 2H, 3/5-H), 7.60–7.64 (m, 1H,
4-H), 7.97–7.99 (m, 2H, 2/6-H).
13C NMR (125 MHz, DMSO-d6) δ 21.54 (C-4′′–7′′), 22.46 (C-4′′–7′′), 23.88 (C-4′′–7′′), 24.35
(C-4′′–7′′), 33.43 (C-5′), 109.84 (C-3′′), 112.77 (CN), 128.88 (C-2/3/5/6), 129.60 (C-2/3/5/6),
133.67 (C-4), 133.98 (C-3a′′), 134.56 (C-1), 138.61 (C-2′′/7a′′), 139.28 (C-2′′/7a′′), 171.43
(C-2′/CO), 172.17 (C-2′/CO), 176.27 (CO).















M = 383.44 g/mol
Reaction of N -benzoyl-N ′-(3-cyano-4,7-dihydro-5H -thieno[2,3-c]pyran-2-yl)thiourea (13) and
ethyl bromoacetate gave 46 as colorless needles; yield: 277 mg (72%); mp 181–182 ℃ (EtOH);
RF = 0.42 (toluene–EtOAc, 4:1). IR (KBr): 2926, 2230, 1756, 1645 cm−1.
86 8 Experimental
1H NMR (500 MHz, DMSO-d6) δ 2.75–2.83 (m, 2H, 4′′-H), 3.98 (t, J = 5.4 Hz, 2H, 5′′-H),
4.28 (s, 2H, 5′-H), 4.81 (t, J = 1.6 Hz, 2H, 7′′-H), 7.48–7.52 (m, 2H, 3/5-H), 7.61–7.63 (m,
1H, 4-H), 7.97–8.00 (m, 2H, 2/6-H).
13C NMR (125 MHz, DMSO-d6) δ 24.28 (C-4′′), 33.50 (C-5′), 63.87 (C-5′′/7′′), 64.30 (C-
5′′/7′′), 109.88 (C-3′′), 112.41 (CN), 128.88 (C-2/3/5/6), 129.61 (C-2/3/5/6), 131.78 (C-3a′′),
133.68 (C-4), 134.55 (C-1), 136.26 (C-2′′/7a′′), 140.61 (C-2′′/7a′′), 171.40 (C-2′/CO), 172.31
(C-2′/CO), 176.24 (CO).















M = 472.58 g/mol
N -Benzoyl-N ′-(6-benzyl-3-cyano-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl)thiourea (14) and
ethyl bromoacetate were reacted according to the aforementioned procedure. Compound
47 was obtained as an orange solid after purification by column chromatography (silica gel,
petroleum ether–EtOAc, 2:1); yield: 105 mg (19%); mp 86–89 ℃; RF = 0.40 (toluene–EtOAc,
4:1). IR (KBr): 2924, 2228, 1756, 1646 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 2.73–2.89 (m, 4H, 4′′/5′′-H), 3.69–3.81 (m, 4H, 7′′-H, CH2),
4.27 (s, 2H, 5′-H), 7.26–7.30 (m, 1H, 4′′′-H), 7.33–7.38 (m, 4H, 2′′′/3′′′/5′′′/6′′′-H), 7.48–7.51
(m, 2H, 3/5-H), 7.60–7.63 (m, 1H, 4-H), 7.97–8.00 (m, 2H, 2/6-H).
13C NMR (125 MHz, DMSO-d6) δ 23.84 (C-4′′), 33.48 (C-5′), 48.62 (C-5′′/7′′), 50.71 (C-
5′′/7′′), 60.45 (CH2), 109.41 (C-3′′), 112.58 (CN), 127.36 (C-4′′′), 128.47 (C-2′′′/3′′′/5′′′/6′′′),
128.87 (C-2/3/5/6), 129.00 (C-2′′′/3′′′/5′′′/6′′′), 129.60 (C-2/3/5/6), 132.59 (C-3a′′), 133.68
(C-4), 134.57 (C-1), 136.09 (C-2′′/7a′′), 137.88 (C-1′′′), 140.17 (C-2′′/7a′′), 171.42 (C-2′/CO),
172.26 (C-2′/CO), 176.26 (CO).













M = 321.35 g/mol
Reaction of N -benzoyl-N ′-(2-cyanophenyl)thiourea (15) and ethyl bromoacetate gave 48 as
yellow plates; yield: 226 mg (70%); mp 196–198 ℃ (EtOH); RF = 0.51 (toluene–EtOAc, 4:1).
IR (KBr): 2240, 1758, 1632 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 4.26 (d, J = 18.6 Hz, 1H, 5′-H), 4.42 (d, J = 18.6 Hz,
1H, 5′-H), 7.40–7.46 (m, 2H, 3/5-H), 7.55–7.59 (m, 1H, 4-H), 7.76–7.79 (m, 2H, 4′′/6′′-H),
7.80–7.83 (m, 2H, 2/6-H), 7.95–7.99 (m, 1H, 5′′-H), 8.12–8.15 (m, 1H, 3′′-H).
13C NMR (125 MHz, DMSO-d6) δ 33.75 (C-5′), 111.84 (C-2′′), 115.80 (CN), 128.79 (C-
2/3/5/6), 129.35 (C-2/3/5/6), 130.26 (C-4′′/6′′), 130.52 (C-4′′/6′′), 133.58 (C-4), 133.74
(C-3′′), 134.67 (C-1), 134.75 (C-5′′), 137.50 (C-1′′), 172.34 (C-2′/CO), 173.03 (C-2′/CO),
176.11 (CO).














M = 381.41 g/mol
Reaction of N -benzoyl-N ′-(2-cyano-4,5-dimethoxyphenyl)thiourea (16) and ethyl bromoac-
etate gave 49 as orange cubes; yield: 251 mg (66%); mp 216–218 ℃ (EtOH); RF = 0.29
(toluene–EtOAc, 4:1). IR (KBr): 2940, 2225, 1755, 1642 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 4.22 (d, J = 18.6 Hz, 1H, 5′-H), 4.40 (d, J = 18.6 Hz, 1H,
5′-H), 7.41 (s, 1H, 3′′/6′′-H), 7.44–7.47 (m, 2H, 3/5-H), 7.57–7.59 (m, 1H, 4-H), 7.65 (s, 1H,
3′′/6′′-H), 7.86–7.89 (m, 2H, 2/6-H).
13C NMR (125 MHz, DMSO-d6) δ 33.50 (C-5′), 56.50 (2 × CH3), 103.21 (C-2′′), 113.11
(C-3′′/6′′/CN), 114.78 (C-3′′/6′′/CN), 116.17 (C-3′′/6′′/CN), 128.81 (C-2/3/5/6), 129.42
(C-2/3/5/6), 131.95 (C-1′′), 133.54 (C-4), 134.76 (C-1), 149.38 (C-4′′/5′′), 153.10 (C-4′′/5′′),
172.37 (C-2′/CO), 172.93 (C-2′/CO), 176.27 (CO).
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M = 307.37 g/mol
A mixture of N -benzoyl-N ′-(2-cyanophenyl)thiourea (15; 281 mg, 1.00 mmol) and NaOAc
(197 mg, 2.40 mmol) in DMF (10 mL) was treated dropwise with 1,2-dibromoethane (225 mg,
103 µL, 1.20 mmol). The reaction was stirred overnight at rt. A precipitate was removed by
filtration and the filtrate was evaporated in vacuo. The crude material was purified by column
chromatography (silica gel, toluene–EtOAc, 4:1) to provide 50 as a white solid; yield: 85 mg
(28%); mp 130–132 ℃; RF = 0.28 (toluene–EtOAc, 4:1). IR (KBr): 3059, 2231, 1617 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 3.43 (t, J = 7.7 Hz, 2H, 5′-H), 4.19 (t, J = 7.7 Hz, 2H,
4′-H), 7.36–7.40 (m, 2H, 3/5-H), 7.47–7.51 (m, 1H, 4-H), 7.59–7.63 (m, 1H, 4′′-H), 7.72 (dd,
J = 8.2, 1.0 Hz, 1H, 6′′-H), 7.84–7.89 (m, 3H, 2/6/5′′-H), 8.02–8.05 (dd, J = 7.9, 1.6 Hz, 1H,
3′′-H).
13C NMR (125 MHz, DMSO-d6) δ 27.66 (C-5′), 51.76 (C-4′), 111.44 (C-2′′), 116.66 (CN),
127.13 (C-6′′), 128.35 (C-2/3/5/6), 128.58 (C-4′′), 129.09 (C-2/3/5/6), 132.36 (C-3′′/5′′),
133.71 (C-4), 134.58 (C-1), 136.03 (C-3′′/5′′), 142.75 (C-1′′), 172.38 (C-2′/CO), 174.45
(C-2′/CO).







CN M = 204.25 g/mol
Compound 51 was prepared by a method according to Brouwer et al.123 An aqueous
formaldehyde solution (37 wt%, 4.5 mL) was added dropwise to a solution of anthranilonitrile
(5.91 g, 50.0 mmol) and thioglycolic acid (4.61 g, 3.48 mL, 50.0 mmol) in EtOH (15 mL).
After stirring for 4 h at rt, the mixture was poured into ice water (75 mL). Precipitated
2-[(2-cyanophenylamino)methylsulfanyl]acetic acid (9.85 g, 44.3 mmol) was recovered by
8.5 2-(Benzoylimino)thiazolidin-4-ones 89
suction filtration, washed with H2O (100 mL), and dried under reduced pressure. It was
then redissolved in p-xylene (60 mL) and refluxed for 6 h using a water trap. The resulting
solution was filtered and the solvent was removed under reduced pressure. Recrystallization
from EtOH afforded 51 as white needles; yield: 3.47 g (43%, 2 steps); mp 124–126 ℃ (EtOH;
lit.123 120–122 ℃); RF = 0.21 (toluene–EtOAc, 4:1). IR (KBr): 2233, 1683 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 3.73 (t, J = 1.0 Hz, 2H, 5′-H), 4.85 (t, J = 1.0 Hz, 2H,
2′-H), 7.53–7.57 (m, 1H, 5-H), 7.62 (dd, J = 8.2, 1.0 Hz, 1H, 3-H), 7.78–7.82 (m, 1H, 4-H),
7.93 (dd, J = 7.9, 1.6 Hz, 1H, 6-H).
13C NMR (125 MHz, DMSO-d6) δ 31.70 (C-5′), 48.86 (C-2′), 111.12 (C-1), 116.41 (CN),
127.52 (C-3), 128.62 (C-5), 133.80 (C-6), 134.50 (C-4), 141.11 (C-2), 170.98 (CO).










M = 296.34 g/mol
N -Benzoyl-N ′-phenylthiourea (256 mg, 1.00 mmol), which was prepared according to Ras-
mussen et al.,241 was dissolved in a mixture of EtOH (5.0 mL) and NaOH (1 M, 1.5 mL). The
solution was heated to 50 ℃ and ethyl bromoacetate (200 mg, 133 µL, 1.20 mmol) was added
within 1 min. After heating at 50 ℃ for 1 h, the mixture was cooled to ambient temperature
and H2O (8 mL) was added. The resulting precipitate was removed by suction filtration,
washed with H2O (50 mL), and dried in vacuo. Recrystallization from EtOAc afforded 52
as colorless needles; yield: 255 mg (86%); mp 221–222 ℃ (EtOAc; lit.96 224 ℃); RF = 0.54
(petroleum ether–EtOAc, 2:1). IR (KBr): 2968, 1733, 1637 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 4.16 (s, 2H, 5′-H), 7.40–7.45 (m, 4H, 3/5/2′′/6′′-H), 7.49–7.59
(m, 4H, 4/3′′–5′′-H), 7.83–7.86 (m, 2H, 2/6-H).
13C NMR (125 MHz, DMSO-d6) δ 33.57 (C-5′), 128.32 (C-2′′/3′′/5′′/6′′), 128.67 (C-2/3/5/6),
129.01 (C-4′′), 129.08 (C-2′′/3′′/5′′/6′′), 129.36 (C-2/3/5/6), 133.30 (C-4), 135.07 (C-1/1′′),
135.39 (C-1/1′′), 173.04 (C-2′/CO), 173.88 (C-2′/CO), 176.24 (CO).








M = 179.24 g/mol
Compound 53 was prepared by a procedure described by Kay et al.124 Thioglycolic acid
(5.68 g, 4.29 mL, 61.7 mmol) was added within 1 min to a solution of aniline (5.75 g,
5.62 mL, 61.7 mmol) in PhMe (120 mL). After 10 min, the solution was treated dropwise
with an aqueous formaldehyde solution (37 wt%, 4.8 mL), followed by the addition of p-
toluenesulfonic acid monohydrate (10 mg, 53 µmol). The mixture was refluxed for 4 h using
a water trap. After the mixture had cooled to rt and been washed with saturated aqueous
NaHCO3 (2 × 50 mL), the solvent was removed under reduced pressure. After purification
by column chromatography (silica gel, toluene–EtOAc, 4:1), 53 was obtained as a white solid;
yield: 6.01 g (54%); mp 110–112 ℃ (EtOH; lit.123 116–119 ℃, lit.242 110–114 ℃); RF = 0.35
(petroleum ether–EtOAc, 4:1). IR (KBr): 3058, 1677 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 3.70 (t, J = 1.0 Hz, 2H, 2/5-H), 4.89 (t, J = 1.0 Hz, 2H,
2/5-H), 7.21–7.25 (m, 1H, 4′-H), 7.38–7.42 (m, 2H, 3′/5′-H), 7.48–7.52 (m, 2H, 2′/6′-H).
13C NMR (125 MHz, DMSO-d6) δ 32.66 (C-5), 48.71 (C-2), 122.57 (C-2′/6′), 125.84 (C-4′),
128.94 (C-3′/5′), 139.05 (C-1′), 170.40 (CO).
Anal. Calcd for C9H9NOS: C, 60.31; H, 5.06; N, 7.81. Found: C, 60.25; H, 5.36; N, 7.86.








2′ M = 270.28 g/mol
Compound was taken from the substance library.
1H NMR (500 MHz, DMSO-d6) δ 4.28 (d, J = 5.7 Hz, 2H, CH2Ph), 6.95 (ddd, J = 8.2,
7.1, 1.3 Hz, 1H, 5-H), 7.21–7.24 (m, 1H, 4′-H), 7.28–7.32 (m, 4H, 2′/3′/5′/6′-H), 7.46 (ddd,
J = 8.5, 7.3, 1.6 Hz, 1H, 4-H), 7.90 (dd, J = 8.2, 1.6 Hz, 1H, 6-H), 7.94–7.97 (m, 1H, NH),
8.39 (dd, J = 8.5, 1.0 Hz, 1H, 3-H), 10.19 (s, 1H, NH), 13.23 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 43.01 (CH2Ph), 114.71 (C-1), 119.30 (C-3/5), 120.22
(C-3/5), 126.83 (C-4′), 127.38 (C-2′/3′/5′/6′), 128.38 (C-2′/3′/5′/6′), 131.04 (C-6), 133.81






M = 236.27 g/mol
Anthranilic acid (688 mg, 5.00 mmol) was added in portions to a stirring solution of N,N ′-
carbonyldiimidazole (811 mg, 5.00 mmol) in CH2Cl2 (50 mL). After 30 min, diethylamine
(731 mg, 1.03 mL, 10.0 mmol) was added dropwise and the mixture was stirred overnight.
The organic layer was washed with HCl (1 M, 2 × 5 mL), filtered, and evaporated to dryness
to obtain 55 as a white solid; yield: 637 mg (54%); mp 144–148 ℃ (lit.127 151 ℃).
1H NMR (500 MHz, CDCl3) δ 1.24 (t, J = 7.3 Hz, 6H, CH2CH3), 3.43 (q, J = 7.3 Hz, 4H,
CH2CH3), 6.96 (ddd, J = 8.2, 7.2, 1.3 Hz, 1H, 5-H), 7.52 (ddd, J = 8.5, 7.2, 1.6 Hz, 1H,
4-H), 8.05 (dd, J = 8.2, 1.6 Hz, 1H, 6-H), 8.62 (dd, J = 8.5, 1.0 Hz, 1H, 3-H), 10.50 (s, 1H,
NH).
13C NMR (125 MHz, CDCl3) δ 13.67 (CH2CH3), 41.73 (CH2CH3), 112.60 (C-1), 119.56
(C-3/5), 120.52 (C-3/5), 131.58 (C-6), 135.56 (C-4), 144.40 (C-2), 154.55 (NHCO), 172.83
(CO2H).









M = 266.25 g/mol
Compound was taken from the substance library.
1H NMR (500 MHz, DMSO-d6) δ 3.07 (s, 3H, NCH3), 3.66 (s, 3H, OCH3), 4.16 (s, 2H, CH2),
7.02 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H, 5-H), 7.52 (ddd, J = 8.5, 7.2, 1.6 Hz, 1H, 4-H), 7.96
(dd, J = 8.0, 1.4 Hz, 1H, 6-H), 8.42 (dd, J = 8.5, 1.0 Hz, 1H, 3-H), 10.67 (s, 1H, NH), 13.56
(br s, 1H, CO2H).
13C NMR (125 MHz, CDCl3) δ 35.30 (NCH3), 50.01 (CH2/OCH3), 51.89 (CH2/OCH3),
114.69 (C-1), 118.65 (C-3/5), 120.92 (C-3/5), 131.15 (C-6), 134.28 (C-4), 143.04 (C-2), 154.89







2 M = 276.33 g/mol
Compound was taken from the substance library.
1H NMR (500 MHz, DMSO-d6) δ 1.05–1.18 (m, 10H, 2′–6′-H), 2.83 (s, 3H, NCH3), 3.90–3.98
(m, 1H, 1′-H), 6.97 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H, 5-H), 7.50 (ddd, J = 8.5, 7.2, 1.6 Hz, 1H,
4-H), 7.94 (dd, J = 8.2, 1.6 Hz, 1H, 6-H), 8.47 (dd, J = 8.5, 1.0 Hz, 1H, 3-H), 10.83 (s, 1H,
NH), 13.51 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 25.09 (C-4′), 25.58 (C-3′/5′), 28.12 (NCH3), 30.07 (C-2′/6′),
53.79 (C-1′), 114.44 (C-1), 118.80 (C-3/5), 120.39 (C-3/5), 131.11 (C-6), 134.16 (C-4), 143.67
(C-2), 154.27 (NHCO), 170.56 (CO2H).






M = 270.28 g/mol








M = 284.31 g/mol
Compound was taken from the substance library.
1H NMR (500 MHz, DMSO-d6) δ 2.98 (s, 3H, NCH3), 4.57 (s, 2H, CH2Ph), 7.00 (ddd,
J = 8.2, 7.1, 1.3 Hz, 1H, 5-H), 7.23–7.28 (m, 3H, 2′/4′/6′-H), 7.32–7.36 (m, 2H, 3′/5′-H), 7.53
(ddd, J = 8.5, 7.3, 1.6 Hz, 1H, 4-H), 7.95 (dd, J = 7.9, 1.6 Hz, 1H, 6-H), 8.51 (dd, J = 8.5,
1.0 Hz, 1H, 3-H), 10.97 (s, 1H, NH), 13.51 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 34.23 (NCH3), 51.33 (CH2Ph), 114.66 (C-1), 118.81
(C-3/5), 120.69 (C-3/5), 127.19 (C-4′), 127.29 (C-2′/3′/5′/6′), 128.66 (C-2′/3′/5′/6′), 131.13






M = 298.34 g/mol






M = 234.25 g/mol






M = 250.25 g/mol







M = 290.36 g/mol







M = 284.31 g/mol
Compound was taken from the substance library.







M = 298.34 g/mol







M = 312.36 g/mol







M = 264.28 g/mol







H3C M = 278.30 g/mol







M = 286.33 g/mol
N,N ′-Carbonyldiimidazole (487 mg, 3.00 mmol) was added in portions to a solution of
3-amino-2-naphthalenecarboxylic acid (562 mg, 3.00 mmol) in anhydrous THF (30 mL). After
2 h, diethylamine (439 mg, 618 µL, 6.00 mmol) was added dropwise, and the mixture was
stirred overnight at rt. The solvent was removed under reduced pressure, and the residue was
dissolved in ethyl acetate (20 mL). The organic layer was washed with HCl (1 M, 2 × 5 mL),
dried over Na2SO4, filtered, and evaporated to dryness. The crude material was recrystallized
from MeOH to obtain 69 as yellowish plates; yield: 586 mg (68%); mp 166–169 ℃ (MeOH).
1H NMR (500 MHz, DMSO-d6) δ 1.17 (t, J = 7.1 Hz, 6H, CH2CH3), 3.38 (q, J = 7.0 Hz,
4H, CH2CH3), 7.38 (ddd, J = 8.0, 6.9, 1.3 Hz, 1H, 6/7-H), 7.54 (ddd, J = 8.0, 6.8, 1.3 Hz,
1H, 6/7-H), 7.76 (d, J = 7.8 Hz, 1H, 5/8-H), 7.95 (d, J = 8.2 Hz, 1H, 5/8-H), 8.66 (s, 1H,
1/4-H), 8.88 (s, 1H, 1/4-H), 10.74 (s, 1H, NH), 13.80 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 13.90 (CH2CH3), 41.08 (CH2CH3), 114.40 (C-4), 116.23
(C-2), 124.58 (C-1/5–8), 126.84 (C-1/5–8), 127.11 (C-8a), 129.16 (C-1/5–8), 129.19 (C-1/5–8),
133.18 (C-1/5–8), 136.21 (C-3/4a), 138.60 (C-3/4a), 153.93 (NHCO), 170.55 (CO2H).
Anal. Calcd for C16H18N2O3: C, 67.12; H, 6.34; N, 9.78. Found: C, 66.79; H, 6.32; N, 9.59.
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M = 266.36 g/mol
Method 1: Diethylamine (476 mg, 670 µL, 6.50 mmol) was added dropwise to a stirring
solution of methyl 2-isothiocyanatobenzoate (966 mg, 5.00 mmol), that was prepared according
to Carpenter et al.,128 in CH2Cl2 (20 mL). The reaction mixture was stirred at rt for 3 h.
The organic layer was washed with HCl (0.5 M, 2 × 5 mL), dried over Na2SO4, filtered, and
evaporated to dryness. Recrystallization from EtOH yielded 70 (0.946 g, 71%) as colorless
needles, mp 85–87 ℃ (EtOH).
1H NMR (500 MHz, CDCl3) δ 1.34 (t, J = 6.9 Hz, 6H, CH2CH3), 3.82 (q, J = 6.9 Hz,
4H, CH2CH3), 3.88 (s, 3H, CO2CH3), 7.03 (ddd, J = 8.2, 7.3, 1.3 Hz, 1H, 5-H), 7.48 (ddd,
J = 8.6, 7.3, 1.6 Hz, 1H, 4-H), 7.93 (dd, J = 8.2, 1.6 Hz, 1H, 6-H), 8.73 (dd, J = 8.6, 1.3 Hz,
1H, 3-H), 10.66 (s, 1H, NH).
13C NMR (125 MHz, CDCl3) δ 12.46 (CH2CH3), 45.68 (CH2CH3), 52.31 (CO2CH3), 116.86
(C-1), 122.22 (C-5), 123.62 (C-3), 130.22 (C-6), 132.82 (C-4), 143.28 (C-2), 168.99 (CO2CH3),
179.23 (NHCS).
Anal. Calcd for C13H18N2O2S: C, 58.62; H, 6.81; N, 10.52. Found: C, 58.37; H, 6.78; N,
10.44.
Method 2: 2-(3,3-Diethylthioureido)-N,N -diethylbenzamide (133, 307 mg, 1.00 mmol) was
heated to reflux in anhydrous methanolic HCl (0.25 M, 5 mL) for 3 h. The mixture was
allowed to cool to rt and kept at −15 ℃. The precipitate was removed by suction filtration









M = 306.42 g/mol
According to the preparation of 70 (Method 1), 71 (1.50 g, 98%) was obtained from methyl
2-isothiocyanatobenzoate and N -methylcyclohexylamine as a semisolid crude material.
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1H NMR (500 MHz, CDCl3) δ 1.05–1.95 (m, 10H, 2′–6′-H), 3.20 (s, 3H, NCH3), 3.88 (s, 3H,
CO2CH3), 5.04 (br s, 1H, 1′-H), 7.03 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H, 5-H), 7.48 (ddd, J = 8.8,
7.1, 1.6 Hz, 1H, 4-H), 7.93 (dd, J = 8.2, 1.6 Hz, 1H, 6-H), 8.71(d, J = 8.2 Hz, 1H, 3-H),
10.70 (s, 1H, NH).
13C NMR (125 MHz, CDCl3) δ 25.48 (C-4′), 25.54 (C-3′/5′), 30.01 (C-2′/6′), 32.57 (NCH3),
52.29 (CO2CH3), 59.23 (C-1′), 116.74 (C-1), 122.16 (C-5), 123.35 (C-3), 130.23 (C-6), 132.86









M = 300.38 g/mol
According to the preparation of 70 (Method 1), 72 (1.28 g, 84%) was obtained from methyl
2-isothiocyanatobenzoate and N -methylaniline as colorless needles, mp 70–71 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 3.61 (s, 3H, NCH3), 3.70 (s, 3H, CO2CH3), 7.15–7.17 (m,
1H, 5-H), 7.39–7.45 (m, 3H, 2′/4′/6′-H), 7.50–7.55 (m, 3H, 4/3′/5′-H), 7.77 (dd, J = 8.2,
1.6 Hz, 1H, 6-H), 8.24 (dd, J = 8.4, 1.0 Hz, 1H, 3-H), 9.67 (s, 1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 43.28 (NCH3), 52.44 (CO2CH3), 120.31 (C-1), 123.65
(C-5), 125.06 (C-3), 127.01 (C-2′/6′), 128.27 (C-4′), 130.01 (C-6), 130.26 (C-3′/5′), 132.46
(C-4), 141.32 (C-2), 143.71 (C-1′), 167.08 (CO2CH3), 180.48 (NHCS).








2′ M = 314.40 g/mol
According to the preparation of 70 (Method 1), 73 (1.45 g, 92%) was obtained from methyl
2-isothiocyanatobenzoate and N -benzylmethylamine as white plates, mp 88–92 ℃ (EtOH).
1H NMR (500 MHz, CDCl3) δ 3.30 (s, 3H, NCH3), 3.87 (s, 3H, CO2CH3), 5.25 (s, 2H,
CH2Ph), 7.08 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H, 5-H), 7.26–7.28 (m, 1H, 4′-H), 7.29–7.34 (m,
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4H, 2′/3′/5′/6′-H), 7.53 (ddd, J = 8.5, 7.3, 1.6 Hz, 1H, 4-H), 7.96 (dd, J = 7.9, 1.6 Hz, 1H,
6-H), 8.87 (d, J = 8.6 Hz, 1H, 3-H), 10.93 (s, 1H, NH).
13C NMR (125 MHz, CDCl3) δ 37.63 (NCH3), 52.36 (CO2CH3), 56.78 (CH2Ph), 117.06 (C-1),
122.64 (C-5), 123.42 (C-3), 127.52 (C-2′/6′), 127.58 (C-4′), 128.72 (C-3′/5′), 130.31 (C-6),
133.01 (C-4), 136.43 (C-1′), 142.98 (C-2), 168.95 (CO2CH3), 180.94 (NHCS).









M = 328.43 g/mol
According to the preparation of 70 (Method 1), 74 (1.47 g, 90%) was obtained from methyl
2-isothiocyanatobenzoate and N -methylphenethylamine as a semisolid crude material.
1H NMR (500 MHz, CDCl3) δ 3.07 (t, J = 7.9 Hz, 2H, CH2CH2Ph), 3.28 (s, 3H, NCH3), 3.90
(s, 3H, CO2CH3), 4.05–4.14 (m, 2H, CH2CH2Ph), 7.06 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H, 5-H),
7.19–7.23 (m, 1H, 4′-H), 7.27–7.31 (m, 4H, 2′/3′/5′/6′-H), 7.51 (ddd, J = 8.6, 7.2, 1.6 Hz, 1H,
4-H), 7.96 (dd, J = 7.9, 1.6 Hz, 1H, 6-H), 8.80 (d, J = 8.6 Hz, 1H, 3-H), 10.84 (s, 1H, NH).
13C NMR (125 MHz, CDCl3) δ 33.38 (CH2CH2Ph), 39.22 (NCH3), 52.35 (CO2CH3), 55.82
(CH2CH2Ph), 116.80 (C-1) 122.41 (C-5), 123.27 (C-3), 126.52 (C-4′), 128.60 (C-2′/6′), 128.91








M = 364.34 g/mol
Method 1: According to the preparation of 70 (Method 1), 75 (1.32 g, 82%) was obtained
from methyl 2-isothiocyanatobenzoate and pyrrolidine as colorless needles, mp 124–127 ℃
(EtOH).
1H NMR (500 MHz, CDCl3) δ 1.87–2.16 (m, 4H, 3′/4′-H), 3.65–3.96 (m, 7H, CO2CH3, 2′/5′-
H), 7.04 (ddd, J = 7.9, 7.3, 1.3 Hz, 1H, 5-H), 7.51 (ddd, J = 8.5, 7.3, 1.6 Hz, 1H, 4-H), 7.95
(dd, J = 7.9, 1.6 Hz, 1H, 6-H), 9.00 (dd, J = 8.5, 1.0 Hz, 1H, 3-H), 10.82 (s, 1H, NH).
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13C NMR (125 MHz, CDCl3) δ 24.59 (C-3′/4′), 26.20 (C-3′/4′), 48.30 (C-2′/5′), 52.13 (C-2′/5′),
52.33 (CO2CH3), 116.40 (C-1), 122.26 (C-3/5), 122.65 (C-3/5), 130.35 (C-6), 133.16 (C-4),
142.88 (C-2), 169.05 (CO2CH3), 176.47 (NHCS).
Anal. Calcd for C13H16N2O2S: C, 59.07; H, 6.10; N, 10.60. Found: C, 59.09; H, 6.35; N,
10.49.
Method 2: According to the preparation of 70 (Method 2), 75 (222 mg, 84%) was obtained






2′ M = 278.37 g/mol
According to the preparation of 70 (Method 1), 76 (1.11 g, 80%) was obtained from methyl
2-isothiocyanatobenzoate and piperidine as colorless plates, mp 116–117 ℃ (EtOH).
1H NMR (500 MHz, CDCl3) δ 1.68–1.73 (m, 6H, 3′–5′-H), 3.88 (s, 3H, CO2CH3), 3.95–4.01
(m, 4H, 2′/6′-H), 7.02 (ddd, J = 8.2, 7.3, 1.3 Hz, 1H, 5-H), 7.48 (ddd, J = 8.8, 7.3, 1.6 Hz,
1H, 4-H), 7.93 (dd, J = 8.1, 1.8 Hz, 1H, 6-H), 8.53 (dd, J = 8.5, 1.3 Hz, 1H, 3-H), 10.75 (s,
1H, NH).
13C NMR (125 MHz, CDCl3) δ 24.40 (C-4′), 25.67 (C-3′/5′), 49.68 (C-2′/6′), 52.33 (CO2CH3),
116.41 (C-1), 122.04 (C-5), 123.03 (C-3), 130.33 (C-6), 132.97 (C-4), 143.40 (C-2), 169.06
(CO2CH3), 179.60 (NHCS).









M = 280.34 g/mol
Method 1: According to the preparation of 70 (Method 1), 77 (1.11 g, 80%) was obtained
from methyl 2-isothiocyanatobenzoate and morpholine as a white solid, mp 103–107 ℃
(EtOH; lit.243 106–110 ℃).
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1H NMR (500 MHz, CDCl3) δ 3.79 (t, J = 4.9 Hz, 4H, 2′/6′-H), 3.89 (s, 3H, CO2CH3), 4.04
(t, J = 4.9 Hz, 4H, 3′/5′-H), 7.06 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H, 5-H), 7.51 (ddd, J = 8.6,
7.3, 1.6 Hz, 1H, 4-H), 7.96 (dd, J = 8.1, 1.6 Hz, 1H, 6-H), 8.67 (dd, J = 8.5, 1.0 Hz, 1H,
3-H), 10.97 (s, 1H, NH).
13C NMR (125 MHz, CDCl3) δ 48.25 (C-3′/5′), 52.48 (CO2CH3), 66.29 (C-2′/6′), 116.57 (C-1),
122.58 (C-3/5), 122.93 (C-3/5), 130.43 (C-6), 133.19 (C-4), 142.95 (C-2), 169.19 (CO2CH3),
180.72 (NHCS).
Anal. Calcd for C13H16N2O3S: C, 55.70; H, 5.75; N, 9.99. Found: C, 55.96; H, 5.94; N,
9.84.
Method 2: According to the preparation of 70 (Method 2), 77 (229 mg, 82%) was obtained
from 135 as a light yellow solid.
Method 3: 2-(Morpholin-4-yl)-4H -3,1-benzothiazin-4-one (130; 160 mg, 640 µmol) was heated
to reflux in anhydrous methanolic HCl (0.25 M, 3 mL) for 3 h. The mixture was allowed to
cool to rt and kept at −15 ℃. The precipitate was removed by suction filtration to give 77
(151 mg, 84%) as a light yellow solid.
2-Thioureidobenzoic Acids 78–85; General Procedure
A mixture of the appropriate methyl 2-thioureidobenzoate (70–77, 2.00 mmol), aqueous
NaOH (1 M, 10 mL) and EtOH (10 mL) was heated to reflux for 1 h. The reaction was
allowed to cool to rt and H2O (30 mL) was added. After filtration and cooling to 0 ℃, the
solution was acidified with 2 M HCl. The precipitate was removed by suction filtration and






M = 252.33 g/mol
White solid; yield: 394 mg (78%); mp 114–116 ℃.
1H NMR (500 MHz, DMSO-d6) δ 1.23 (t, J = 7.1 Hz, 6H, CH2CH3), 3.76 (q, J = 7.0 Hz,
4H, CH2CH3), 7.11 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H, 5-H), 7.50 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H,
4-H), 7.90 (dd, J = 7.9, 1.6 Hz, 1H, 6-H), 8.49 (dd, J = 8.5, 1.0 Hz, 1H, 3-H), 10.62 (s, 1H,
NH), 13.53 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 12.50 (CH2CH3), 45.03 (CH2CH3), 119.10 (C-1), 122.65 (C-
5), 123.93 (C-3), 130.49 (C-6), 132.40 (C-4), 142.97 (C-2), 169.83 (CO2H), 178.41 (NHCS).
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M = 292.40 g/mol
White solid; yield: 525 mg (90%); mp 130–132 ℃.
1H NMR (500 MHz, DMSO-d6) δ 1.07–1.35 (m, 10H, 2′–6′-H), 3.13 (s, 3H, NCH3), 4.88 (br s,
1H, 1′-H), 7.11 (ddd, J = 7.9, 7.3, 1.3 Hz, 1H, 5-H), 7.50 (ddd, J = 8.5, 7.3, 1.6 Hz, 1H,
4-H), 7.90 (dd, J = 7.9, 1.6 Hz, 1H, 6-H), 8.42 (dd, J = 8.5, 1.0 Hz, 1H, 3-H), 10.66 (s, 1H,
NH), 13.48 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 25.01 (C-4′), 25.41 (C-3′/5′), 29.45 (C-2′/6′), 32.60 (NCH3),
58.71 (C-1′), 119.31 (C-1), 122.69 (C-5), 123.84 (C-3), 130.51 (C-6), 132.39 (C-4), 142.88
(C-2), 169.74 (CO2H), 179.37 (NHCS).









M = 286.35 g/mol
White solid; yield: 378 mg (66%); mp 135–138 ℃.
1H NMR (500 MHz, DMSO-d6) δ 3.61 (s, 3H, NCH3), 7.08 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H,
5-H), 7.38–7.41 (m, 3H, 2′/4′/6′-H), 7.48–7.51 (m, 3H, 4/3′/5′-H), 7.80 (dd, J = 7.9, 1.6 Hz,
1H, 6-H), 8.68 (dd, J = 8.5, 1.0 Hz, 1H, 3-H), 10.54 (s, 1H, NH), 13.33 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 43.23 (NCH3), 118.36 (C-1), 122.75 (C-3/5), 122.98
(C-3/5), 127.12 (C-2′/6′), 128.45 (C-4′), 130.32 (C-3′/5′), 130.40 (C-6), 132.43 (C-4), 142.13
(C-2/1′), 143.53 (C-2/1′), 169.33 (CO2H), 179.74 (NHCS).
Anal. Calcd for C15H14N2O2S: C, 62.92; H, 4.93; N, 9.78. Found: C, 62.72; H, 5.07; N, 9.69.








2′ M = 300.38 g/mol
White solid; yield: 365 mg, (61%); mp 117–119 ℃.
1H NMR (500 MHz, DMSO-d6) δ 3.24 (s, 3H, NCH3), 5.19 (s, 2H, CH2Ph), 7.17 (ddd,
J = 8.2, 7.3, 1.0 Hz, 1H, 5-H), 7.25–7.29 (m, 5H, 2′–6′-H), 7.54 (ddd, J = 8.5, 7.3, 1.3 Hz,
1H, 4-H), 7.92 (dd, J = 7.9, 1.3 Hz, 1H, 6-H), 8.44 (dd, J = 8.5, 1.0 Hz, 1H, 3-H), 10.75 (s,
1H, NH), 13.46 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 37.78 (NCH3), 55.92 (CH2Ph), 120.41 (C-1), 123.34 (C-5),
124.50 (C-3), 127.26 (C-2′/6′), 127.32 (C-4′), 128.66 (C-3′/5′), 130.54 (C-6), 132.42 (C-4),
137.11 (C-1′), 142.55 (C-2), 169.42 (CO2H), 180.53 (NHCS).









M = 314.40 g/mol
Light yellow solid; yield: 509 mg (81%); mp 130–133 ℃.
1H NMR (500 MHz, DMSO-d6) δ 2.97 (t, J = 7.9 Hz, 2H, CH2CH2Ph), 3.25 (s, 3H, NCH3),
4.02 (t, J = 7.6 Hz, 2H, CH2CH2Ph), 7.12–7.16 (m, 1H, 5-H), 7.19–7.23 (m, 1H, 4-H′),
7.28–7.31 (m, 4H, 2′/3′/5′/6′-H), 7.53 (ddd, J = 8.5, 7.3, 1.6 Hz, 1H, 4-H), 7.92 (dd, J = 7.9,
1.6 Hz, 1H, 6-H), 8.46 (d, J = 7.9 Hz, 1H, 3-H), 10.71 (s, 1H, NH), 13.52 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 32.69 (CH2CH2Ph), 54.78 (CH2CH2Ph), 119.45 (C-1),
122.91 (C-5), 123.95 (C-3), 126.42 (C-4′), 128.54 (C-2′/3′/5′/6′), 128.91 (C-2′/3′/5′/6′), 130.52
(C-6), 132.45 (C-4), 138.83 (C-1′), 142.69 (C-2), 169.69 (CO2H), 179.32 (NHCS).








M = 250.32 g/mol
White solid; yield: 425 mg (85%); mp 164–166 ℃.
1H NMR (500 MHz, DMSO-d6) δ 1.85–2.18 (m, 4H, 3′/4′-H), 3.55–3.75 (m, 4H, 2′/5′-H),
7.11 (ddd, J = 7.9, 7.3, 1.3 Hz, 1H, 5-H), 7.53 (ddd, J = 8.5, 7.1, 1.6 Hz, 1H, 4-H), 7.93
(dd, J = 7.9, 1.6 Hz, 1H, 6-H), 8.80 (dd, J = 8.5, 1.0 Hz, 1H, 3-H), 10.86 (s, 1H, NH), 13.52
(br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 24.25 (C-3′/4′), 25.61 (C-3′/4′), 48.24 (C-2′/5′), 51.94
(C-2′/5′), 118.14 (C-1), 122.49 (C-3/5), 122.59 (C-3/5), 130.67 (C-6), 132.66 (C-4), 142.64
(C-2), 169.87 (CO2H), 175.83 (NHCS).







2′ M = 264.34 g/mol
White solid; yield: 444 mg (84%); mp 124–127 ℃.
1H NMR (500 MHz, DMSO-d6) δ 1.55–1.69 (m, 6H, 3′–5′-H), 3.89–3.93 (m, 4H, 2′/6′-H),
7.11 (ddd, J = 7.9, 7.3, 1.3 Hz, 1H, 5-H), 7.50 (ddd, J = 8.5, 7.3, 1.6 Hz, 1H, 4-H), 7.89
(dd, J = 8.0, 1.6 Hz, 1H, 6-H), 8.17 (dd, J = 8.5, 1.0 Hz, 1H, 3-H), 10.60 (s, 1H, NH), 13.44
(br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 24.00 (C-4′), 25.52 (C-3′/5′), 49.23 (C-2′/6′), 119.58 (C-1),
122.73 (C-5), 123.89 (C-3), 130.55 (C-6), 132.47 (C-4), 142.85 (C-2), 169.60 (CO2H), 179.07
(NHCS).
Anal. Calcd for C13H16N2O2S: C, 59.07; H, 6.10; N, 10.60. Found: C, 58.70; H, 6.14; N,
10.68.








M = 266.32 g/mol
White solid; yield: 399 mg (75%); mp 132–135 ℃.
1H NMR (500 MHz, DMSO-d6) δ 3.67 (t, J = 4.9 Hz, 4H, 2′/6′-H), 3.93 (t, J = 4.9 Hz, 4H,
3′/5′-H), 7.16 (ddd, J = 7.9, 7.0, 1.3 Hz, 1H, 5-H), 7.52 (ddd, J = 8.4, 7.3, 1.6 Hz, 1H, 4-H),
7.89 (dd, J = 7.9, 1.6 Hz, 1H, 6-H), 8.11 (dd, J = 8.2, 1.0 Hz, 1H, 3-H), 10.53 (s, 1H, NH),
13.37 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 48.31 (C-3′/5′), 65.82 (C-2′/6′), 120.95 (C-1), 123.44
(C-3/5), 124.68 (C-3/5), 130.58 (C-6), 132.47 (C-4), 142.31 (C-2), 169.23 (CO2H), 180.47
(NHCS).










M = 282.36 g/mol








M = 282.36 g/mol







M = 296.39 g/mol
This compound was prepared according to Gütschow et al.129 A mixture of 2-(diethylamino)-
5,6,7,8-tetrahydro-4H -[1]benzothieno[2,3-d][1,3]oxazin-4-one (100 mg, 0.36 mmol), aqueous
NaOH (1.5 M, 10 mL), and acetone (5 mL) was refluxed for 5 min. The reaction mixture
was allowed to cool to rt and filtrated into HCl (3 M, 10 mL). The precipitate was collected
by suction filtration to obtain 88 as a white solid; 77 mg (72%); mp 168–170 ℃ (lit.129
168–169 ℃).
1H NMR (500 MHz, DMSO-d6) δ 1.13 (t, J = 7.1 Hz, 6H, CH2CH3), 1.64–1.73 (m, 4H,
5/6-H), 2.50–2.62 (m, 2H, 4/7-H), 2.64–2.74 (m, 2H, 4/7-H), 3.32 (q, J = 7.0 Hz, 4H,
CH2CH3), 11.17 (s, 1H, NH), 12.80 (br s, 1H, CO2H).
8.8 2-Ureidothiophene-3-carboxylic Acids 107
13C NMR (125 MHz, DMSO-d6) δ 13.69 (CH2CH3), 22.51 (C-4–7), 22.80 (C-4–7), 23.79
(C-4–7), 25.99 (C-4–7), 41.25 (CH2CH3), 109.04 (C-3), 123.65 (C-7a), 130.49 (C-3a), 150.96
(C-2), 152.30 (NHCO), 168.26 (CO2H).








M = 310.37 g/mol
Compound was taken from the substance library.
1H NMR (500 MHz, DMSO-d6) δ 1.65–1.74 (m, 4H, 5/6-H), 2.51–2.62 (m, 2H, 4/7-H),
2.64–2.75 (m, 2H, 4/7-H), 3.38 (t, J = 4.8 Hz, 4H, 3′/5′-H), 3.64 (t, J = 4.8 Hz, 4H, 2′/6′-H),
11.18 (s, 1H, NH), 12.79 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 22.47 (C-4–7), 22.76 (C-4–7), 23.79 (C-4–7), 26.01 (C-4–7),
43.57 (C-3′/5′), 65.73 (C-2′/6′), 109.63 (C-3), 124.11 (C-7a), 130.68 (C-3a), 150.37 (C-2),
152.69 (NHCO), 168.06 (CO2H).
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M = 225.31 g/mol
Compound 90 was prepared by a procedure described by Gewald et al.81 Diethylamine
(21.3 g, 30.0 mL, 291 mmol) was slowly added to a stirred mixture of cyclohexanone (29.4 g,
31.1 mL, 300 mmol), ethyl cyanoacetate (33.9 g, 32.0 mL, 300 mmol), and sulfur (9.62 g,
300 mmol) in EtOH (100 mL), so that the temperature did not exceed 50 ℃. After 1 h
the reaction mixture was cooled to 5 ℃. The precipitate was removed by suction filtration
and recrystallized from EtOH to obtain 90 as colorless needles; yield: 56.5 g (84%); mp
114–115 ℃ (EtOH; lit.81 115 ℃).
1H NMR (500 MHz, DMSO-d6) δ 1.23 (t, J = 7.1 Hz, 3H, CH2CH3), 1.61–1.71 (m, 4H,
5/6-H), 2.37–2.42 (m, 2H, 4/7-H), 2.57–2.60 (m, 2H, 4/7-H), 4.13 (q, J = 7.0 Hz, 2H,
CH2CH3), 7.17 (br s, 2H, NH2).
13C NMR (125 MHz, DMSO-d6) δ 14.48 (CH2CH3), 22.56 (C-4–7), 22.96 (C-4–7), 24.06
(C-4–7), 26.63 (C-4–7), 58.71 (CH2CH3), 102.82 (C-3), 115.60 (C-7a), 131.44 (C-3a), 162.99
(C-2), 165.18 (CO2CH2).






M = 267.34 g/mol
Compounds 91–93 were synthesized according to ref.134 Ethyl 2-amino-4,5,6,7-tetrahydro-
benzo[b]thiophene-3-carboxylate (90; 113 g, 500 mmol) was refluxed in Ac2O (250 mL) for
10 min (caution: boiling delay). After cooling to 5 ℃, the precipitate was removed by suction
filtration and washed with hot water (100 mL) to recover 91 as white needles; yield: 117 g
(88%); mp 120–121 ℃ (lit.134 123 ℃).
1H NMR (500 MHz, DMSO-d6) δ 1.30 (t, J = 7.1 Hz, 3H, CH2CH3), 1.67–1.74 (m, 4H,
5/6-H), 2.20 (s, 3H, COCH3), 2.54–2.58 (m, 2H, 4/7-H), 2.66–2.70 (m, 2H, 4/7-H), 4.27 (q,
J = 7.1 Hz, 2H, CH2CH3), 10.92 (s, 1H, NH).
8.9 2-Substituted Ethyl Benzo[b]thiophene-3-carboxylates 109
13C NMR (125 MHz, DMSO-d6) δ 14.20 (CH2CH3), 22.45 (C-4–7/COCH3), 22.61 (C-4–
7/COCH3), 23.36 (C-4–7/COCH3), 23.81 (C-4–7/COCH3), 25.93 (C-4–7/COCH3), 60.38
(CH2CH3), 111.17 (C-3), 125.99 (C-7a), 130.37 (C-3a), 146.31 (C-2), 165.12 (CO2CH2), 167.26
(COCH3).






M = 263.31 g/mol
A mixture of ethyl 2-(acetylamino)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (91;
107 g, 400 mmol), sulfur (25.7 g, 800 mmol), and dimethyl phthalate (150 mL) was heated to
220 ℃. After 6 h, the reaction mixture was poured into EtOH (100 mL) and kept at 5 ℃.
The precipitate was removed by suction filtration and washed with EtOH (300 mL, −15 ℃)






M = 221.28 g/mol
A solution of KOH (2.40 g, 42.7 mmol) in H2O (6.0 mL) was added dropwise to a refluxing
mixture of ethyl 2-(acetylamino)benzo[b]thiophene-3-carboxylate (92; 10.5 g, 40.0 mmol) in
EtOH (40 mL). After complete addition of the base, the resulting solution was poured into
ice water (300 mL). The precipitate was removed and recrystallized from PhMe to obtain 93
as a yellow solid; yield: 6.10 g (69%); mp 106–107 ℃ (PhMe; lit.134 107–108 ℃).
1H NMR (500 MHz, DMSO-d6) δ 1.34 (t, J = 7.1 Hz, 3H, CH2CH3), 4.30 (q, J = 7.0 Hz,
2H, CH2CH3), 7.03–7.07 (m, 1H, 5/6-H), 7.22–7.26 (m, 1H, 5/6-H), 7.59 (dt, J = 7.9, 1.0 Hz,
1H, 4/7-H), 7.95 (br s, 2H, NH2), 7.96–7.99 (m, 1H, 4/7-H).
13C NMR (125 MHz, DMSO-d6) δ 14.61 (CH2CH3), 59.21 (CH2CH3), 96.57 (C-3), 121.37
(C-4–7), 121.60 (C-4–7), 121.75 (C-4–7), 125.28 (C-4–7), 128.52 (C-3a/7a), 137.52 (C-3a/7a),
165.16 (C-2/CO2CH2), 165.58 (C-2/CO2CH2).






M = 263.34 g/mol
Compound 94 was prepared by a method according to Gütschow et al.131 A mixture prepared
from thiophosgene (5.75 g, 3.81 mL, 50.0 mmol), CaCO3 (5.00 g, 50.0 mmol), CH2Cl2
(25 mL), and H2O (50 mL) was stirred at 0 ℃. A solution of ethyl 2-aminobenzo[b]thiophene-
3-carboxylate (93; 11.1 g, 50.0 mmol) in CH2Cl2 (90 mL) was added dropwise over a period
of 45 min. The mixture was stirred overnight at rt. The organic layer was washed with H2O
(2 × 30 mL) and dried over Na2SO4. After removal of the solvent, the crude product was
purified by column chromatography (petroleum ether–EtOAc, 4:1) to give 94 as a yellowish
solid; yield: 5.52 g (42%); mp 72–73 ℃ (lit.131 70–71 ℃).
Anal. Calcd for C12H9NO2S2: C, 54.73; H, 3.44; N, 5.32. Found: C, 54.52; H, 3.53; N, 5.33.











M = 326.48 g/mol
N -Methylcyclohexylamine (736 mg, 856 µL, 6.50 mmol) was added dropwise to a stirring
solution of ethyl 2-(isothiocyanato)thiophene-3-carboxylate131 (1.07 g, 5.00 mmol) in CH2Cl2
(20 mL). The reaction mixture was stirred at rt for 3 h. The organic layer was washed with HCl
(0.5 M, 2 × 5 mL), dried over Na2SO4, filtered, and evaporated to dryness. Recrystallization
from EtOH gave 95 as orange needles; yield: 1.26 g (77%); mp 143–145 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 1.11–1.82 (m, 13H, CH2CH3/2′–6′-H), 3.16 (s, 3H, NCH3),
4.32 (q, J = 7.0 Hz, 2H, CH2CH3), 4.49 (br s, 1H, 1′-H), 6.83 (d, J = 5.7 Hz, 1H, 4/5-H),
7.18 (d, J = 5.7 Hz, 1H, 4/5-H), 11.70 (s, 1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 14.30 (CH2CH3), 24.92 (C-4′), 25.38 (C-3′/5′), 29.22
(C-2′/6′), 31.75 (NCH3), 59.32 (C-1′), 60.80 (CH2CH3), 112.46 (C-3), 115.90 (C-4/5), 123.12
(C-4/5), 152.85 (C-2), 165.91 (CO2CH2), 175.17 (NHCS).










M = 362.51 g/mol
Diethylamine (219 mg, 308 µL, 3.00 mmol) was added dropwise to a stirring solution of ethyl
2-isothiocyanato-5-phenylthiophene-3-carboxylate244 (578 mg, 2.00 mmol) in CH2Cl2 (25 mL).
The reaction mixture was stirred at rt for 2 h. The organic layer was washed with HCl (0.5 M,
2 × 5 mL), dried over Na2SO4, filtered, and evaporated to dryness. Recrystallization from
EtOH gave 96 as white needles; yield: 560 mg (77%); mp 122–123 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 1.25 (t, J = 7.1 Hz, 6H, CH2CH3), 1.34 (t, J = 7.1 Hz,
3H, CH2CH3), 3.74–3.82 (m, 4H, CH2CH3), 4.35 (q, J = 7.0 Hz, 2H, CH2CH3), 7.26–7.30
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(m, 1H, 4′-H), 7.37–7.41 (m, 2H, 3′/5′-H), 7.51 (s, 1H, 4-H), 7.60–7.64 (m, 2H, 2′/6′-H), 11.78
(s, 1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 12.28 (CH2CH3), 14.30 (CH2CH3), 45.77 (CH2CH3), 61.01
(CH2CH3), 113.17 (C-3), 118.86 (C-4), 125.18 (C-2′/6′), 127.44 (C-4′), 129.25 (C-3′/5′), 131.11
(C-5/1′), 133.46 (C-5/1′), 152.14 (C-2), 165.90 (CO2CH2), 174.12 (NHCS).











M = 376.49 g/mol
Morpholine (261 mg, 264 µL, 3.00 mmol) was added dropwise to a stirring solution of ethyl
2-isothiocyanato-5-phenylthiophene-3-carboxylate244 (578 mg, 2.00 mmol) in CH2Cl2 (25 mL).
The reaction mixture was stirred at rt for 2 h. The organic layer was washed with HCl (0.5 M,
2 × 5 mL), dried over Na2SO4, filtered, and evaporated to dryness. Recrystallization from
EtOAc gave 97 as yellow needles; yield: 708 mg (94%); mp 186–188 ℃ (EtOAc).
1H NMR (500 MHz, DMSO-d6) δ 1.34 (t, J = 7.1 Hz, 3H, CH2CH3), 3.73 (t, J = 4.9 Hz, 4H,
3′′/5′′-H), 3.92 (t, J = 4.9 Hz, 4H, 2′′/6′′-H), 4.35 (q, J = 7.0 Hz, 2H, CH2CH3), 7.27–7.30
(m, 1H, 4′-H), 7.38–7.42 (m, 2H, 3′/5′-H), 7.54 (s, 1H, 4-H), 7.62–7.65 (m, 2H, 2′/6′-H), 11.82
(s, 1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 14.32 (CH2CH3), 47.89 (C-3′′/5′′), 61.10 (CH2CH3), 65.45
(C-2′′/6′′), 113.80 (C-3), 119.07 (C-4), 125.21 (C-2′/6′), 127.56 (C-4′), 129.28 (C-3′/5′), 131.51
(C-5/1′), 133.23 (C-5/1′), 151.65 (C-2), 165.70 (CO2CH2), 175.63 (NHCS).
Anal. Calcd for C18H20N2O3S2: C, 57.42; H, 5.35; N, 7.44. Found: C, 56.94; H, 5.55; N, 7.38.
Ethyl 2-Thioureidobenzo[b]thiophene-3-carboxylates 98–100; General Procedure131
The appropriate secondary amine (7.50 mmol) was added dropwise to a solution of ethyl
2-(isothiocyanato)benzo[b]thiophene-3-carboxylate (94; 1.30 g, 5.00 mmol) in CH2Cl2 (5 mL)
at 0 ℃. The mixture was allowed to warm to ambient temperature, stirred for further 2 h,
and acidified with 1M HCl/EtOH. The precipitate was collected by suction filtration and
recrystallized from EtOH.








M = 336.47 g/mol
White needles; yield: 1.05 g (62%); mp 136–138 ℃ (EtOH; lit.131 137–138 ℃).
1H NMR (500 MHz, DMSO-d6) δ 1.26 (t, J = 6.8 Hz, 6H, CH2CH3), 1.42 (t, J = 7.1 Hz,
3H, CH2CH3), 3.79–3.86 (m, 4H, CH2CH3), 4.46 (q, J = 7.1 Hz, 2H, CH2CH3), 7.29 (ddd,
J = 8.0, 7.0, 1.1 Hz, 1H, 5/6-H), 7.41 (ddd, J = 8.2, 7.3, 1.3 Hz, 1H, 5/6-H), 7.88 (d,
J = 7.9 Hz, 1H, 4/7-H), 8.20 (dt, J = 8.2, 1.0 Hz, 1H, 4/7-H), 12.56 (s, 1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 12.25 (CH2CH3), 14.28 (CH2CH3), 46.06 (CH2CH3), 61.27
(CH2CH3), 105.21 (C-3), 122.00 (C-4–7), 122.49 (C-4–7), 123.80 (C-4–7), 125.72 (C-4–7),
132.70 (C-3a/7a), 133.18 (C-3a/7a), 156.96 (C-2), 167.18 (CO2CH2), 174.77 (NHCS).










M = 376.54 g/mol
Yellowish plates; yield: 1.30 g (69%); mp 177–178 ℃ (EtOH).
1H NMR (500 MHz, CDCl3) δ 1.10–1.87 (m, 13H, CH2CH3/2′–6′-H), 3.05 (s, 3H, NCH3),
4.47 (q, J = 7.2 Hz, 2H, CH2CH3), 5.17 (br s, 1H, 1′-H), 7.25 (ddd, J = 8.2, 7.1, 1.3 Hz,
1H, 5/6-H), 7.36 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H, 5/6-H), 7.70 (ddd, J = 7.9, 1.3, 1.0 Hz, 1H,
4/7-H), 8.23 (ddd, J = 8.2, 1.3, 1.0 Hz, 1H, 4/7-H), 12.74 (s, 1H, NH).
13C NMR (125 MHz, CDCl3) δ 14.38 (CH2CH3), 25.41 (C-4′), 25.48 (C-3′/5′), 29.93 (C-2′/6′),
59.71 (C-1′), 61.01 (CH2CH3), 105.89 (C-3), 121.57 (C-4–7), 122.70 (C-4–7), 123.49 (C-4–7),
125.26 (C-4–7), 133.40 (C-3a/7a), 133.61 (C-3a/7a), 157.90 (C-2), 167.99 (CO2CH2), 176.61
(NHCS).











M = 350.46 g/mol
Yellow needles; yield: 1.14 g (65%); mp 175–176 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 1.42 (t, J = 7.1 Hz, 3H, CH2CH3), 3.75 (t, J = 4.9 Hz,
4H, 3′/5′-H), 3.96 (t, J = 4.9 Hz, 4H, 2′/6′-H), 4.45 (q, J = 7.0 Hz, 2H, CH2CH3), 7.31
(ddd, J = 8.0, 7.1, 1.0 Hz, 1H, 5/6-H), 7.42 (ddd, J = 8.2, 7.3, 1.0 Hz, 1H, 5/6-H), 7.90 (d,
J = 7.9 Hz, 1H, 4/7-H), 8.20 (d, J = 8.2 Hz, 1H, 4/7-H), 12.58 (s, 1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 14.30 (CH2CH3) 48.10 (C-3′/5′), 61.37 (CH2CH3), 65.45
(C-2′/6′), 105.70 (C-3), 122.05 (C-4–7), 122.58 (C-4–7), 123.96 (C-4–7), 125.79 (C-4–7), 132.72
(C-3a/7a), 133.23 (C-3a/7a), 156.59 (C-2), 166.99 (CO2CH2), 176.17 (NHCS).
Anal. Calcd for C16H18N2O3S2: C, 54.83; H, 5.18; N, 7.99. Found: C, 55.01; H, 5.26; N, 7.96.








M = 258.36 g/mol







M = 258.36 g/mol
Compound was taken from the substance library.
2-Thioureidothiophene-3-carboxylic Acids 103 and 105–107; General Procedure
A mixture of the appropriate ethyl 2-thioureidothiophene-3-carboxylate (2.00 mmol), NaOH
(1 M, 10 mL), and EtOH (10 mL) was refluxed for 1 h. The reaction was allowed to cool to
rt, and H2O (30 mL) was added. The mixture was filtered, cooled to 0 ℃, and acidified with









M = 298.42 g/mol
Saponification of ethyl 2-(3-cyclohexyl-3-methylthioureido)thiophene-3-carboxylate (95) ac-
cording to the aforementioned procedure gave 103 as a white solid; yield: 480 mg (78%); mp
174–175 ℃.
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1H NMR (500 MHz, DMSO-d6) δ 1.06–1.87 (m, 10H, 2′–6′-H), 3.15 (s, 3H, NCH3), 4.83 (br s,
1H, 1′-H), 6.79 (d, J = 5.7 Hz, 1H, 4/5-H), 7.15 (d, J = 6.0 Hz, 1H, 4/5-H), 12.08 (s, 1H,
NH), 13.20 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 24.91 (C-4′), 25.40 (C-3′/5′), 29.32 (C-2′/6′), 32.29 (NCH3),
59.18 (C-1′), 113.21 (C-3), 115.40 (C-4/5), 123.69 (C-4/5), 152.73 (C-2), 167.88 (CO2H),
175.20 (NHCS).









M = 300.44 g/mol









M = 348.44 g/mol
Saponification of ethyl 2-[(4-morpholinylthiocarbonyl)amino]-4-phenylthiophene-3-carboxyl-
ate166 gave 105 as a white solid; yield: 585 mg (84%); mp 142–144 ℃.
1H NMR (500 MHz, DMSO-d6) δ 3.71 (t, J = 4.9 Hz, 4H, 3′′/5′′-H), 3.91 (t, J = 4.7 Hz, 4H,
2′′/6′′-H), 6.70 (s, 1H, 5-H), 7.26–7.34 (m, 5H, 2′–6′-H), 12.55 (s, 1H, NH), 13.05 (br s, 1H,
CO2H).
13C NMR (125 MHz, DMSO-d6) δ 47.89 (C-3′′/5′′), 65.53 (C-2′′/6′′), 112.27 (C-3), 114.79
(C-5), 126.88 (C-4′), 127.49 (C-2′/6′), 129.06 (C-3′/5′), 137.76 (C-4/1′), 139.39 (C-4/1′),
153.73 (C-2), 168.23 (CO2H), 176.11 (NHCS).
Anal. Calcd for C16H16N2O3S2: C, 55.15; H, 4.63; N, 8.04. Found: C, 55.13; H, 4.91; N, 8.08.









M = 334.46 g/mol
Saponification of ethyl 2-(3,3-diethylthioureido)-5-phenylthiophene-3-carboxylate (96) gave
106 as a white solid; yield: 600 mg (90%); mp 181–182 ℃. Material for X-ray crystallography
was recrystallized from MeOH.
1H NMR (500 MHz, DMSO-d6) δ 1.24 (t, J = 7.1 Hz, 6H, CH2CH3), 3.74–3.83 (m, 4H,
CH2CH3), 7.24–7.28 (m, 1H, 4′-H), 7.36–7.40 (m, 2H, 3′/5′-H), 7.50 (s, 1H, 4-H), 7.59–7.64
(m, 2H, 2′/6′-H), 12.24 (s, 1H, NH), 13.47 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 12.30 (CH2CH3), 45.52 (CH2CH3), 114.06 (C-3), 119.50
(C-4), 125.10 (C-2′/6′), 127.28 (C-4′), 129.23 (C-3′/5′), 130.68 (C-5), 133.68 (C-1′), 152.12
(C-2), 167.91 (CO2H), 174.15 (NHCS).









M = 348.44 g/mol
Saponification of ethyl 2-[(4-morpholinylthiocarbonyl)amino]-5-phenylthiophene-3-carboxyl-
ate (97) gave 107 as a white solid; yield: 511 mg (73%); mp 199–200 ℃.
1H NMR (500 MHz, DMSO-d6) δ 3.72 (t, J = 4.9 Hz, 4H, 3′′/5′′-H), 3.90 (t, J = 4.9 Hz, 4H,
2′′/6′′-H), 7.22–7.30 (m, 1H, 4′-H), 7.35–7.41 (m, 2H, 3′/5′-H), 7.52 (s, 1H, 4-H), 7.60–7.64
(m, 2H, 2′/6′-H), 12.25 (s, 1H, NH), 13.42 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 47.88 (C-3′′/5′′), 65.49 (C-2′′/6′′), 114.61 (C-3), 119.69
(C-4), 125.14 (C-2′/6′), 127.39 (C-4′), 129.26 (C-3′/5′), 131.08 (C-5), 133.55 (C-1′), 151.63
(C-2), 167.64 (CO2H), 175.63 (NHCS).










M = 286.41 g/mol









M = 326.48 g/mol









M = 300.40 g/mol










M = 315.41 g/mol
Compound was taken from the substance library.







M = 298.42 g/mol








M = 284.40 g/mol







M = 312.45 g/mol








M = 352.51 g/mol









M = 326.43 g/mol








M = 339.48 g/mol









M = 326.48 g/mol
Compound was taken from the substance library.








M = 326.48 g/mol
Compound was taken from the substance library.
2-Thioureidobenzo[b]thiophene-3-carboxylic Acids 120–122; General Procedure
A mixture of the appropriate ethyl 2-thioureidobenzo[b]thiophene-3-carboxylate (98–100,
2.00 mmol), NaOH (1 M, 10 mL), and EtOH (10 mL) was refluxed for 1 h. The reaction
was allowed to cool to rt, and H2O (30 mL) was added. The solution was cooled to 0 ℃ and
acidified with 2 M HCl. The precipitate was removed by suction filtration, washed with H2O







M = 308.42 g/mol
Yellowish needles; yield: 250 mg (41%); mp 153–155 ℃ (EtOH; lit.131 142–144 ℃).
1H NMR (500 MHz, DMSO-d6) δ 1.26 (t, J = 6.8 Hz, 6H, CH2CH3), 3.70–3.90 (m, 4H,
CH2CH3), 7.27 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H, 5/6-H), 7.38 (ddd, J = 8.4, 7.2, 1.3 Hz, 1H,
5/6-H), 7.86 (ddd, J = 7.9, 1.3, 0.6 Hz, 1H, 4/7-H), 8.23 (dt, J = 8.2, 1.0 Hz, 1H), 13.02 (s,
1H, NH), 13.78 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 12.28 (CH2CH3), 46.13 (CH2CH3), 105.85 (C-3), 121.88
(C-4–7), 122.54 (C-4–7), 123.58 (C-4–7), 125.53 (C-4–7), 132.67 (C-3a/7a), 133.84 (C-3a/7a),
156.85 (C-2), 169.09 (CO2H), 174.86 (NHCS).










M = 348.48 g/mol
Yellow needles; yield: 563 mg (81%); mp 167–170 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 1.14–1.82 (m, 10H, 2′–6′-H), 3.21 (s, 3H, NCH3), 5.03 (br s,
1H, 1′-H), 7.27 (ddd, J = 8.0, 6.9, 1.1 Hz, 1H, 5/6-H), 7.38 (ddd, J = 8.2, 7.1, 1.1 Hz, 1H,
5/6-H), 7.86 (d, J = 7.9 Hz, 1H, 4/7-H), 8.24 (d, J = 8.2 Hz, 1H, 4/7-H), 12.98 (s, 1H, NH),
13.71 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 24.90 (C-4′), 25.38 (C-3′/5′), 29.24 (C-2′/6′), 31.81 (NCH3),
59.49 (C-1′), 106.08 (C-3), 121.86 (C-4–7), 122.58 (C-4–7), 123.59 (C-4–7), 125.49 (C-4–7),
132.73 (C-3a/7a), 133.89 (C-3a/7a), 156.83 (C-2), 168.93 (CO2H), 175.65 (NHCS).








M = 322.40 g/mol
Orange needles; yield: 418 mg (65%); mp 136–139 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 3.74 (t, J = 4.9 Hz, 4H, 3′/5′-H), 3.96 (t, J = 4.7 Hz, 4H,
2′/6′-H), 7.28 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H, 5/6-H), 7.39 (ddd, J = 8.2, 7.1, 1.1 Hz, 1H,
5/6-H), 7.87 (d, J = 7.6 Hz, 1H, 4/7-H), 8.24 (d, J = 8.2 Hz, 1H, 4/7-H), 12.05 (s, 1H, NH),
13.68 (br s, 1H, CO2H).
13C NMR (125 MHz, DMSO-d6) δ 48.11 (C-3′/5′), 65.49 (C-2′/6′), 106.37 (C-3), 121.93
(C-4–7), 122.67 (C-4–7), 123.76 (C-4–7), 125.60 (C-4–7), 132.70 (C-3a/7a), 133.87 (C-3a/7a),
156.45 (C-2), 168.84 (CO2H), 176.22 (NHCS).










M = 234.30 g/mol
Method 1: Methyl 2-(3,3-diethylthioureido)benzoate (70; 0.799 g, 3.00 mmol) was kept in
concd H2SO4 (12 mL) at rt for 24 h. The solution was poured into a mixture of ice–water
(100 mL) and EtOAc (100 mL). After neutralization, the aqueous layer was further extracted
with EtOAc (2 × 100 mL). The combined organic layers were dried over Na2SO4, filtered,
and evaporated to dryness. Recrystallisation from MeOH yielded 123 (0.505 g, 72%) as
colorless needles, mp 74–75 ℃ (MeOH; lit.189 72–74 ℃).
1H NMR (500 MHz, CDCl3) δ 1.24 (t, J = 7.3 Hz, 6H, CH2CH3), 3.59 (q, J = 7.3 Hz, 4H,
CH2CH3), 7.10 (ddd, J = 8.2, 7.6, 1.3 Hz, 1H, 6-H), 7.37 (dd, J = 7.9, 1.3 Hz, 1H, 8-H),
7.55 (ddd, J = 8.5, 6.9, 1.6 Hz, 1H, 7-H), 8.00 (dd, J = 8.0, 1.6 Hz, 1H, 5-H).
13C NMR (125 MHz, CDCl3) δ 13.03 (CH2CH3), 43.35 (CH2CH3), 116.29 (C-4a), 122.93
(C-6), 124.71 (C-5), 128.21 (C-8), 135.61 (C-7), 151.50 (C-8a), 155.43 (C-2), 184.52 (C-4).
Anal. Calcd for C12H14N2OS: C, 61.51; H, 6.02; N, 11.96. Found: C, 61.50; H, 5.99; N,
11.96.
Method 2: 2-(3,3-Diethylthioureido)-N,N -diethylbenzamide (133; 0.615 g, 2.00 mmol) was
treated with concd H2SO4 (8 mL) as described under Method 1 obtaining 123 (0.449 g, 96%)
as a white solid.
Method 3: 2-(3,3-Diethylthioureido)benzoic acid (78; 0.450 g, 1.78 mmol) and TFAA (4.5 mL)
were kept at rt for 12 h. After removal of the solvent, the resulting crude material was
purified by column chromatography on silica gel using petroleum ether–EtOAc (2:1) as eluent








M = 274.38 g/mol
According to the preparation of 123 (Method 1), 124 (0.607 g, 74%) was obtained from
methyl 2-(3-cyclohexyl-3-methylthioureido)benzoate (71) as colorless plates, mp 111–114 ℃
(EtOH).
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1H NMR (500 MHz, CDCl3) δ 1.05–1.88 (m, 10H, 2′/3′/4′/5′/6′-H), 3.05 (s, 3H, NCH3), 4.22
(br s, 1H, 1′-H), 7.10 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H, 6-H), 7.38 (dd, J = 8.2, 1.3 Hz, 1H,
8-H), 7.56 (ddd, J = 8.5, 6.9, 1.6 Hz, 1H, 7-H), 8.00 (dd, J = 8.2, 1.6 Hz, 1H, 5-H).
13C NMR (125 MHz, CDCl3) δ 25.40 (C-4′), 25.73 (C-3′/5′), 30.14 (C-2′/6′), 30.45 (NCH3),
56.82 (C-1′), 116.50 (C-4a), 123.01 (C-6), 124.75 (C-5), 128.18 (C-8), 135.64 (C-7), 151.36
(C-8a), 156.68 (C-2), 184.48 (C-4).








M = 268.33 g/mol
Method 1: According to the preparation of 123 (Method 1), 125 (0.160 g, 20%) was obtained
from methyl 2-(3-methyl-3-phenylthioureido)benzoate (72) as colorless needles, mp 78–79 ℃
(EtOH).
1H NMR (500 MHz, CDCl3) δ 3.59 (s, 3H, NCH3), 7.18 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H, 6-H),
7.25–7.29 (m, 2H, 2′/6′-H), 7.37–7.42 (m, 1H, 4′-H), 7.42–7.47 (m, 2H, 3′/5′-H), 7.51 (dd,
J = 8.2, 1.0 Hz, 1H, 8-H), 7.62 (ddd, J = 8.5, 6.9, 1.6 Hz, 1H, 7-H), 8.02 (dd, J = 8.0, 1.6 Hz,
1H, 5-H).
13C NMR (125 MHz, CDCl3) δ 39.93 (NCH3), 117.07 (C-4a), 123.93 (C-6), 125.00 (C-5),
128.26 (C-2′/6′), 128.29 (C-8), 128.76 (C-4′), 130.16 (C-3′/5′), 135.72 (C-7), 142.20 (C-1′),
150.50 (C-8a), 156.97 (C-2), 184.20 (C-4).
Anal. Calcd for C15H12N2OS: C, 67.14; H, 4.51; N, 10.44. Found: C, 67.02; H, 4.61; N,
10.40.
Method 2: 2-(3-Methyl-3-phenylthioureido)benzoic acid (80; 0.859 g, 3.00 mmol) and Ac2O
(7.0 mL) were kept at rt for 12 h. The solvent was removed under reduced pressure.









M = 282.36 g/mol
2-(3-Benzyl-3-methylthioureido)benzoic acid (81; 0.150 g, 0.500 mmol) and Ac2O (1.0 mL)
were kept at rt for 8 h. The resulting crystals were removed by suction filtration to obtain
126 (0.109 g, 77%) as colorless needles, mp 70–71 ℃.
1H NMR (500 MHz, CDCl3) δ 3.13 (s, 3H, NCH3), 4.87 (s, 2H, CH2Ph), 7.15 (ddd, J = 8.0,
6.9, 1.0 Hz, 1H, 6-H), 7.26–7.36 (m, 5H, 2′/3′/4′/5′/6′-H), 7.42 (dd, J = 8.2, 1.0 Hz, 1H,
8-H), 7.59 (ddd, J = 8.4, 6.9, 1.6 Hz, 1H, 7-H), 8.03 (dd, J = 8.0, 1.6 Hz, 1H, 5-H).
13C NMR (125 MHz, CDCl3) δ 35.95 (NCH3), 53.56 (CH2Ph), 116.34 (C-4a), 123.42 (C-6),
124.84 (C-5), 127.58 (C-2′/6′), 127.73 (C-4′), 128.30 (C-8), 128.79 (C-3′/5′), 135.76 (C-7),
136.31 (C-1′), 151.04 (C-8a), 157.07 (C-2), 183.95 (C-4).








M = 296.39 g/mol
Method 1: According to the preparation of 125 (Method 2), 127 (0.578 g, 65%) was obtained
from 2-[3-methyl-3-(2-phenylethyl)thioureido]benzoic acid (82) as a white solid, mp 72–75 ℃
(EtOH).
1H NMR (500 MHz, CDCl3) δ 2.96 (t, J = 7.6 Hz, 2H, CH2CH2Ph), 3.08 (s, 3H, NCH3),
3.81 (t, J = 7.6 Hz, 2H, CH2CH2Ph), 7.14 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H, 6-H), 7.20–7.33
(m, 5H, 2′/3′/4′/5′/6′-H), 7.44 (dd, J = 8.2, 1.0 Hz, 1H, 8-H), 7.59 (ddd, J = 8.2, 6.9, 1.6 Hz,
1H, 7-H), 8.03 (dd, J = 7.9, 1.6 Hz, 1H, 5-H).
13C NMR (125 MHz, CDCl3) δ 33.76 (CH2CH2Ph), 37.07 (NCH3), 53.03 (CH2CH2Ph),
116.23 (C-4a), 123.38 (C-6), 124.83 (C-5), 126.68 (C-4′), 128.18 (C-8), 128.70 (C-2′/6′), 128.84
(C-3′/5′), 135.77 (C-7), 138.32 (C-1′), 150.90 (C-8a), 156.35 (C-2), 183.91 (C-4).
Anal. Calcd for C17H16N2OS: C, 68.89; H, 5.44; N, 9.45. Found: C, 68.93; H, 5.44; N, 9.50.
Method 2: 2-[3-Methyl-3-(2-phenylethyl)thioureido]benzoic acid (82; 0.940 g, 3.00 mmol) and
TFAA (7.0 mL) were kept at rt for 12 h. After removal of the solvent, the resulting crude
material was purified by column chromatography on silica gel using petroleum ether–EtOAc







2′ M = 232.30 g/mol
Method 1: According to the preparation of 123 (Method 1), 128 (0.514 g, 74%) was obtained
from methyl 2-[(1-pyrrolidinylthiocarbonyl)amino]benzoate (75) as white needles, mp 105–
107 ℃ (EtOH).
1H NMR (500 MHz, CDCl3) δ 1.97–2.04 (m, 4H, 3′/4′-H), 3.58 (br s, 4H, 2′/5′-H), 7.10 (ddd,
J = 8.2, 6.9, 1.3 Hz, 1H, 6-H), 7.39 (dd, J = 8.2, 1.0 Hz, 1H, 8-H), 7.56 (ddd, J = 8.5, 7.3,
1.6 Hz, 1H, 7-H), 8.01 (dd, J = 8.4, 1.6 Hz, 1H, 5-H).
13C NMR (125 MHz, CDCl3) δ 24.97 (C-3′/4′), 47.67 (C-2′/5′), 116.58 (C-4a), 122.87 (C-6),
124.86 (C-5), 128.06 (C-8), 135.65 (C-7), 151.57 (C-8a), 154.62 (C-2), 184.22 (C-4).
Anal. Calcd for C12H12N2OS: C, 62.04; H, 5.21; N, 12.06. Found: C, 61.88; H, 5.28; N,
11.87.
Method 2: According to the preparation of 123 (Method 2), 128 (0.435 g, 94%) was







2′ M = 246.36 g/mol
According to the preparation of 123 (Method 1), 129 (0.594 g, 80%) was obtained from
methyl 2-[(1-piperidinylthiocarbonyl)amino]benzoate (76) as white needles, mp 87–88 ℃
(EtOH).
1H NMR (500 MHz, CDCl3) δ 1.60–1.72 (m, 6H, 3′/4′/5′-H), 3.67–3.72 (m, 4H, 2′/6′-H), 7.12
(ddd, J = 8.2, 6.9, 1.3 Hz, 1H, 6-H), 7.36 (dd, J = 8.2, 1.0 Hz, 1H, 8-H), 7.56 (ddd, J = 8.5,
6.9, 1.6 Hz, 1H, 7-H), 8.00 (dd, J = 7.9, 1.6 Hz, 1H, 5-H).
13C NMR (125 MHz, CDCl3) δ 24.64 (C-4′), 25.62 (C-3′/5′), 46.84 (C-2′/6′), 116.36 (C-4a),
123.28 (C-6), 124.81 (C-5), 128.13 (C-8), 135.69 (C-7), 151.22 (C-8a), 156.27 (C-2), 184.29
(C-4).









M = 248.30 g/mol
Method 1: According to the preparation of 123 (Method 1), 130 (0.395 g, 53%) was obtained
from methyl 2-[(4-morpholinylthiocarbonyl)amino]benzoate (77) as colorless needles, mp
137–138 ℃ (EtOH; lit.245 136–137 ℃).
1H NMR (500 MHz, CDCl3) δ 3.71–3.79 (m, 8H, 2′/3′/5′/6′-H), 7.18 (ddd, J = 8.0, 6.9,
1.3 Hz, 1H, 6-H), 7.38 (dd, J = 8.2, 1.3 Hz, 1H, 8-H), 7.60 (ddd, J = 8.5, 6.9, 1.6 Hz, 1H,
7-H), 8.02 (dd, J = 8.1, 1.7 Hz, 1H, 5-H).
13C NMR (125 MHz, CDCl3) δ 45.90 (C-3′/5′), 66.40 (C-2′/6′), 116.74 (C-4a), 124.08 (C-6),
124.95 (C-5), 128.32 (C-8), 135.88 (C-7), 150.45 (C-8a), 156.75 (C-2), 183.44 (C-4).
Anal. Calcd for C12H12N2O2S: C, 58.05; H, 4.87; N, 11.28. Found: C, 58.08; H, 4.90; N,
11.22.
Method 2: According to the preparation of 123 (Method 2), 130 (0.453 g, 92%) was obtained
from N -[2-(morpholin-4-ylcarbonyl)phenyl]morpholine-4-carbothioamide (135) as light yellow
needles.
Method 3: N -[2-(Morpholin-4-ylcarbonyl)phenyl]morpholine-4-carbothioamide (135; 0.711 g,
2.00 mmol) was heated under reflux in anhydrous methanolic HCl (0.25 M, 10 mL) for 2 min.
After cooling to rt, the precipitate was removed by suction filtration, washed with H2O







M = 227.30 g/mol
Triethylamine (1.70 g, 2.34 mL, 16.8 mmol) was added dropwise to an ice-cooled solution
of anthranilic acid (0.960 g, 7.00 mmol) and carbon disulfide (1.07 g, 0.845 mL, 14.0 mmol)
in 1,4-dioxane (30 mL). The cooled mixture was stirred for 5.5 h, followed by a dropwise
addition of methyl iodide (1.09 g, 0.479 mL, 7.70 mmol) in 1,4-dioxane (20 mL). After stirring
for further 1.5 h in the ice bath, the reaction mixture was allowed to warm to rt and stirred
for 21 h under light protection. The solvent was removed under reduced pressure, and the
crude material was partionated between EtOAc (100 mL) and HCl (0.2 M, 100 mL). The
aqueous phase was further extracted with EtOAc (2 × 200 mL). The combined organic layers
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were dried (Na2SO4), filtered and evaporated to dryness. Recrystallization from PhMe gave
131 (1.22 g, 77%) as light yellow needles, mp 148–150 ℃ (PhMe).
1H NMR (500 MHz, CDCl3) δ 2.67 (s, 3H, SCH3), 7.22 (td, J = 7.8, 1.3 Hz, 1H, 5-H), 7.62
(ddd, J = 8.5, 7.1, 1.6 Hz, 1H, 4-H), 8.15 (dd, J = 8.0, 1.7 Hz, 1H, 6-H), 9.16 (d, J = 8.5 Hz,
1H, 3-H), 11.91 (br s, 1H, NH).
13C NMR (125 MHz, CDCl3) δ 18.52 (SCH3), 115.88 (C-1), 122.17 (C-3), 124.43 (C-5), 131.95
(C-6), 134.90 (C-4), 142.15 (C-2), 171.44 (CO2H), 198.34 (NHCS).






M = 209.29 g/mol
Method 1: 2-[(Methylthio)thiocarbonylamino]benzoic acid (131; 0.909 g, 4.00 mmol) was
heated to reflux in Ac2O (10 mL) for 30 min. The solvent was removed under reduced
pressure, and the crude material was recrystallized from MeOH to obtain 132 (0.782 g, 93%)
as colorless needles, mp 54–56 ℃ (MeOH).
1H NMR (500 MHz, DMSO-d6) δ 2.72 (s, 3H, SCH3), 7.58 (ddd, J = 7.9, 7.3, 1.3 Hz, 1H,
6-H), 7.72 (dd, J = 8.0, 1.2 Hz, 1H, 8-H), 7.92 (ddd, J = 8.5, 7.3, 1.9 Hz, 1H, 7-H), 8.06 (dd,
J = 8.2, 1.9 Hz, 1H, 5-H).
13C NMR (125 MHz, DMSO-d6) δ 13.92 (SCH3), 118.65 (C-4a), 124.68 (C-5), 128.33 (C-6),
129.86 (C-8), 136.84 (C-7), 147.50 (C-8a), 163.47 (C-2), 182.33 (C-4).
Anal. Calcd for C9H7NOS2: C, 51.65; H, 3.37; N, 6.69. Found: C, 51.72; H, 3.36; N, 6.68.
Method 2: 2-[(Methylthio)thiocarbonylamino]benzoic acid (131; 0.682 g, 3.00 mmol) and
TFAA (7.0 mL) were kept at rt for 12 h. After removal of the solvent, the resulting crude
material was purified by column chromatography on silica gel using petroleum ether–EtOAc











CH32 M = 307.45 g/mol
Diethylamine (0.914 g, 1.29 mL, 12.5 mmol) was added dropwise to a solution of 2-(methylthio)-
4H -3,1-benzothiazin-4-one (132; 1.05 g, 5.00 mmol) in acetone (15 mL). After stirring for
1 h, the mixture was heated to reflux for 1 h, and allowed to cool to ambient temperature.
The solvent was removed under reduced pressure. Recrystallization from EtOH gave 133
(0.998 g, 65%) as colorless prisms, mp 116–117 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 1.01–1.08 (m, 6H, 2 × CH2CH3), 1.14 (t, J = 7.1 Hz, 6H,
2 × CH2CH3), 3.20 (q, J = 6.9 Hz, 2H, CH2CH3), 3.37 (q, J = 6.9 Hz, 2H, CH2CH3), 3.67
(q, J = 6.9 Hz, 4H, 2 × CH2CH3), 7.20–7.26 (m, 2H, 5/6-H), 7.33–7.38 (m, 1H, 4-H), 7.41
(d, J = 7.9 Hz, 1H, 3-H), 8.67 (s, 1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 12.44 (CH2CH3), 12.64 (CH2CH3), 13.91 (CH2CH3), 38.20
(CH2CH3), 43.09 (CH2CH3), 44.88 (CH2CH3), 125.37 (C-5/6), 125.84 (C-5/6), 128.58 (C-4),
130.00 (C-3), 134.59 (C-1), 138.17 (C-2), 168.26 (CON), 179.34 (NHCS).









M = 303.42 g/mol
According to the preparation of 133, compound 134 (1.13 g, 74%) was obtained from 132
and pyrrolidine as light yellow prisms, mp 160–162 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 1.71–2.08 (m, 8H, 3/4/3′′/4′′-H), 3.38–3.70 (m, 8H,
2/5/2′′/5′′-H), 7.16 (td, J = 7.6, 1.3 Hz, 1H, 4′-H), 7.38 (td, J = 7.9, 1.6 Hz, 1H, 5′-H), 7.42
(dd, J = 7.7, 1.4 Hz, 1H, 3′-H), 7.88 (d, J = 7.9 Hz, 1H, 6′-H), 9.35 (s, 1H, NH).
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13C NMR (125 MHz, DMSO-d6) δ 24.02 (C-3/4/3′′/4′′), 25.91 (C-3/4/3′′/4′′), 46.03 (C-
2/5/2′′/5′′), 49.13 (C-2/5/2′′/5′′), 124.03 (C-4′), 126.53 (C-6′), 127.20 (C-3′), 129.26 (C-5′),
130.52 (C-2′), 138.44 (C-1′), 167.39 (CON), 176.74 (NHCS).











M = 335.42 g/mol
Method 1: According to the preparation of 133, compound 135 (1.51 g, 90%) was obtained
from 132 and morpholine as colorless prisms, mp 170–173 ℃ (EtOH).
1H NMR (500 MHz, DMSO-d6) δ 3.48–3.63 (m, 12H, 2/6/2′/3′/5′/6′-H) 3.85 (t, J = 4.6 Hz,
4H, 3/5-H), 7.23–7.29 (m, 3H, 3′/4′/6′-H), 7.39 (ddd, J = 7.8, 6.9, 1.9 Hz, 1H, 5′-H), 9.31 (s,
1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 41.70 (C-2/3/5/6/2′′/3′′/5′′/6′′), 47.48 (C-2/3/5/6/
2′′/3′′/5′′/6′′), 48.85 (C-2/3/5/6/2′′/3′′/5′′/6′′), 66.06 (C-2/3/5/6/2′′/3′′/5′′/6′′), 66.12 (C-
2/3/5/6/2′′/3′′/5′′/6′′), 66.30 (C-2/3/5/6/2′′/3′′/5′′/6′′), 125.75 (C-3′), 127.26 (C-4′), 129.29
(C-5′), 129.35 (C-6′), 133.38 (C-2′), 138.38 (C-1′), 167.06 (CON), 181.93 (NHCS).
Anal. Calcd for C16H21N3O3S: C, 57.29; H, 6.31; N, 12.53. Found: C, 57.52; H, 6.35; N,
12.35.
Method 2: Morpholine (0.392 g, 0.396 mL, 4.50 mmol) was added dropwise to a solution of
2-(morpholin-4-yl)-4H -3,1-benzothiazin-4-one (130; 0.497 g, 2.00 mmol) in acetone (6.0 mL).
After stirring for 1 h, the mixture was heated to reflux for 1 h, and allowed to cool to rt. The
formed precipitate was removed by suction filtration and washed with cold acetone (5.0 mL)










M = 296.41 g/mol
Morpholine (0.392 g, 0.396 mL, 4.50 mmol) was added dropwise to a solution of 2-(methylthio)-
4H -3,1-benzothiazin-4-one (132; 0.418 g, 2.00 mmol) in acetone (6.0 mL). After stirring for
1 h, the resulting precipitate was removed by suction filtration and washed with cold acetone
(5.0 mL) to obtain 136 (0.299 g, 50%) as a white solid, mp 143–145 ℃.
1H NMR (500 MHz, DMSO-d6) δ 2.55 (s, 3H, SCH3), 3.15–3.64 (m, 8H, 2′/3′/5′/6′-H),
7.35–7.49 (m, 4H, 3/4/5/6-H), 11.52 (s, 1H, NH).
13C NMR (125 MHz, DMSO-d6) δ 18.24 (SCH3), 41.90 (C-3′/5′), 47.39 (C-3′/5′), 66.09
(C-2′/6′), 66.13 (C-2′/6′), 127.50 (C-3/4), 127.98 (C-3/4), 128.65 (C-5/6), 129.77 (C-5/6),
133.22 (C-2), 136.57 (C-1), 166.40 (CO), 199.94 (NHCS).










M = 218.25 g/mol
In the course of the preparation of 2-(diethylamino)-4H -3,1-benzothiazin-4-one (123) using
TFAA (Method 3), purification of the crude material by column chromatography on silica
gave 137 (0.253 g, 65%) as colorless semisolid material (lit.149 46–47 ℃).
1H NMR (500 MHz, CDCl3) δ 1.22 (t, J = 7.1 Hz, 6H, CH2CH3), 3.53 (q, J = 7.0 Hz, 4H,
CH2CH3), 7.06 (ddd, J = 8.2, 6.9, 1.0 Hz, 1H, 6-H), 7.20 (d, J = 8.2 Hz, 1H, 8-H), 7.55
(ddd, J = 8.5, 6.9, 1.6 Hz, 1H, 7-H), 7.96 (dd, J = 7.9, 1.6 Hz, 1H, 5-H).
13C NMR (125 MHz, CDCl3) δ 13.30 (CH2CH3), 42.19 (CH2CH3), 112.02 (C-4a), 122.70









M = 280.32 g/mol
In the course of the preparation of 2-[N -methyl-N -(2-phenylethyl)amino]-4H -3,1-benzothiazin-
4-one (127) using TFAA (Method 2), purification of the crude material by column chromato-
graphy on silica gave 138 (0.570 g, 68%) as a white solid, mp 68–70 ℃ (lit.154 68.5–69 ℃).
1H NMR (500 MHz, CDCl3) δ 2.94 (t, J = 7.3 Hz, 2H, CH2CH2Ph), 3.05 (s, 3H, NCH3),
3.75 (t, J = 7.3 Hz, 2H, CH2CH2Ph), 7.07–7.12 (m, 1H, 6-H), 7.18–7.30 (m, 6H, 8/2′–6′-H),
7.58 (ddd, J = 7.8, 7.4, 1.8 Hz, 1H, 7-H), 7.97 (dd, J = 7.9, 1.6 Hz, 1H, 5-H).
13C NMR (125 MHz, CDCl3) δ 34.01 (CH2CH2Ph), 35.68 (NCH3), 51.35 (CH2CH2Ph), 112.06
(C-4a), 123.00 (C-5/6/8), 124.15 (C-5/6/8), 128.61 (C-5/6/8), 126.54 (C-4′), 128.57 (C-2′/6′),
128.82 (C-3′/5′), 136.56 (C-7), 138.42 (C-1′), 150.93 (C-8a), 153.84 (C-2), 159.90 (C-4).







M = 193.22 g/mol
In the course of the preparation of 2-(methylthio)-4H -3,1-benzothiazin-4-one (132) using
TFAA (Method 2), purification of the crude material by column chromatography on silica
yielded 139 (0.010 g, 2%) as a white solid, mp 103–105 ℃ (lit.149 108–109 ℃).
1H NMR (500 MHz, CDCl3) δ 2.58 (s, 3H, SCH3), 7.40 (ddd, J = 8.2, 7.2, 1.3 Hz, 1H, 6-H),
7.45 (d, J = 7.9 Hz, 1H, 8-H), 7.74 (ddd, J = 7.9, 7.3, 1.6 Hz, 1H, 7-H), 8.11 (dd, J = 8.0,
1.6 Hz, 1H, 5-H).
13C NMR (125 MHz, CDCl3) δ 14.16 (SCH3), 115.59 (C-4a), 125.59 (C-5/6/8), 127.22













2 × M = 356.31 g/mol
This substance was prepared according to an unpublished procedure.246 A mixture of tetra-
fluorophthalic acid (357 mg, 1.50 mmol), isopropylamine (177 mg, 257 µL, 3.00 mmol) and
anhydrous PhMe (100 mL) was refluxed for 3 h and kept at rt for additional 2 h. The
precipitate was isolated by suction filtrations and dried to give pure 140 as a white solid;
yield: 475 mg (89%); mp 197–200 ℃. IR (KBr): 3205, 2988, 2952, 2548, 1651, 1570, 1528,
1464, 1376, 1216, 1171, 1109, 1061, 1008 cm−1. Material for X-ray crystallography was
obtained as follows: Compound 140 was dissolved in 1-propanol/water (500:1 v/v). Slow
evaporation of this solution at rt afforded colorless single crystals.
1H NMR (500 MHz, DMSO-d6) δ 1.12 (d, 3J = 6.6 Hz, 12H, CH3), 3.20 (sept, 3J = 6.5 Hz,
2H, CH), 7.93 (br s, 6H, NH).
13C NMR (125 MHz, DMSO-d6) δ 20.76 (CH3), 42.69 (CH), 125.85 (d, 2JC–F = 16 Hz, C-1/2),
137.63 (d, 1JC–F = 244 Hz, C-4/5), 142.43 (d, 1JC–F = 236 Hz, C-3/6), 164.46 (CO).
Solid-state 13C NMR δ 20.9 (CH3), 43.1 (CH), 125.7 (C-1/2), 136–149 (C-3–6), 168.1 (CO).











M = 297.20 g/mol
A solution of isopropylamine (120 mg, 173 µL, 2.00 mmol) in water (2.0 mL) was added to
tetrafluorophthalic acid (714 mg, 2.00 mmol). After the mixture was stirred at rt for 10 min,
the solvent was evaporated under reduced pressure. The crude product was recrystallized
from CH3CN to give 141 as colorless rhombs; yield: 502 mg (84%); mp 154–156 ℃ (CH3CN).
IR (KBr): 3161, 2942, 2570, 1917, 1718, 1628, 1592, 1475, 1376, 1124, 1068 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 1.16 (d, 3J = 6.6 Hz, 6H, CH3), 3.26 (sept, 3J = 6.6 Hz,
1H, CH), 7.90 (br s, 3H, NH).
8.15 Isopropylammonium Tetrafluoro(hydrogen)phthalates 135
13C NMR (125 MHz, DMSO-d6) δ 20.53 (CH3), 43.00 (CH), 122.19 (d, 2JC–F = 14 Hz, C-1/2),
139.60 (d, 1JC–F = 253 Hz, C-4/5), 143.78 (d, 1JC–F = 248 Hz, C-3/6), 163.13 (CO).
Solid-state 13C NMR δ 20.1 (CH3), 46.6 (CH), 118.0 (C-1/2), 122.9 (C-1/2), 134–149 (C-3–6),
165.4 (CO).
Anal. Calcd for C11H11F4NO4: C, 44.45; H, 3.73; N, 4.71. Found: C, 44.44; H, 3.79; N, 4.65.
















M = 535.30 g/mol
This substance was prepared according to an unpublished procedure.246 Compound 140
(356 mg, 1.00 mmol) was dissolved in water (5 mL). After addition of HCl (2 M, 2.5 mL) the
mixture was kept at rt in an open vessel. Evaporation gave a reduced volume of the solution,
and colorless needles were formed; yield: 139 mg (52%); mp 152–155 ℃. IR (KBr): 3226,
3161, 2870, 2550, 1900, 1717, 1628, 1575, 1527, 1475, 1425, 1376, 1322, 1295, 1247, 1123,
1067 cm−1.
1H NMR (500 MHz, DMSO-d6) δ 1.17 (d, 3J = 6.6 Hz, 6H, CH3), 3.27 (sept, 3J = 6.0 Hz,
1H, CH), 7.87 (br s, 3H, NH).
13C NMR (125 MHz, DMSO-d6) δ 20.54 (CH3), 43.07 (CH), 120.34 (d, 2JC–F = 14 Hz, C-1/2),
140.41 (d, 1JC–F = 253 Hz, C-4/5), 144.23 (d, 1JC–F = 244 Hz, C-3/6), 162.90 (CO).
Solid-state 13C NMR δ 21.3 (CH3), 47.1 (CH), 114.2 (C-1/2), 120.3 (C-1/2), 122.3 (C-1′/2′),
138–151 (C-3–6/3′–6′), 167.1 (CO).
Anal. Calcd for C19H13F8NO8: C, 42.63; H, 2.45; N, 2.62. Found: C, 42.77; H, 2.82; N, 3.29.
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272 Two-Dimensional NMR Spectra













































For details see Supplementary Information of ref.87
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274 Two-Dimensional NMR Spectra
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276 Two-Dimensional NMR Spectra









































































































278 Two-Dimensional NMR Spectra







































































































280 Two-Dimensional NMR Spectra































































































282 Two-Dimensional NMR Spectra































































































284 Two-Dimensional NMR Spectra

































































































286 Two-Dimensional NMR Spectra









































































































288 Two-Dimensional NMR Spectra







































































































290 Two-Dimensional NMR Spectra

































































































292 Two-Dimensional NMR Spectra



























































































294 Two-Dimensional NMR Spectra































































































296 Two-Dimensional NMR Spectra

























































































298 Two-Dimensional NMR Spectra











































































































































300 Two-Dimensional NMR Spectra







































































































































302 Two-Dimensional NMR Spectra

































































































304 Two-Dimensional NMR Spectra





































































































306 Two-Dimensional NMR Spectra















































































































308 Two-Dimensional NMR Spectra









































































































310 Two-Dimensional NMR Spectra







































































































312 Two-Dimensional NMR Spectra

































































































Table 1: Crystallographic data for 17 and 36
Crystal data 17 36
CCDC number 706312 743232
Empirical formula C10H11N3O2S2 C20H22N4O2S2
Formula weight 269.34 414.54
Temperature (K) 100(2) 123(2)
Wavelength (Å) 0.71073 0.71073
Crystal size (mm) 0.34 × 0.24 × 0.10 0.60 × 0.36 × 0.24
Crystal system Triclinic Triclinic
Space group P−1 P−1
a (Å) 6.9565(3) 8.9281(3)
b (Å) 7.6288(2) 9.0083(5)
c (Å) 11.0688(4) 14.0333(6)
α (°) 98.289(2) 89.437(2)
β (°) 97.257(2) 77.579(3)
γ (°) 91.730(2) 65.822(3)
V (Å3) 575.92(4) 1001.66(8)
Z 2 2
Calculated density (g/cm3) 1.553 1.374
Absorption coefficient (mm−1) 0.455 0.290
F (000) 280 436
θ Range for data collection (°) 3.05–27.47 2.57–32.04
Completeness to θ (%) 98.7 (θmax = 27.47°) 96.4 (θmax = 32.04°)
Range of h,k,l −9/9, −9/9, −14/14 −12/13, −13/13, −20/20
Reflections collected/unique 10420/2598 [R(int) = 0.0383] 16369/6737 [R(int) = 0.0461]
Absorption correction Analytical None
Max. and min. transmission 0.9559 and 0.8607 0.9337 and 0.8453
Refinement method Full-matrix least-squares on F 2 Full-matrix least-squares on F 2
Data/restraints/parameters 2598/0/198 6737/0/342
Goodness-of-fit on F 2 1.078 0.909
Final R indices [I > 2σ(I)] R1 = 0.0331, ωR2 = 0.0824 R1 = 0.0395, ωR2 = 0.0753
R indices (all data) R1 = 0.0418, ωR2 = 0.0865 R1 = 0.0841, ωR2 = 0.0851
Largest diff. peak and hole (e/Å3) 0.311 and −0.520 0.325 and −0.296
317
Table 2: Crystallographic data for 42 and 43
Crystal data 42 43
CCDC number 706313 706314
Empirical formula C17H13N3O3S2 C17H13N3O2S2
Formula weight 371.42 355.42
Temperature (K) 100(2) 123(2)
Wavelength (Å) 0.71073 0.71073
Crystal size (mm) 0.52 × 0.09 × 0.04 0.40 × 0.12 × 0.01
Crystal system Triclinic Monoclinic
Space group P−1 P21/c
a (Å) 7.9203(7) 8.2696(6)
b (Å) 9.5787(8) 18.7233(17)
c (Å) 11.8410(10) 10.6990(6)
α (°) 75.019(4) 90
β (°) 77.427(4) 101.037(4)
γ (°) 78.011(5) 90
V (Å3) 835.99(12) 1625.9(2)
Z 2 4
Calculated density (g/cm3) 1.476 1.452
Absorption coefficient (mm−1) 0.341 0.342
F (000) 384 736
θ Range for data collection (°) 2.54–27.51 2.91–28.99
Completeness to θ (%) 97.9 (θmax = 27.51°) 95.1 (θmax = 28.99°)
Range of h,k,l −9/10, −12/12, −15/15 −11/7, −25/23, −14/14
Reflections collected/unique 14557/3777 [R(int) = 0.0486] 9914/4112 [R(int) = 0.0832]
Absorption correction Analytical Semi-empirical from equivalents
Max. and min. transmission 0.9865 and 0.8428 0.98525 and 0.93160
Refinement method Full-matrix least-squares on F 2 Full-matrix least-squares on F 2
Data/restraints/parameters 3777/0/291 4112/0/219
Goodness-of-fit on F 2 0.948 0.921
Final R indices [I > 2σ(I)] R1 = 0.0367, ωR2 = 0.0783 R1 = 0.0551, ωR2 = 0.1016
R indices (all data) R1 = 0.0644, ωR2 = 0.0860 R1 = 0.1477, ωR2 = 0.1305
Largest diff. peak and hole (e/Å3) 0.276 and −0.314 0.334 and −0.445
318 Crystallographic Data
Table 3: Crystallographic data for 48 and 106
Crystal data 48 106
CCDC number 706315 749825
Empirical formula C17H11N3O2S C16H18N2O2S2
Formula weight 321.36 334.44
Temperature (K) 293(2) 100(2)
Wavelength (Å) 0.71073 0.71073
Crystal size (mm) 0.231 × 0.15 × 0.08 0.62 × 0.16 × 0.05
Crystal system Monoclinic Monoclinic
Space group P21/a P21/c
a (Å) 10.3434(4) 15.5096(6)
b (Å) 9.6504(5) 9.1662(3)
c (Å) 15.0913(7) 23.1287(9)
α (°) 90 90
β (°) 102.649(3) 100.876(2)
γ (°) 90 90
V (Å3) 1469.82(12) 3229.0(2)
Z 4 8
Calculated density (g/cm3) 1.452 1.376
Absorption coefficient (mm−1) 0.234 0.338
F (000) 664 1408
θ Range for data collection (°) 2.92–30.03 2.59–27.47
Completeness to θ (%) 96.3 (θmax = 30.03°) 97.1 (θmax = 27.47°)
Range of h,k,l −14/13, −13/12, −21/21 −18/20, −11/10, −30/24
Reflections collected/unique 17540/4139 [R(int) = 0.0651] 21578/7171 [R(int) = 0.0721]
Absorption correction Analytical Analytical
Max. and min. transmission 0.9823 and 0.9559 0.9833 and 0.8179
Refinement method Full-matrix least-squares on F 2 Full-matrix least-squares on F 2
Data/restraints/parameters 4139/0/252 7171/0/541
Goodness-of-fit on F 2 0.904 0.876
Final R indices [I > 2σ(I)] R1 = 0.0417, ωR2 = 0.0861 R1 = 0.0398, ωR2 = 0.0646
R indices (all data) R1 = 0.1092, ωR2 = 0.0994 R1 = 0.0937, ωR2 = 0.0740
Largest diff. peak and hole (e/Å3) 0.326 and −0.315 0.316 and −0.317
319
Table 4: Crystallographic data for 126 and 140
Crystal data 126 140
CCDC number 704615 647436
Empirical formula C16H14N2OS C14H20F4N2O4
Formula weight 282.35 356.32
Temperature (K) 123(2) 123(2)
Wavelength (Å) 0.71073 0.71073
Crystal size (mm) 0.60 × 0.24 × 0.20 0.48 × 0.06 × 0.06
Crystal system Triclinic Monoclinic
Space group P−1 C2/c
a (Å) 5.2288(3) 12.196(1)
b (Å) 9.5012(5) 19.608(2)
c (Å) 13.6203(9) 7.3393(6)
α (°) 95.276(3) 90
β (°) 92.293(3) 103.175(7)
γ (°) 94.088(4) 90
V (Å3) 671.33(7) 1709.0(3)
Z 2 4
Calculated density (g/cm3) 1.397 1.385
Absorption coefficient (mm−1) 0.237 0.128
F (000) 296 744
θ Range for data collection (°) 2.51–27.88 3.43–27.49
Completeness to θ (%) 95.0 (θmax = 27.88°) 98.0 (θmax = 27.49°)
Range of h,k,l −6/6, −12/11, −16/17 −13/15, −21/25, −7/9
Reflections collected/unique 7138/3040 [R(int) = 0.0569] 5383/1926 [R(int) = 0.0516]
Absorption correction Semi-empirical from equivalents None
Max. and min. transmission 0.9799 and 0.8704 0.9923 and 0.9409
Refinement method Full-matrix least-squares on F 2 Full-matrix least-squares on F 2
Data/restraints/parameters 3040/0/182 1926/0/150
Goodness-of-fit on F 2 1.067 0.859
Final R indices [I > 2σ(I)] R1 = 0.0398, ωR2 = 0.1018 R1 = 0.0345, ωR2 = 0.0640
R indices (all data) R1 = 0.0507, ωR2 = 0.1074 R1 = 0.0797, ωR2 = 0.0724
Largest diff. peak and hole (e/Å3) 0.339 and −0.485 0.192 and −0.150
320 Crystallographic Data
Table 5: Crystallographic data for 141 and 142
Crystal data 141 142
CCDC number 730532 646562
Empirical formula C11H11F4NO4 C19H13F8NO8
Formula weight 297.20 535.30
Temperature (K) 123(2) 123(2)
Wavelength (Å) 0.71073 0.71073
Crystal size (mm) 0.34 × 0.20 × 0.10 0.35 × 0.15 × 0.10
Crystal system Monoclinic Monoclinic
Space group P21/n P21/n
a (Å) 7.8520(2) 9.4897(1)
b (Å) 16.2123(5) 10.6655(1)
c (Å) 9.2330(3) 19.8758(3)
α (°) 90 90
β (°) 98.026(2) 90.874(1)
γ (°) 90 90
V (Å3) 1163.84(6) 2011.44(4)
Z 4 4
Calculated density (g/cm3) 1.696 1.768
Absorption coefficient (mm−1) 0.168 0.183
F (000) 608 1080
θ Range for data collection (°) 2.91–30.04 3.04–25.03
Completeness to θ (%) 98.6 (θmax = 30.04°) 99.2 (θmax = 25.03°)
Range of h,k,l −10/11, −22/18, −13/12 −11/11, −12/12, −23/23
Reflections collected/unique 15278/3345 [R(int) = 0.0479] 32213/3517 [R(int) = 0.0452]
Absorption correction Analytical None
Max. and min. transmission 0.9840 and 0.9616
Refinement method Full-matrix least-squares on F 2 Full-matrix least-squares on F 2
Data/restraints/parameters 3345/0/225 3517/18/343
Goodness-of-fit on F 2 0.943 1.102
Final R indices [I > 2σ(I)] R1 = 0.0373, ωR2 = 0.0816 R1 = 0.0541, ωR2 = 0.1421
R indices (all data) R1 = 0.0660, ωR2 = 0.0904 R1 = 0.0630, ωR2 = 0.1456
Largest diff. peak and hole (e/Å3) 0.250 and −0.352 0.351 and −0.351
